U.S. patent application number 12/836136 was filed with the patent office on 2010-11-04 for substituted thiophenes.
This patent application is currently assigned to AUSPEX PHARMACEUTICALS, INC.. Invention is credited to Thomas G. Gant, Sepehr Sarshar.
Application Number | 20100280086 12/836136 |
Document ID | / |
Family ID | 39629167 |
Filed Date | 2010-11-04 |
United States Patent
Application |
20100280086 |
Kind Code |
A1 |
Gant; Thomas G. ; et
al. |
November 4, 2010 |
SUBSTITUTED THIOPHENES
Abstract
Disclosed herein are substituted pyrimidine-based endothelin
modulators of Formula I, processes of preparation thereof,
pharmaceutical compositions thereof, and methods of use thereof.
##STR00001##
Inventors: |
Gant; Thomas G.; (Carlsbad,
CA) ; Sarshar; Sepehr; (Cardiff by the Sea,
CA) |
Correspondence
Address: |
GLOBAL PATENT GROUP - APX
1005 North Warson Road, Suite 201
ST. LOUIS
MO
63132
US
|
Assignee: |
AUSPEX PHARMACEUTICALS,
INC.
Vista
CA
|
Family ID: |
39629167 |
Appl. No.: |
12/836136 |
Filed: |
July 14, 2010 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12100555 |
Apr 10, 2008 |
|
|
|
12836136 |
|
|
|
|
60911036 |
Apr 10, 2007 |
|
|
|
Current U.S.
Class: |
514/380 |
Current CPC
Class: |
A61P 15/00 20180101;
A61P 43/00 20180101; A61P 17/02 20180101; A61P 15/10 20180101; A61P
37/00 20180101; A61P 19/10 20180101; A61P 9/00 20180101; A61P 1/04
20180101; A61P 11/00 20180101; A61P 19/00 20180101; A61P 13/12
20180101; A61P 29/00 20180101; A61P 9/12 20180101; A61P 3/00
20180101; C07D 413/12 20130101; C07D 413/14 20130101; A61P 27/02
20180101 |
Class at
Publication: |
514/380 |
International
Class: |
A61K 31/422 20060101
A61K031/422; A61P 3/00 20060101 A61P003/00; A61P 1/04 20060101
A61P001/04; A61P 9/00 20060101 A61P009/00; A61P 9/12 20060101
A61P009/12; A61P 15/00 20060101 A61P015/00; A61P 17/02 20060101
A61P017/02; A61P 19/10 20060101 A61P019/10; A61P 11/00 20060101
A61P011/00; A61P 29/00 20060101 A61P029/00; A61P 37/00 20060101
A61P037/00 |
Claims
1. A method for the treatment, prevention, or amelioration of one
or more symptoms of an endothelin-mediated disorder in a subject,
by administering a therapeutically effective amount of a compound
having structural Formula I ##STR00191## or a pharmaceutically
acceptable salt thereof; wherein: R.sub.1 is selected from the
group consisting of chloride, and ##STR00192## Z is selected from
the group consisting of ##STR00193## R.sub.2, R.sub.3, R.sub.4,
R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11,
R.sub.12, R.sub.13, R.sub.14, R.sub.15, R.sub.16, R.sub.17,
R.sub.18, R.sub.19, R.sub.20, R.sub.21, R.sub.22, R.sub.23,
R.sub.24, R.sub.25, R.sub.26, R.sub.27, R.sub.28, R.sub.29,
R.sub.30, and R.sub.31 are independently selected from the group
consisting of hydrogen and deuterium; and at least one of R.sub.2,
R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9,
R.sub.10, R.sub.11, R.sub.12, R.sub.13, R.sub.14, R.sub.15,
R.sub.16, R.sub.17, R.sub.18, R.sub.19, R.sub.20, R.sub.21,
R.sub.22, R.sub.23, R.sub.24, R.sub.25, R.sub.26, R.sub.27,
R.sub.28, R.sub.29, R.sub.30, and R.sub.31 is deuterium.
2. The method as recited in claim 1, wherein the
endothelin-mediated disorder is selected from the group consisting
of hypertension, cardiovascular disease, cardiac disease, pulmonary
hypertension, neonatal pulmonary hypertension,
erythropoietin-mediated hypertension, respiratory disease,
inflammatory disease, opthalmologic disease, gastroenteric disease,
renal failure, endotoxin shock, menstrual disorder, obstetric
condition, wound, laminitis, erectile dysfunction, menopause,
osteoporosis, metabolic bone disorder, climacteric disorder,
disorder associated with the reduction in ovarian function in
middle-aged women, pre-eclampsia, management of labor during
pregnancy, nitric oxide attenuated disorder, anaphylactic shock,
interstitial lung disease, congestive heart failure, hemorrhagic
shock, and immunosuppressant-mediated renal vasoconstriction.
3. The method as recited in claim 2, wherein the
endothelin-mediated disorder is pulmonary hypertension.
4. The method as recited in claim 2, wherein the
endothelin-mediated disorder is congestive heart failure.
5. The method as recited in claim 1, wherein the
endothelin-mediated disorder can be lessened, alleviated, or
prevented by administering an endothelin receptor modulator.
6. The method as recited claim 1, wherein said compound has at
least one of the following properties: a) decreased
inter-individual variation in plasma levels of said compound or a
metabolite thereof as compared to the non-isotopically enriched
compound; b) increased average plasma levels of said compound per
dosage unit thereof as compared to the non-isotopically enriched
compound; c) decreased average plasma levels of at least one
metabolite of said compound per dosage unit thereof as compared to
the non-isotopically enriched compound; d) increased average plasma
levels of at least one metabolite of said compound per dosage unit
thereof as compared to the non-isotopically enriched compound; and
e) an improved clinical effect during the treatment in said subject
per dosage unit thereof as compared to the non-isotopically
enriched compound.
7. The method as recited claim 1, wherein said compound has at
least two of the following properties: a) decreased
inter-individual variation in plasma levels of said compound or a
metabolite thereof as compared to the non-isotopically enriched
compound; b) increased average plasma levels of said compound per
dosage unit thereof as compared to the non-isotopically enriched
compound; c) decreased average plasma levels of at least one
metabolite of said compound per dosage unit thereof as compared to
the non-isotopically enriched compound; d) increased average plasma
levels of at least one metabolite of said compound per dosage unit
thereof as compared to the non-isotopically enriched compound; and
e) an improved clinical effect during the treatment in said subject
per dosage unit thereof as compared to the non-isotopically
enriched compound.
8. The method as recited in claim 1, wherein the method affects a
decreased metabolism of the compound per dosage unit thereof by at
least one polymorphically-expressed cytochrome P.sub.450 isoform in
the subject, as compared to the corresponding non-isotopically
enriched compound.
9. The method as recited in claim 8, wherein the cytochrome
P.sub.450 isoform is selected from the group consisting of CYP2C8,
CYP2C9, CYP2C19, and CYP2D6.
10. The method as recited in claim 1, wherein said compound is
characterized by decreased inhibition of at least one cytochrome
P.sub.450 or monoamine oxidase isoform in said subject per dosage
unit thereof as compared to the non-isotopically enriched
compound.
11. The method as recited in claim 10, wherein said cytochrome
P.sub.450 or monoamine oxidase isoform is selected from the group
consisting of CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2A13, CYP2B6,
CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP2G1, CYP2J2,
CYP2R1, CYP2S1, CYP3A4, CYP3A5, CYP3A5P1, CYP3A5P2, CYP3A7,
CYP4A11, CYP4B1, CYP4F2, CYP4F3, CYP4F8, CYP4F11, CYP4F12, CYP4X1,
CYP4Z1, CYP5A1, CYP7A1, CYP7B1, CYP8A1, CYP8B1, CYP11A1, CYP11B1,
CYP11B2, CYP17, CYP19, CYP21, CYP24, CYP26A1, CYP26B1, CYP27A1,
CYP27B1, CYP39, CYP46, CYP51, MAO.sub.A, and MAO.sub.B.
12. The method as recited in claim 1, wherein the method affects
the treatment of the disorder while reducing or eliminating a
deleterious change in a diagnostic hepatobiliary function endpoint,
as compared to the corresponding non-isotopically enriched
compound.
13. The method as recited in claim 12, wherein the diagnostic
hepatobiliary function endpoint is selected from the group
consisting of alanine aminotransferase ("ALT"), serum
glutamic-pyruvic transaminase ("SGPT"), aspartate aminotransferase
("AST," "SGOT"), ALT/AST ratios, serum aldolase, alkaline
phosphatase ("ALP"), ammonia levels, bilirubin, gamma-glutamyl
transpeptidase ("GGTP," ".gamma.-GTP," "GGT"), leucine
aminopeptidase ("LAP"), liver biopsy, liver ultrasonography, liver
nuclear scan, 5'-nucleotidase, and blood protein.
14. The method as recited in claim 1, wherein the compound is
selected from the group consisting of: ##STR00194## or a
pharmaceutically acceptable salt thereof.
15. The method as recited in claim 14, wherein the
endothelin-mediated disorder is selected from the group consisting
of hypertension, cardiovascular disease, cardiac disease, pulmonary
hypertension, neonatal pulmonary hypertension,
erythropoietin-mediated hypertension, respiratory disease,
inflammatory disease, opthalmologic disease, gastroenteric disease,
renal failure, endotoxin shock, menstrual disorder, obstetric
condition, wound, laminitis, erectile dysfunction, menopause,
osteoporosis, metabolic bone disorder, climacteric disorder,
disorder associated with the reduction in ovarian function in
middle-aged women, pre-eclampsia, management of labor during
pregnancy, nitric oxide attenuated disorder, anaphylactic shock,
interstitial lung disease, congestive heart failure, hemorrhagic
shock, and immunosuppressant-mediated renal vasoconstriction.
16. The method as recited in claim 15, wherein the
endothelin-mediated disorder is pulmonary hypertension.
17. The method as recited in claim 15, wherein the
endothelin-mediated disorder is congestive heart failure.
18. The method as recited in claim 14, wherein the
endothelin-mediated disorder can be lessened, alleviated, or
prevented by administering an endothelin receptor modulator.
19. The method as recited in claim 14, wherein said compound has at
least one of the following properties: a) decreased
inter-individual variation in plasma levels of said compound or a
metabolite thereof as compared to the non-isotopically enriched
compound; b) increased average plasma levels of said compound per
dosage unit thereof as compared to the non-isotopically enriched
compound; c) decreased average plasma levels of at least one
metabolite of said compound per dosage unit thereof as compared to
the non-isotopically enriched compound; d) increased average plasma
levels of at least one metabolite of said compound per dosage unit
thereof as compared to the non-isotopically enriched compound; and
e) an improved clinical effect during the treatment in said subject
per dosage unit thereof as compared to the non-isotopically
enriched compound.
20. The method as recited in claim 14, wherein said compound has at
least two of the following properties: a) decreased
inter-individual variation in plasma levels of said compound or a
metabolite thereof as compared to the non-isotopically enriched
compound; b) increased average plasma levels of said compound per
dosage unit thereof as compared to the non-isotopically enriched
compound; c) decreased average plasma levels of at least one
metabolite of said compound per dosage unit thereof as compared to
the non-isotopically enriched compound; d) increased average plasma
levels of at least one metabolite of said compound per dosage unit
thereof as compared to the non-isotopically enriched compound; and
e) an improved clinical effect during the treatment in said subject
per dosage unit thereof as compared to the non-isotopically
enriched compound.
21. The method as recited in claim 14, wherein the method affects a
decreased metabolism of the compound per dosage unit thereof by at
least one polymorphically-expressed cytochrome P.sub.450 isoform in
the subject, as compared to the corresponding non-isotopically
enriched compound.
22. The method as recited in claim 21, wherein the cytochrome
P.sub.450 isoform is selected from the group consisting of CYP2C8,
CYP2C9, CYP2C19, and CYP2D6.
23. The method as recited in claim 14, wherein said compound is
characterized by decreased inhibition of at least one cytochrome
P.sub.450 or monoamine oxidase isoform in said subject per dosage
unit thereof as compared to the non-isotopically enriched
compound.
24. The method as recited in claim 23, wherein said cytochrome
P.sub.450 or monoamine oxidase isoform is selected from the group
consisting of CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2A13, CYP2B6,
CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP2G1, CYP2J2,
CYP2R1, CYP2S1, CYP3A4, CYP3A5, CYP3A5P1, CYP3A5P2, CYP3A7,
CYP4A11, CYP4B1, CYP4F2, CYP4F3, CYP4F8, CYP4F11, CYP4F12, CYP4X1,
CYP4Z1, CYP5A1, CYP7A1, CYP7B1, CYP8A1, CYP8B1, CYP11A1, CYP11B1,
CYP11B2, CYP17, CYP19, CYP21, CYP24, CYP26A1, CYP26B1, CYP27A1,
CYP27B1, CYP39, CYP46, CYP51, MAO.sub.A, and MAO.sub.B.
25. The method as recited in claim 14, wherein the method affects
the treatment of the disorder while reducing or eliminating a
deleterious change in a diagnostic hepatobiliary function endpoint,
as compared to the corresponding non-isotopically enriched
compound.
26. The method as recited in claim 25, wherein the diagnostic
hepatobiliary function endpoint is selected from the group
consisting of alanine aminotransferase ("ALT"), serum
glutamic-pyruvic transaminase ("SGPT"), aspartate aminotransferase
("AST," "SGOT"), ALT/AST ratios, serum aldolase, alkaline
phosphatase ("ALP"), ammonia levels, bilirubin, gamma-glutamyl
transpeptidase ("GGTP," ".gamma.-GTP," "GGT"), leucine
aminopeptidase ("LAP"), liver biopsy, liver ultrasonography, liver
nuclear scan, 5'-nucleotidase, and blood protein.
27. The method as recited in claim 14, wherein the compound has the
structural formula: ##STR00195## or a pharmaceutically acceptable
salt thereof.
28. The method as recited in claim 14, wherein the compound has the
structural formula: ##STR00196## or a pharmaceutically acceptable
salt thereof.
29. The method as recited in claim 14, wherein the compound has the
structural formula: ##STR00197## or a pharmaceutically acceptable
salt thereof.
30. The method as recited in claim 14, wherein the compound has the
structural formula: ##STR00198## or a pharmaceutically acceptable
salt thereof.
31. The method as recited in claim 14, wherein the compound has the
structural formula: ##STR00199## or a pharmaceutically acceptable
salt thereof.
32. A method for inhibiting the binding of an endothelin to an
ET.sub.A or ET.sub.B receptor, comprising contacting the receptor
with a compound having structural Formula I ##STR00200## or a
pharmaceutically acceptable salt thereof; wherein: R.sub.1 is
selected from the group consisting of chloride, and ##STR00201## Z
is selected from the group consisting of ##STR00202## R.sub.2,
R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9,
R.sub.10, R.sub.11, R.sub.12, R.sub.13, R.sub.14, R.sub.15,
R.sub.16, R.sub.17, R.sub.18, R.sub.19, R.sub.20, R.sub.21,
R.sub.22, R.sub.23, R.sub.24, R.sub.25, R.sub.26, R.sub.27,
R.sub.28, R.sub.29, R.sub.30, and R.sub.31 are independently
selected from the group consisting of hydrogen and deuterium; and
at least one of R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6,
R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11, R.sub.12, R.sub.13,
R.sub.14, R.sub.15, R.sub.16, R.sub.17, R.sub.18, R.sub.19,
R.sub.20, R.sub.21, R.sub.22, R.sub.23, R.sub.24, R.sub.25,
R.sub.26, R.sub.27, R.sub.28, R.sub.29, R.sub.30, and R.sub.31 is
deuterium.
33. The method as recited in claim 32, wherein the endothelin is
endothelin-1, endothelin-2, or endothelin-3.
34. A method for modulating endothelin receptor-mediated activity,
comprising contacting an endothelin receptor with a compound having
structural Formula I ##STR00203## or a pharmaceutically acceptable
salt thereof; wherein: R.sub.1 is selected from the group
consisting of chloride, and ##STR00204## Z is selected from the
group consisting of ##STR00205## R.sub.2, R.sub.3, R.sub.4,
R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11,
R.sub.12, R.sub.13, R.sub.14, R.sub.15, R.sub.16, R.sub.17,
R.sub.18, R.sub.19, R.sub.20, R.sub.21, R.sub.22, R.sub.23,
R.sub.24, R.sub.25, R.sub.26, R.sub.27, R.sub.28, R.sub.29,
R.sub.30, and R.sub.31 are independently selected from the group
consisting of hydrogen and deuterium; and at least one of R.sub.2,
R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9,
R.sub.10, R.sub.11, R.sub.12, R.sub.13, R.sub.14, R.sub.15,
R.sub.16, R.sub.17, R.sub.18, R.sub.19, R.sub.20, R.sub.21,
R.sub.22, R.sub.23, R.sub.24, R.sub.25, R.sub.26, R.sub.27,
R.sub.28, R.sub.29, R.sub.30, and R.sub.31 is deuterium.
Description
[0001] This application is a divisional of U.S. application Ser.
No. 12/100,555, filed Apr. 10, 2008, which claims the benefit of
priority of U.S. provisional application No. 60/911,036, filed Apr.
10, 2007, the disclosures of which are hereby incorporated by
reference as if written herein in their entirety.
FIELD
[0002] The present invention is directed to thiophene-based
endothelin modulators, pharmaceutically acceptable salts and
prodrugs thereof, the chemical synthesis thereof, and medical use
of such compounds for the treatment and/or management of
endothelin-mediated disorders.
BACKGROUND
[0003] Sitaxsentan (Thelin.RTM.),
(2-[2-(6-methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3-sulfonic
acid (4-chloro-3-methyl-isoxazol-5-yl)-amide) is a purported
selective endothelin receptor A (ET.sub.A) antagonist that is
approved by the Food and Drug Administration for the treatment of
hypertension and heart failure. Sitaxsentan, the first
ET.sub.A-selective EMA-approved member of this mechanistic class,
blocks the binding of the neurohormone endothelin-1 (ET-1) to
ET.sub.A. TBC3711
(3-(3,4-dimethyl-isoxazol-5-ylsulfamoyl)-thiophene-2-carboxylic
acid (2-acetyl-4,6-dimethyl-phenyl)-amide), another member of this
class, is currently undergoing clinical trials (O'Callaghan et al.,
International Journal of Clinical Practice 2006, 60(4), 475-481;
Souza et al., International Journal of Clinical Practice 2007,
61(1), 153-156; Wu et al., Journal of Medicinal Chemistry 1999,
42(22), 4485-4499).
##STR00002##
[0004] A common and severe side effect of sitaxsentan
administration is hepatotoxicity. This hepatotoxicity is likely
related to sixaxsentan's metabolism. The methylenedioxy moiety of
sitaxsentan is a potential site of oxidative metabolism, which can
undergo further biotransformations to form a reactive electrophilic
metabolite. This electrophic metabolite could then account for the
hepatotoxicity. Sitaxsentan is also known to significantly inhibit
CYP2C9, one of the enzymes responsible for its oxidative
transformation in vivo. Accordingly, sitaxsentan may cause
undesirable drug-drug interactions when coadministered with other
medications.
SUMMARY OF THE INVENTION
[0005] Disclosed herein is a compound having structural Formula
I
##STR00003##
[0006] or a pharmaceutically acceptable salt, solvate, or prodrug
thereof;
[0007] wherein:
[0008] R.sub.1 is selected from the group consisting of chloride,
and
##STR00004##
[0009] Z is selected from the group consisting of
##STR00005##
[0010] R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7,
R.sub.8, R.sub.9, R.sub.10, R.sub.11, R.sub.12, R.sub.13, R.sub.14,
R.sub.15, R.sub.16, R.sub.17, R.sub.18, R.sub.19, R.sub.20,
R.sub.21, R.sub.22, R.sub.23, R.sub.24, R.sub.25, R.sub.26,
R.sub.27, R.sub.28, R.sub.29, R.sub.30, and R.sub.31 are
independently selected from the group consisting of hydrogen and
deuterium; and
[0011] at least one of R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6,
R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11, R.sub.12, R.sub.13,
R.sub.14, R.sub.15, R.sub.16, R.sub.17, R.sub.18, R.sub.19,
R.sub.20, R.sub.21, R.sub.22, R.sub.23, R.sub.24, R.sub.25,
R.sub.26, R.sub.27, R.sub.28, R.sub.29, R.sub.30, and R.sub.31 is
deuterium. Additionally, disclosed herein are methods of modulating
endothelin receptors.
[0012] Further disclosed herein is a method for treating,
preventing, or ameliorating one or more symptoms of a
endothelin-mediated disorder which comprises administering to a
subject a therapeutically effective amount of at least one compound
as disclosed herein or a pharmaceutically acceptable salt, solvate,
or prodrug thereof.
[0013] Additionally disclosed is a method for treating, preventing,
or ameliorating one or more symptoms of a disorder involving, but
not limited to, hypertension, cardiovascular disease, cardiac
disease, pulmonary hypertension, neonatal pulmonary hypertension,
erythropoietin-mediated hypertension, respiratory disease,
inflammatory disease, opthalmologic disease, gastroenteric disease,
renal failure, endotoxin shock, menstrual disorder, obstetric
condition, wound, laminitis, erectile dysfunction, menopause,
osteoporosis, metabolic bone disorder, climacteric disorder,
disorder associated with the reduction in ovarian function in
middle-aged women, pre-eclampsia, management of labor during
pregnancy, nitric oxide attenuated disorder, anaphylactic shock,
interstitial lung disease, congestive heart failure, hemorrhagic
shock, immunosuppressant-mediated renal vasoconstriction and/or any
disorder which can be lessened, alleviated, or prevented by
administering an endothelin receptor modulator.
[0014] Also disclosed herein are articles of manufacture and kits
containing compounds as disclosed herein. By way of example only a
kit or article of manufacture can include a container (such as a
bottle) with a desired amount of at least one compound (or
pharmaceutical composition of a compound) as disclosed herein.
Further, such a kit or article of manufacture can further include
instructions for using said compound (or pharmaceutical composition
of a compound) disclosed herein. The instructions can be attached
to the container, or can be included in a package (such as a box or
a plastic or foil bag) holding the container.
[0015] In another aspect is the use of at least one compound as
disclosed herein in the manufacture of a medicament for treating a
disorder in a subject in which modulating endothelin receptors
contributes to the pathology and/or symptomology of the disorder.
In a further or alternative embodiment, said disorder is, but not
limited to, hypertension, cardiovascular disease, cardiac disease,
pulmonary hypertension, neonatal pulmonary hypertension,
erythropoietin-mediated hypertension, respiratory disease,
inflammatory disease, opthalmologic disease, gastroenteric disease,
renal failure, endotoxin shock, menstrual disorder, obstetric
condition, wound, laminitis, erectile dysfunction, menopause,
osteoporosis, metabolic bone disorder, climacteric disorder,
disorder associated with the reduction in ovarian function in
middle-aged women, pre-eclampsia, management of labor during
pregnancy, nitric oxide attenuated disorder, anaphylactic shock,
interstitial lung disease, congestive heart failure, hemorrhagic
shock, immunosuppressant-mediated renal vasoconstriction and/or any
disorder which can be lessened, alleviated, or prevented by
administering an endothelin receptor modulator.
[0016] In another aspect are processes for preparing a compound as
disclosed herein as an endothelin receptor modulator, or other
pharmaceutically acceptable derivatives such as salts, solvates, or
prodrugs
[0017] Also disclosed herein are processes for formulating
pharmaceutical compositions with a compound disclosed herein.
[0018] In further embodiments, said pharmaceutical composition
comprises a compound disclosed herein and one or more
pharmaceutically acceptable carriers.
[0019] In certain embodiments said pharmaceutical composition
comprises one or more release-controlling excipients.
[0020] In other embodiments said pharmaceutical composition further
comprises one or more non-release controlling excipients.
[0021] In certain embodiments said pharmaceutical composition is
suitable for oral, parenteral, or intravenous infusion
administration.
[0022] In yet other embodiments said pharmaceutical composition
comprises a tablet or capsule.
[0023] In certain embodiments the compounds as disclosed herein are
administered in a dose of 0.5 milligram to 1000 milligram.
[0024] In yet further embodiments said pharmaceutical compositions
further comprise another therapeutic agent.
[0025] In other embodiments said therapeutic agent is selected from
the group consisting of endothelin antagonists, congestive heart
failure treatments, endothelin converting enzyme (ECE) inhibitors,
thromboxane enzyme antagonists, potassium channel openers, thrombin
inhibitors, growth factor inhibitors, platelet activating factor
(PAF) antagonists, anti-platelet agents, Factor VIIa Inhibitors,
Factor Xa Inhibitors, renin inhibitors, neutral endopeptidase (NEP)
inhibitors, vasopepsidase inhibitors, HMG CoA reductase inhibitors,
squalene synthetase inhibitors, fibrates, bile acid sequestrants,
anti-atherosclerotic agents, MTP Inhibitors, calcium channel
blockers, potassium channel activators, alpha-PDE5 agents,
beta-PDE5 agents, antiarrhythmic agents, diuretics, anti-diabetic
agents, PPAR-gamma agonists, mineralocorticoid enzyme antagonists,
aP2 inhibitors, protein tyrosine kinase inhibitors,
antiinflammatories, antiproliferatives, chemotherapeutic agents,
immunosuppressants, anticancer agents, cytotoxic agents,
antimetabolites, farnesyl-protein transferase inhibitors, hormonal
agents, microtubule-disruptor agents, microtubule-stabilizing
agents, topoisomerase inhibitors, prenyl-protein transferase
inhibitors, cyclosporins, TNF-alpha inhibitors, cyclooxygenase-2
(COX-2) inhibitors, gold compounds, and platinum coordination
complexes.
[0026] In other embodiments said therapeutic agent is an endothelin
antagonist.
[0027] In further embodiments said endothelin antagonist is
selected from the group consisting of cyclic pentapeptides,
acyltripeptides, hexapeptide analogs, anthraquinone derivatives,
indanecarboxylic acids, N-pyriminylbenzenesulfonamides,
benzenesulfonamides, naphthalenesulfonamides, BE-18257B, BQ-123, PD
156707, L-754,142, SB 209670, SB 217242, A-127722, TAK-044,
ambrisentan, bosentan, and sitaxsentan.
[0028] In yet further embodiments said endothelin antagonist is
selected from an endothelin antagonist identified in the group of
patents or patent applications consisting of DE 4341663, EP 743307,
EP 733626, EP 713875, EP 682016, EP 658548, EP 633259, EP 628569,
EP 617001, EP 601386, EP 555537, EP 552417, EP 526708, EP 510526,
EP 496-452, EP 436189, GB 2295616, GB 2277446, GB 2276383, GB
2275926, GB 2266890, JP 8059635, JP 7330622, JP 7316188, JP
7258098, JP 7133254, JP 6256261, JP 6122625, U.S. Pat. No.
6,953,780, U.S. Pat. No. 6,946,481, U.S. Pat. No. 6,686,382, U.S.
Pat. No. 6,683,103, U.S. Pat. No. 6,852,745, U.S. Pat. No.
6,835,741, U.S. Pat. No. 6,673,824, U.S. Pat. No. 6,670,367, U.S.
Pat. No. 6,670,362, U.S. Pat. No. 6,432,994, U.S. Pat. No.
6,248,767, U.S. Pat. No. 5,962,490, U.S. Pat. No. 5,783,705, U.S.
Pat. No. 5,594,021, U.S. Pat. No. 5,591,761, U.S. Pat. No.
5,571,821, U.S. Pat. No. 5,514,691, U.S. Pat. No. 5,352,800, U.S.
Pat. No. 5,352,659, U.S. Pat. No. 5,334,598, U.S. Pat. No.
5,248,807, U.S. Pat. No. 5,240,910, U.S. Pat. No. 5,198,548, U.S.
Pat. No. 5,187,195, U.S. Pat. No. 5,082,838, U.S. Pat. No.
6,080,774, U.S. Pat. No. 5,780,473, U.S. Pat. No. 5,543,521, U.S.
Pat. No. 5,965,732, U.S. Pat. No. 5,571,821, U.S. Pat. No.
5,559,105, U.S. Pat. No. 5,541,186, U.S. Pat. No. 5,482,960, U.S.
Pat. No. 5,420,123, U.S. Pat. No. 5,389,620, U.S. Pat. No.
5,292,740, WO 96/33190, WO 96/33170, WO 96/31492, WO 96/30358, WO
96/23773, WO 96/22978, WO 96/20177, WO 96/19459, WO 96/19455, WO
96/15109, WO 96/12706, WO 96/11927, WO 96/11914, WO 96/09818, WO
96/08487, WO 96/08483, WO 96/08486, WO 96/07653, WO 96/06095, WO
96/04905, WO 95/35107, WO 95/33752, WO 95/33748, WO 95/26957, WO
95/26716, WO 95/26360, WO 95/15963, WO 95/15944, WO 95/13262, WO
95/12611, WO 95/05376, WO 95/08989, WO 95/08550, WO 95/05374, WO
95/05372, WO 95/04534, WO 95/04530, WO 95/03295, WO 95/03044, WO
94/25013, WO 94/24084, WO 94/21590, WO 94/21259, WO 94/14434, WO
94/03483, WO 94/02474, WO 93/25580, WO 93/23404, WO 93/21219, and
WO 93/08799.
[0029] In other embodiments said therapeutic agent is a congestive
heart failure treatment.
[0030] In yet other embodiments said congestive heart treatment is
selected from the group consisting of bumetanide, furosemide,
torsemide, chlorthalidone, HCTZ, amiloride, spironolactone,
glyceryl trinitrate, isosorbide dinitrate, isosorbide mononitrate,
molsidomin pentaerythritol tetranitrate, alprenolol, oxprenolol,
pindolol, propranolol, timolol, sotalol, nadolol, mepindolol,
carteolol, tertatolol, bopindolol, bupranolol, penbutolol,
cloranolol, practolol, metoprolol, atenolol, acebutolol, betaxolol,
bevantolol, bisoprolol, celiprolol, esmolol, epanolol, s-atenolol,
nebivolol, talinolol, labetalol, carvedilol, amlodipine,
felodipine, isradipine, nicardipine, nifedipine, nimodipine,
nisoldipine, nitrendipine, lacidipine, nilvadipine, manidipine,
barnidipine, lercanidipine, cilnidipine, benidipine, mibefradil,
verapamil, gallopamil, diltiazem, fendiline, bepridil, lidoflazine,
perhexyline, aliskiren, remikiren, alacepril, benazepril,
captopril, ceranapril, delapril, enalapril, fosinopril, lisinopril,
moexipril, perindopril, quinapril, ramipril, spirapril,
trandolapril, zofenopril candesartan, eprosartan, irbesartan,
losartan, olmesartan, tasosartan, telmisartan, valsartan,
spironolactone and eplerenone.
[0031] In further embodiments of the present invention, a method
for the treatment, prevention, or amelioration of one or more
symptoms of an endothelin-mediated disorder in a subject by
administering a therapeutically effective amount of a compound as
disclosed herein.
[0032] In other embodiments said endothelin-mediated disorder is
selected from the group consisting of hypertension, cardiovascular
disease, cardiac disease, pulmonary hypertension, neonatal
pulmonary hypertension, erythropoietin-mediated hypertension,
respiratory disease, inflammatory disease, opthalmologic disease,
gastroenteric disease, renal failure, endotoxin shock, menstrual
disorder, obstetric condition, wound, laminitis, erectile
dysfunction, menopause, osteoporosis, metabolic bone disorder,
climacteric disorder, disorder associated with the reduction in
ovarian function in middle-aged women, pre-eclampsia, management of
labor during pregnancy, nitric oxide attenuated disorder,
anaphylactic shock, interstitial lung disease, congestive heart
failure, hemorrhagic shock, and immunosuppressant-mediated renal
vasoconstriction.
[0033] In further embodiments the endothelin-mediated disorder is
pulmonary hypertension.
[0034] In certain embodiments the endothelin-mediated disorder is
congestive heart failure.
[0035] In other embodiments said endothelin-mediated disorder can
be lessened, alleviated, or prevented by administering an
endothelin receptor modulator.
[0036] In other embodiments said compound has at least one of the
following properties: [0037] a) decreased inter-individual
variation in plasma levels of said compound or a metabolite thereof
as compared to the non-isotopically enriched compound; [0038] b)
increased average plasma levels of said compound per dosage unit
thereof as compared to the non-isotopically enriched compound;
[0039] c) decreased average plasma levels of at least one
metabolite of said compound per dosage unit thereof as compared to
the non-isotopically enriched compound; [0040] d) increased average
plasma levels of at least one metabolite of said compound per
dosage unit thereof as compared to the non-isotopically enriched
compound; and [0041] e) an improved clinical effect during the
treatment in said subject per dosage unit thereof as compared to
the non-isotopically enriched compound.
[0042] In yet further embodiments said compound has at least two of
the following properties: [0043] a) decreased inter-individual
variation in plasma levels of said compound or a metabolite thereof
as compared to the non-isotopically enriched compound; [0044] b)
increased average plasma levels of said compound per dosage unit
thereof as compared to the non-isotopically enriched compound;
[0045] c) decreased average plasma levels of at least one
metabolite of said compound per dosage unit thereof as compared to
the non-isotopically enriched compound; [0046] d) increased average
plasma levels of at least one metabolite of said compound per
dosage unit thereof as compared to the non-isotopically enriched
compound; and [0047] e) an improved clinical effect during the
treatment in said subject per dosage unit thereof as compared to
the non-isotopically enriched compound.
[0048] In certain embodiments said compound has a decreased
metabolism by at least one polymorphically-expressed cytochrome
P.sub.450 isoform in said subject per dosage unit thereof as
compared to the non-isotopically enriched compound.
[0049] In other embodiments said cytochrome P.sub.450 isoform is
selected from the group consisting of CYP2C8, CYP2C9, CYP2C19, and
CYP2D6.
[0050] In yet further embodiments said compound is characterized by
decreased inhibition of at least one cytochrome P.sub.450 or
monoamine oxidase isoform in said subject per dosage unit thereof
as compared to the non-isotopically enriched compound.
[0051] In certain embodiments said cytochrome P.sub.450 or
monoamine oxidase isoform is selected from the group consisting of
CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2A13, CYP2B6, CYP2C8, CYP2C9,
CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP2G1, CYP2J2, CYP2R1, CYP2S1,
CYP3A4, CYP3A5, CYP3A5P1, CYP3A5P2, CYP3A7, CYP4A11, CYP4B1,
CYP4F2, CYP4F3, CYP4F8, CYP4F11, CYP4F12, CYP4X1, CYP4Z1, CYP5A1,
CYP7A1, CYP7B1, CYP8A1, CYP8B1, CYP11A1, CYP11B1, CYP11B2, CYP17,
CYP19, CYP21, CYP24, CYP26A1, CYP26B1, CYP27A1, CYP27B1, CYP39,
CYP46, CYP51, MAOA, and MAOB.
[0052] In other embodiments said method affects the treatment of
the disorder while reducing or eliminating a deleterious change in
a diagnostic hepatobiliary function endpoint, as compared to the
corresponding non-isotopically enriched compound.
[0053] In yet further embodiments said diagnostic hepatobiliary
function endpoint is selected from the group consisting of alanine
aminotransferase ("ALT"), serum glutamic-pyruvic transaminase
("SGPT"), aspartate aminotransferase ("AST," "SGOT"), ALT/AST
ratios, serum aldolase, alkaline phosphatase ("ALP"), ammonia
levels, bilirubin, gamma-glutamyl transpeptidase ("GGTP,"
".gamma.-GTP," "GGT"), leucine aminopeptidase ("LAP"), liver
biopsy, liver ultrasonography, liver nuclear scan, 5'-nucleotidase,
and blood protein.
[0054] In further embodiments of the present invention, a method
for inhibiting the binding of an endothelin to an ET.sub.A or
ET.sub.B receptor, comprising contacting the receptor with a
compound as recited herein.
[0055] In other embodiments said endothelin is endothelin-1,
endothelin-2, or endothelin-3.
[0056] In yet other embodiments of the present invention, a method
for modulating endothelin receptor-mediated activity, comprising
contacting an endothelin receptor with a compound as recited
herein.
INCORPORATION BY REFERENCE
[0057] All publications and references cited herein, including
those in the background section, are expressly incorporated herein
by reference in their entirety. However, with respect to any
similar or identical terms found in both the incorporated
publications or references and those explicitly put forth or
defined in this document, then those terms definitions or meanings
explicitly put forth in this document shall control in all
respects.
DETAILED DESCRIPTION
[0058] To facilitate understanding of the disclosure set forth
herein, a number of terms are defined below. Generally, the
nomenclature used herein and the laboratory procedures in organic
chemistry, medicinal chemistry, and pharmacology described herein
are those well known and commonly employed in the art. Unless
defined otherwise, all technical and scientific terms used herein
generally have the same meaning as commonly understood in the art
to which this disclosure belongs. In the event that there is a
plurality of definitions for a term used herein, those in this
section prevail unless stated otherwise.
[0059] As used herein, the singular forms "a," "an," and "the" may
refer to plural articles unless specifically stated otherwise.
[0060] The term "subject" refers to an animal, including, but not
limited to, a primate (e.g., human monkey, chimpanzee, gorilla, and
the like), rodents (e.g., rats, mice, gerbils, hamsters, ferrets,
and the like), lagomorphs, swine (e.g., pig, miniature pig),
equine, canine, feline, and the like. The terms "subject" and
"patient" are used interchangeably herein in reference, for
example, to a mammalian subject, such as a human patient.
[0061] The terms "treat," "treating," and "treatment" are meant to
include alleviating or abrogating a disorder; or alleviating or
abrogating one or more of the symptoms associated with the
disorder; and/or alleviating or eradicating the cause(s) of the
disorder itself.
[0062] The terms "prevent," "preventing," and "prevention" refer to
a method of delaying or precluding the onset of a disorder;
delaying or precluding its attendant symptoms; barring a subject
from acquiring a disorder; and/or reducing a subject's risk of
acquiring a disorder.
[0063] The term "therapeutically effective amount" refers to the
amount of a compound that, when administered, is sufficient to
prevent development of, or alleviate to some extent, one or more of
the symptoms of the disorder being treated. The term
"therapeutically effective amount" also refers to the amount of a
compound that is sufficient to elicit the biological or medical
response of a cell, tissue, system, animal, or human that is being
sought by a researcher, veterinarian, medical doctor, or
clinician.
[0064] The term "pharmaceutically acceptable carrier,"
"pharmaceutically acceptable excipient," "physiologically
acceptable carrier," or "physiologically acceptable excipient"
refers to a pharmaceutically-acceptable material, composition, or
vehicle, such as a liquid or solid filler, diluent, excipient,
solvent, or encapsulating material. Each component must be
"pharmaceutically acceptable" in the sense of being compatible with
the other ingredients of a pharmaceutical formulation. It must also
be suitable for use in contact with the tissue or organ of humans
and animals without excessive toxicity, irritation, allergic
response, immunogenecity, or other problems or complications,
commensurate with a reasonable benefit/risk ratio. See, Remington:
The Science and Practice of Pharmacy, 21st Edition; Lippincott
Williams & Wilkins: Philadelphia, Pa., 2005; Handbook of
Pharmaceutical Excipients, 5th Edition; Rowe et al., Eds., The
Pharmaceutical Press and the American Pharmaceutical Association:
2005; and Handbook of Pharmaceutical Additives, 3rd Edition; Ash
and Ash Eds., Gower Publishing Company: 2007; Pharmaceutical
Preformulation and Formulation, Gibson Ed., CRC Press LLC: Boca
Raton, Fla., 2004).
[0065] The term "deuterium enrichment" refers to the percentage of
incorporation of deuterium at a given position in a molecule in the
place of hydrogen. For example, deuterium enrichment of 1% at a
given position means that 1% of molecules in a given sample contain
deuterium at the specified position. Because the naturally
occurring distribution of deuterium is about 0.0156%, deuterium
enrichment at any position in a compound synthesized using
non-enriched starting materials is about 0.0156%. The deuterium
enrichment can be determined using conventional analytical methods
known to one of ordinary skill in the art, including mass
spectrometry and nuclear magnetic resonance spectroscopy.
[0066] The term "is/are deuterium," when used to describe a given
position in a molecule such as R.sub.2, R.sub.3, R.sub.4, R.sub.5,
R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11, R.sub.12,
R.sub.13, R.sub.14, R.sub.15, R.sub.16, R.sub.17, R.sub.18,
R.sub.19, R.sub.20, R.sub.21, R.sub.22, R.sub.23, R.sub.24,
R.sub.25, R.sub.26, R.sub.27, R.sub.28, R.sub.29, R.sub.30 and
R.sub.31 or the symbol "D," when used to represent a given position
in a drawing of a molecular structure, means that the specified
position is enriched with deuterium above the naturally occurring
distribution of deuterium. In an embodiment deuterium enrichment is
of no less than about 1%, in another no less than about 5%, in
another no less than about 10%, in another no less than about 20%,
in another no less than about 50%, in another no less than about
70%, in another no less than about 80%, in another no less than
about 90%, or in another no less than about 98% of deuterium at the
specified position.
[0067] The term "isotopic enrichment" refers to the percentage of
incorporation of a less prevalent isotope of an element at a given
position in a molecule in the place of the more prevalent isotope
of the element.
[0068] The term "non-isotopically enriched" refers to a molecule in
which the percentages of the various isotopes are substantially the
same as the naturally occurring percentages.
[0069] The terms "substantially pure" and "substantially
homogeneous" mean sufficiently homogeneous to appear free of
readily detectable impurities as determined by standard analytical
methods, including, but not limited to, thin layer chromatography
(TLC), gel electrophoresis, high performance liquid chromatography
(HPLC), nuclear magnetic resonance (NMR), and mass spectrometry
(MS); or sufficiently pure such that further purification would not
detectably alter the physical and chemical properties, or
biological and pharmacological properties, such as enzymatic and
biological activities, of the substance. In certain embodiments,
"substantially pure" or "substantially homogeneous" refers to a
collection of molecules, wherein at least about 50%, at least about
70%, at least about 80%, at least about 90%, at least about 95%, at
least about 98%, at least about 99%, or at least about 99.5% of the
molecules are a single compound, including a racemic mixture or
single stereoisomer thereof, as determined by standard analytical
methods.
[0070] The term "about" or "approximately" means an acceptable
error for a particular value, which depends in part on how the
value is measured or determined. In certain embodiments, "about"
can mean 1 or more standard deviations.
[0071] The terms "active ingredient" and "active substance" refer
to a compound, which is administered, alone or in combination with
one or more pharmaceutically acceptable excipients and/or carriers,
to a subject for treating, preventing, or ameliorating one or more
symptoms of a disorder.
[0072] The terms "drug," "therapeutic agent," and "chemotherapeutic
agent" refer to a compound, or a pharmaceutical composition
thereof, which is administered to a subject for treating,
preventing, or ameliorating one or more symptoms of a disorder.
[0073] The term "disorder" as used herein is intended to be
generally synonymous, and is used interchangeably with, the terms
"disease," "sydrome" and "condition" (as in medical condition), in
that all reflect an abnormal condition of the body or of one of its
parts that impairs normal functioning and is typically manifested
by distinguishing signs and symptoms.
[0074] The term "pharmaceutically acceptable carrier,"
"pharmaceutically acceptable excipient," "physiologically
acceptable carrier," or "physiologically acceptable excipient"
refers to a pharmaceutically-acceptable material, composition, or
vehicle, such as a liquid or solid filler, diluent, excipient,
solvent, or encapsulating material. Each component must be
"pharmaceutically acceptable" in the sense of being compatible with
the other ingredients of a pharmaceutical formulation. It must also
be suitable for use in contact with the tissue or organ of humans
and animals without excessive toxicity, irritation, allergic
response, immunogenecity, or other problems or complications,
commensurate with a reasonable benefit/risk ratio. See, Remington:
The Science and Practice of Pharmacy, 21st Edition; Lippincott
Williams & Wilkins: Philadelphia, Pa., 2005; Handbook of
Pharmaceutical Excipients, 5th Edition; Rowe et al., Eds., The
Pharmaceutical Press and the American Pharmaceutical Association:
2005; and Handbook of Pharmaceutical Additives, 3rd Edition; Ash
and Ash Eds., Gower Publishing Company: 2007; Pharmaceutical
Preformulation and Formulation, Gibson Ed., CRC Press LLC: Boca
Raton, Fla., 2004).
[0075] The term "release controlling excipient" refers to an
excipient whose primary function is to modify the duration or place
of release of the active substance from a dosage form as compared
with a conventional immediate release dosage form.
[0076] The term "nonrelease controlling excipient" refers to an
excipient whose primary function do not include modifying the
duration or place of release of the active substance from a dosage
form as compared with a conventional immediate release dosage
form.
[0077] The term "endothelin" refers to a peptide that has
substantially the amino acid sequence of endothelin-1, endothelin-2
or endothelin-3; and acts as a potent endogenous vasoconstrictor
peptide.
[0078] The terms "endothelin-mediated disorder" refers to a
disorder that is characterized by abnormal endothelin activity. An
endothelin-mediated disorder may be completely or partially
mediated by the abnormal endothelin activity through the
interactions of the endothelin with its receptor(s), such as
ET.sub.A and ET.sub.B. In particular, an endothelin-mediated
disorder is one in which modulation of the endothelin activity
results in some effect on the underlying disorder, e.g.,
administration of an ET.sub.A and/or ET.sub.B antagonist or agonist
results in some improvement in at least some of patients being
treated.
[0079] The term "endothelin receptor modulator," refers to the
ability of a compound disclosed herein to alter the function of
endothelin receptors. A modulator may activate the activity of
endothelin receptors, may activate or inhibit the activity of
endothelin receptors depending on the concentration of the compound
exposed to the endothelin receptors, or may inhibit the activity of
endothelin receptors. Such activation or inhibition may be
contingent on the occurrence of a specific event, such as
activation of a signal transduction pathway, and/or may be manifest
only in particular cell types. The term "modulate" or "modulation"
also refers to altering the function of endothelin receptors by
increasing or decreasing the probability that a complex forms
between endothelin receptors and a natural binding partner. A
modulator may increase the probability that such a complex forms
between the endothelin receptors and the natural binding partner,
may increase or decrease the probability that a complex forms
between the endothelin receptors and the natural binding partner
depending on the concentration of the compound exposed to the
endothelin receptors, and or may decrease the probability that a
complex forms between the endothelin receptors and the natural
binding partner. In some embodiments, modulation of the endothelin
receptors may be assessed using Receptor Selection and
Amplification Technology (R-SAT) as described in U.S. Pat. No.
5,707,798, the disclosure of which is incorporated herein by
reference in its entirety.
[0080] The term "endothelin antagonist" refers to a compound that,
e.g., partially or totally blocks, decreases, prevents, inhibits,
or downregulates endothelin receptor activity. The term "endothelin
antagonist" also refers to a compound that binds to, delays the
activation of, inactivates, or desensitizes one or more endothelin
receptors, such as ET.sub.A and/or ET.sub.B. An endothelin
antagonist may act by interfering with the interaction of an
endothelin with one or more endothelin receptors.
[0081] The term "protecting group" or "removable protecting group"
refers to a group which, when bound to a functionality, such as the
oxygen atom of a hydroxyl or carboxyl group, or the nitrogen atom
of an amino group, prevents reactions from occurring at that
functional group, and which can be removed by a conventional
chemical or enzymatic step to reestablish the functional group.
[0082] The term "chlorinating reagent" refers to a reactive
chemical reagent used in chlorination reactions, whereby chlorine
is transferred to a substrate. Examples of chlorinating agents
include, but are not limited to, thionyl chloride, chlorine gas,
carbon tetrachloride, cyanuric chloride, hexachloro-2-propanone,
N-chlorosuccinimide, phosphorus oxychloride, oxayl chloride,
phosphorus pentachloride, phosphorus trichloride, phosphorus (V)
oxychloride, and sulfuryl chloride.
[0083] The term "coupling reagent" refers to any reagent that will
activate the carbonyl of a carboxylic acid and facilitate the
formation of an ester or amide bond. The definition of "coupling
reagent" includes but is not limited to: acetyl chloride, ethyl
chloroformate, 1,1'-carbonyldiimidazole, N,O-dimethylhydroxylamine,
dicyclohexylcarbodiimide (DCC), diisopropyl carbodiiimide (DIC),
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDCI),
N-hydroxybenzotriazole (HOBT), N-hydroxysuccinimide (HOSu),
4-nitrophenol, pentafluorophenol,
2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
tetrafluoroborate (TBTU),
0-benzotriazole-N,N,N'N'-tetramethyluronium hexafluorophosphate
(HBTU), benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium
hexafluorophosphate (BOP),
benzotriazole-1-yl-oxy-tris-pyrrolidinophosphonium
hexafluorophosphate, bromo-trispyrrolidino-phosphonium
hexafluorophosphate,
2-(5-norbornene-2,3-dicarboximido)-1,1,3,3-tetramethyluronium
tetrafluoroborate (TNTU),
O-(N-succinimidyl)-1,1,3,3-tetramethyluronium tetrafluoroborate
(TSTU), tetramethylfluoroformamidinium hexafluorophosphate and the
like.
[0084] The term "catalyst" refers to a substance, which increases
the rate of a chemical reaction, which itself is not consumed in an
overall chemical or biological reaction. More generally, one may at
times call anything that accelerates a process, a "catalyst" (From
the Greek .kappa..alpha..tau..alpha..lamda.{acute over
(.upsilon.)}.epsilon.lv, meaning to annul or to untie or to pick
up). A "catalyst" does not allow for a reaction to take place, but
it provides an alternative route to products, the catalytic route
being subject to lower activation energy than in the uncatalyzed
reaction. A lowered activation energy increases the reaction rate.
Catalysts generally change in the course of a reaction but are
regenerated.
[0085] The term "inert gas" refers to any gas that is not reactive
under normal circumstances. Like the noble gases the tendency for
non-reactivity is due to the valence, the outermost electron shell,
being complete in all the inert gases. This is a tendency, not a
rule, as noble gases and other "inert" gases can react to form
compounds. But unlike the noble gases, an inert gas includes
molecular gases as well as elemental gases. Because of the
non-reactive properties of inert gases they are often useful to
prevent undesirable chemical reactions from taking place. Commonly
used inert gases, include, but are not limited to, nitrogen, argon,
carbon dioxide, helium, neon, krypton, radon, xenon, fluorocarbons
(excepting flammable forms).
[0086] The term "halogen", "halide" or "halo" includes fluorine,
chlorine, bromine, and iodine.
Deuterium Kinetic Isotope Effect
[0087] In an attempt to eliminate foreign substances, such as
therapeutic agents, from its circulation system, the animal body
expresses various enzymes, such as the cytochrome P.sub.450 enzymes
or CYPs, esterases, proteases, reductases, dehydrogenases, and
monoamine oxidases, to react with and convert these foreign
substances to more polar intermediates or metabolites for renal
excretion. Some of the most common metabolic reactions of
pharmaceutical compounds involve the oxidation of a carbon-hydrogen
(C--H) bond to either a carbon-oxygen (C-0) or carbon-carbon (C--C)
.pi.-bond. The resultant metabolites may be stable or unstable
under physiological conditions, and can have substantially
different pharmacokinetic, pharmacodynamic, and acute and long-term
toxicity profiles relative to the parent compounds. For most drugs,
such oxidations are generally rapid and ultimately lead to
administration of multiple or high daily doses.
[0088] The relationship between the activation energy and the rate
of reaction may be quantified by the Arrhenius equation,
k=Ae.sup.-Eact/RT, where E.sub.act is the activation energy, T is
temperature, R is the molar gas constant, k is the rate constant
for the reaction, and A (the frequency factor) is a constant
specific to each reaction that depends on the probability that the
molecules will collide with the correct orientation. The Arrhenius
equation states that the fraction of molecules that have enough
energy to overcome an energy barrier, that is, those with energy at
least equal to the activation energy, depends exponentially on the
ratio of the activation energy to thermal energy (RT), the average
amount of thermal energy that molecules possess at a certain
temperature.
[0089] The transition state in a reaction is a short lived state
(on the order of 10.sup.-14 sec) along the reaction pathway during
which the original bonds have stretched to their limit. By
definition, the activation energy E.sub.act for a reaction is the
energy required to reach the transition state of that reaction.
Reactions that involve multiple steps will necessarily have a
number of transition states, and in these instances, the activation
energy for the reaction is equal to the energy difference between
the reactants and the most unstable transition state. Once the
transition state is reached, the molecules can either revert, thus
reforming the original reactants, or the new bonds form giving rise
to the products. This dichotomy is possible because both pathways,
forward and reverse, result in the release of energy. A catalyst
facilitates a reaction process by lowering the activation energy
leading to a transition state. Enzymes are examples of biological
catalysts that reduce the energy necessary to achieve a particular
transition state.
[0090] A carbon-hydrogen bond is by nature a covalent chemical
bond. Such a bond forms when two atoms of similar electronegativity
share some of their valence electrons, thereby creating a force
that holds the atoms together. This force or bond strength can be
quantified and is expressed in units of energy, and as such,
covalent bonds between various atoms can be classified according to
how much energy must be applied to the bond in order to break the
bond or separate the two atoms.
[0091] The bond strength is directly proportional to the absolute
value of the ground-state vibrational energy of the bond. This
vibrational energy, which is also known as the zero-point
vibrational energy, depends on the mass of the atoms that form the
bond. The absolute value of the zero-point vibrational energy
increases as the mass of one or both of the atoms making the bond
increases. Since deuterium (D) is two-fold more massive than
hydrogen (H), it follows that a C-D bond is stronger than the
corresponding C--H bond. Compounds with C-D bonds are frequently
indefinitely stable in H.sub.2O, and have been widely used for
isotopic studies. If a C--H bond is broken during a
rate-determining step in a chemical reaction (i.e. the step with
the highest transition state energy), then substituting a deuterium
for that hydrogen will cause a decrease in the reaction rate and
the process will slow down. This phenomenon is known as the
Deuterium Kinetic Isotope Effect (DKIE) and can range from about 1
(no isotope effect) to very large numbers, such as 50 or more,
meaning that the reaction can be fifty, or more, times slower when
deuterium is substituted for hydrogen. High DKIE values may be due
in part to a phenomenon known as tunneling, which is a consequence
of the uncertainty principle. Tunneling is ascribed to the small
size of a hydrogen atom, and occurs because transition states
involving a proton can sometimes form in the absence of the
required activation energy. A deuterium is larger and statistically
has a much lower probability of undergoing this phenomenon.
Substitution of tritium for hydrogen results in yet a stronger bond
than deuterium and gives numerically larger isotope effects.
[0092] Discovered in 1932 by Urey, deuterium (D) is a stable and
non-radioactive isotope of hydrogen. It was the first isotope to be
separated from its element in pure form and is twice as massive as
hydrogen, and makes up about 0.02% of the total mass of hydrogen
(in this usage meaning all hydrogen isotopes) on earth. When two
deuteriums bond with one oxygen, deuterium oxide (D.sub.2O or
"heavy water") is formed. D.sub.2O looks and tastes like H.sub.2O,
but has different physical properties. It boils at 101.41.degree.
C. and freezes at 3.79.degree. C. Its heat capacity, heat of
fusion, heat of vaporization, and entropy are all higher than
H.sub.2O. It is also more viscous and is not as powerful a solvent
as H.sub.2O.
[0093] When pure D.sub.2O is given to rodents, it is readily
absorbed and reaches an equilibrium level that is usually about
eighty percent of the concentration of what was consumed. The
quantity of deuterium required to induce toxicity is extremely
high. When 0% to as much as 15% of the body water has been replaced
by D.sub.2O, animals are healthy but are unable to gain weight as
fast as the control (untreated) group. When about 15% to about 20%
of the body water has been replaced with D.sub.2O, the animals
become excitable. When about 20% to about 25% of the body water has
been replaced with D.sub.2O, the animals are so excitable that they
go into frequent convulsions when stimulated. Skin lesions, ulcers
on the paws and muzzles, and necrosis of the tails appear. The
animals also become very aggressive; males becoming almost
unmanageable. When about 30%, of the body water has been replaced
with D.sub.2O, the animals refuse to eat and become comatose. Their
body weight drops sharply and their metabolic rates drop far below
normal, with death occurring at about 30 to about 35% replacement
with D.sub.2O. The effects are reversible unless more than thirty
percent of the previous body weight has been lost due to D.sub.2O,
Studies have also shown that the use of D.sub.2O can delay the
growth of cancer cells and enhance the cytotoxicity of certain
antineoplastic agents.
[0094] Tritium (T) is a radioactive isotope of hydrogen, used in
research, fusion reactors, neutron generators and
radiopharmaceuticals. Mixing tritium with a phosphor provides a
continuous light source, a technique that is commonly used in
wristwatches, compasses, rifle sights and exit signs. It was
discovered by Rutherford, Oliphant and Harteck in 1934, and is
produced naturally in the upper atmosphere when cosmic rays react
with H.sub.2 molecules. Tritium is a hydrogen atom that has 2
neutrons in the nucleus and has an atomic weight close to 3. It
occurs naturally in the environment in very low concentrations,
most commonly found as T.sub.2O, a colorless and odorless liquid.
Tritium decays slowly (half-life=12.3 years) and emits a low energy
beta particle that cannot penetrate the outer layer of human skin.
Internal exposure is the main hazard associated with this isotope,
yet it must be ingested in large amounts to pose a significant
health risk. As compared with deuterium, a lesser amount of tritium
must be consumed before it reaches a hazardous level.
[0095] Deuteration of pharmaceuticals to improve pharmacokinetics
(PK), pharmacodynamics (PD), and toxicity profiles, has been
demonstrated previously with some classes of drugs. For example,
DKIE was used to decrease the hepatotoxicity of halothane by
presumably limiting the production of reactive species such as
trifluoroacetyl chloride. However, this method may not be
applicable to all drug classes. For example, deuterium
incorporation can lead to metabolic switching which may even give
rise to an oxidative intermediate with a faster off-rate from an
activating Phase I enzyme (e.g., cytochrome P.sub.450 3A4). The
concept of metabolic switching asserts that xenogens, when
sequestered by Phase I enzymes, may bind transiently and re-bind in
a variety of conformations prior to the chemical reaction (e.g.,
oxidation). This hypothesis is supported by the relatively vast
size of binding pockets in many Phase I enzymes and the promiscuous
nature of many metabolic reactions. Metabolic switching can
potentially lead to different proportions of known metabolites as
well as altogether new metabolites. This new metabolic profile may
impart more or less toxicity. Such pitfalls are non-obvious and
have not been heretofore sufficiently predictable a priori for any
drug class.
Deuterated Thiophene Derivatives
[0096] Sitaxsentan is a substituted thiophene-based endothelin
receptor antagonist. The carbon-hydrogen bonds of sitaxsentan
contain a naturally occurring distribution of hydrogen isotopes,
namely .sup.1H or protium (about 99.9844%), .sup.2H or deuterium
(about 0.0156%), and .sup.3H or tritium (in the range between about
0.5 and 67 tritium atoms per 10.sup.18 protium atoms). Increased
levels of deuterium incorporation may produce a detectable Kinetic
Isotope Effect (KIE) that could affect the pharmacokinetic,
pharmacologic and/or toxicologic profiles of such endothelin
receptor modulators in comparison with the compound having
naturally occurring levels of deuterium.
[0097] Sitaxsentan is likely metabolized at the methylene group of
its methylenedioxy moiety (the CH.sub.2 group on the
--O--CH.sub.2--O-- moiety). This metabolite may be further
biotransformed to a potentially reactive electrophilic
metabolite(s). These reactive metabolite(s) may be responsible for
the hepatotoxicity seen with sitaxsentan administration. Limiting
the production of such metabolites has the potential to decrease
the danger of the administration of such drugs and may even allow
increased dosage and concomitant increased efficacy. Sitaxentan is
also known to be a substrate and inhibitor of the
polymorphically-expressed CYP2C9. This may account, in part, for
the observed nonlinearity of the dose-response for sitaxsentan.
Various deuteration patterns can be used to a) reduce or eliminate
unwanted metabolites, b) increase the half-life of the drug, c)
decrease the number of doses needed to achieve a desired effect, d)
decrease the amount of a dose needed to achieve a desired effect,
e) increase the formation of active metabolites, if any are formed,
and/or f) decrease the production of deleterious metabolites in
specific tissues and/or create a more effective drug and/or a safer
drug for polypharmacy, whether the polypharmacy be intentional or
not. The deuteration approach has strong potential to slow the
metabolism via various oxidative mechanisms and attenuate
interpatient variatability.
[0098] In one embodiment, disclosed herein is a compound having
structural Formula I
##STR00006##
[0099] or a pharmaceutically acceptable salt, solvate, or prodrug
thereof;
[0100] wherein:
[0101] R.sub.1 is selected from the group consisting of chloride,
and
##STR00007##
[0102] Z is selected from the group consisting of
##STR00008##
[0103] R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7,
R.sub.8, R.sub.9, R.sub.10, R.sub.11, R.sub.12, R.sub.13, R.sub.14,
R.sub.15, R.sub.16, R.sub.17, R.sub.18, R.sub.19, R.sub.20,
R.sub.21, R.sub.22, R.sub.23, R.sub.24, R.sub.25, R.sub.26,
R.sub.27, R.sub.28, R.sub.29, R.sub.30, and R.sub.31 are
independently selected from the group consisting of hydrogen and
deuterium; and
[0104] at least one of R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6,
R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11, R.sub.12, R.sub.13,
R.sub.14, R.sub.15, R.sub.16, R.sub.17, R.sub.18, R.sub.19,
R.sub.20, R.sub.21, R.sub.22, R.sub.23, R.sub.24, R.sub.25,
R.sub.26, R.sub.27, R.sub.28, R.sub.29, R.sub.30, and R.sub.31 is
deuterium.
[0105] In a further embodiment, said compound is substantially a
single enantiomer, a mixture of about 90% or more by weight of the
(-)-enantiomer and about 10% or less by weight of the
(+)-enantiomer, a mixture of about 90% or more by weight of the
(+)-enantiomer and about 10% or less by weight of the
(-)-enantiomer, substantially an individual diastereomer, or a
mixture of about 90% or more by weight of an individual
diastereomer and about 10% or less by weight of any other
diastereomer.
[0106] In another embodiment, at least one of R.sub.2, R.sub.3,
R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10,
R.sub.11, R.sub.12, R.sub.13, R.sub.14, R.sub.15, R.sub.16,
R.sub.17, R.sub.18, R.sub.19, R.sub.20, R.sub.21, R.sub.22,
R.sub.23, R.sub.24, R.sub.25, R.sub.26, R.sub.27, R.sub.28,
R.sub.29, R.sub.30, and R.sub.31 independently has deuterium
enrichment of no less than about 1%, no less than about 5%, no less
than about 10%, no less than about 20%, no less than about 50%, no
less than about 70%, no less than about 80%, no less than about
90%, or no less than about 98%.
[0107] In certain embodiments, R.sub.2 is hydrogen. In yet other
embodiments, R.sub.3 is hydrogen. In some embodiments, R.sub.4 is
hydrogen. In other embodiments, R.sub.5 is hydrogen. In yet other
embodiments, R.sub.6 is hydrogen. In still other embodiments,
R.sub.7 is hydrogen. In still other embodiments, R.sub.8 is
hydrogen. In some embodiments, R.sub.9 is hydrogen. In other
embodiments, R.sub.10 is hydrogen. In yet other embodiments,
R.sub.11 is hydrogen. In still other embodiments, R.sub.12 is
hydrogen. In yet other embodiments, R.sub.13 is hydrogen. In other
embodiments, R.sub.14 is hydrogen. In certain embodiments, R.sub.15
is hydrogen. In other embodiments, R.sub.16 is hydrogen. In yet
other embodiments, R.sub.17 is hydrogen. In some embodiments,
R.sub.18 is hydrogen. In other embodiments, R.sub.19 is hydrogen.
In yet other embodiments, R.sub.20 is hydrogen. In still other
embodiments, R.sub.21 is hydrogen. In still other embodiments,
R.sub.22 is hydrogen. In some embodiments, R.sub.23 is hydrogen. In
other embodiments, R.sub.24 is hydrogen. In yet other embodiments,
R.sub.25 is hydrogen. In still other embodiments, R.sub.26 is
hydrogen. In yet other embodiments, R.sub.27 is hydrogen. In other
embodiments, R.sub.28 is hydrogen. In some embodiments, R.sub.29 is
hydrogen. In some embodiments, R.sub.30 is hydrogen. In some
embodiments, R.sub.31 is hydrogen.
[0108] In certain embodiments, R.sub.2 is deuterium. In yet other
embodiments, R.sub.3 is deuterium. In some embodiments, R.sub.4 is
deuterium. In other embodiments, R.sub.5 is deuterium. In yet other
embodiments, R.sub.6 is deuterium. In still other embodiments,
R.sub.7 is deuterium. In still other embodiments, R.sub.8 is
deuterium. In some embodiments, R.sub.9 is deuterium. In other
embodiments, R.sub.10 is deuterium. In yet other embodiments,
R.sub.11 is deuterium. In still other embodiments, R.sub.12 is
deuterium. In yet other embodiments, R.sub.13 is deuterium. In
other embodiments, R.sub.14 is deuterium. In certain embodiments,
R.sub.15 is deuterium. In other embodiments, R.sub.16 is deuterium.
In yet other embodiments, R.sub.17 is deuterium. In some
embodiments, R.sub.18 is deuterium. In other embodiments, R.sub.19
is deuterium. In yet other embodiments, R.sub.20 is deuterium. In
still other embodiments, R.sub.21 is deuterium. In still other
embodiments, R.sub.22 is deuterium. In some embodiments, R.sub.23
is deuterium. In other embodiments, R.sub.24 is deuterium. In yet
other embodiments, R.sub.25 is deuterium. In still other
embodiments, R.sub.26 is deuterium. In yet other embodiments,
R.sub.27 is deuterium. In other embodiments, R.sub.28 is deuterium.
In some embodiments, R.sub.29 is deuterium. In some embodiments,
R.sub.30 is deuterium.
[0109] In some embodiments, R.sub.31 is deuterium.
[0110] In yet another embodiment, at least one of R.sub.9, and
R.sub.10 is deuterium.
[0111] In yet another embodiment, R.sub.9, and R.sub.10 are
deuterium.
[0112] In yet another embodiment, at least one of R.sub.9, and
R.sub.10 is deuterium; and R.sub.2, R.sub.3, R.sub.4, R.sub.5,
R.sub.6, R.sub.7, R.sub.8, R.sub.11, R.sub.12, R.sub.13, R.sub.14,
R.sub.15, R.sub.16, R.sub.17, R.sub.18, R.sub.19, R.sub.20,
R.sub.21, R.sub.22, R.sub.23, R.sub.24, R.sub.25, R.sub.26,
R.sub.27, R.sub.28, R.sub.29, R.sub.30, and R.sub.31 are
hydrogen.
[0113] In yet another embodiment, R.sub.9, and R.sub.10 are
deuterium; and R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6,
R.sub.7, R.sub.8, R.sub.11, R.sub.12, R.sub.13, R.sub.14, R.sub.15,
R.sub.16, R.sub.17, R.sub.18, R.sub.19, R.sub.20, R.sub.21,
R.sub.22, R.sub.23, R.sub.24, R.sub.25, R.sub.26, R.sub.27,
R.sub.28, R.sub.29, R.sub.30, and R.sub.31 are hydrogen.
[0114] In yet another embodiment, R.sub.1 is chloride; and at least
one of R.sub.9, and R.sub.10 is deuterium.
[0115] In yet another embodiment, R.sub.1 is chloride; and R.sub.9,
and R.sub.10 are deuterium.
[0116] In yet another embodiment, R.sub.1 is chloride; and at least
one of R.sub.9, and R.sub.10 is deuterium; and R.sub.2, R.sub.3,
R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.11, R.sub.12,
R.sub.13, R.sub.14, R.sub.15, R.sub.16, R.sub.17, R.sub.18,
R.sub.19, R.sub.20, R.sub.21, R.sub.22, R.sub.23, R.sub.24,
R.sub.25, R.sub.26, R.sub.27, R.sub.28, R.sub.29, R.sub.30, and
R.sub.31 are hydrogen.
[0117] In yet another embodiment, R.sub.1 is chloride; and R.sub.9,
and R.sub.10 are deuterium; and R.sub.2, R.sub.3, R.sub.4, R.sub.5,
R.sub.6, R.sub.7, R.sub.8, R.sub.11, R.sub.12, R.sub.13, R.sub.14,
R.sub.15, R.sub.16, R.sub.17, R.sub.18, R.sub.19, R.sub.20,
R.sub.21, R.sub.22, R.sub.23, R.sub.24, R.sub.25, R.sub.26,
R.sub.27, R.sub.28, R.sub.29, R.sub.30, and R.sub.31 are
hydrogen.
[0118] In yet another embodiment, R.sub.1 is
##STR00009##
and at least one of R.sub.9, and R.sub.10 is deuterium.
[0119] In yet another embodiment, R.sub.1 is
##STR00010##
and R.sub.9, and R.sub.10 are deuterium.
[0120] In yet another embodiment, R.sub.1 is
##STR00011##
at least one of R.sub.9, and R.sub.10 is deuterium; and R.sub.2,
R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.11,
R.sub.12, R.sub.13, R.sub.14, R.sub.15, R.sub.16, R.sub.17,
R.sub.18, R.sub.19, R.sub.20, R.sub.21, R.sub.22, R.sub.23,
R.sub.24, R.sub.25, R.sub.26, R.sub.27, R.sub.28, R.sub.29,
R.sub.30, and R.sub.31 are hydrogen.
[0121] In yet another embodiment, R.sub.1 is
##STR00012##
R.sub.9, and R.sub.10 are deuterium; and R.sub.2, R.sub.3, R.sub.4,
R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.11, R.sub.12, R.sub.13,
R.sub.14, R.sub.15, R.sub.16, R.sub.17, R.sub.18, R.sub.19,
R.sub.20, R.sub.21, R.sub.22, R.sub.23, R.sub.24, R.sub.25,
R.sub.26, R.sub.27, R.sub.28, R.sub.29, R.sub.30, and R.sub.31 are
hydrogen.
[0122] In yet another embodiment, Z is
##STR00013##
and at least one of R.sub.9, and R.sub.10 is deuterium.
[0123] In yet another embodiment, Z is
##STR00014##
and R.sub.9, and R.sub.10 are deuterium.
[0124] In yet another embodiment, Z is
##STR00015##
and at least one of R.sub.9, and R.sub.10 is deuterium; and
R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8,
R.sub.11, R.sub.12, R.sub.13, R.sub.14, R.sub.15, R.sub.16,
R.sub.17, R.sub.18, R.sub.19, R.sub.20, R.sub.21, R.sub.22,
R.sub.23, R.sub.24, R.sub.25, R.sub.26, R.sub.27, R.sub.28,
R.sub.29, R.sub.30, and R.sub.31 are hydrogen.
[0125] In yet another embodiment, Z is
##STR00016##
and R.sub.9, and R.sub.10 are deuterium; and R.sub.2, R.sub.3,
R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.11, R.sub.12,
R.sub.13, R.sub.14, R.sub.15, R.sub.16, R.sub.17, R.sub.18,
R.sub.19, R.sub.20, R.sub.21, R.sub.22, R.sub.23, R.sub.24,
R.sub.25, R.sub.26, R.sub.27, R.sub.28, R.sub.29, R.sub.30, and
R.sub.31 are hydrogen.
[0126] In yet another embodiment, R.sub.5 or R.sub.26 is
deuterium.
[0127] In yet another embodiment, R.sub.5 and R.sub.26 are
deuterium.
[0128] In yet another embodiment, R.sub.1 is chloride; R.sub.5 and
R.sub.26 are deuterium; and at least one of R.sub.2, R.sub.3,
R.sub.4, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11,
R.sub.12, R.sub.13, R.sub.14, R.sub.15, R.sub.16, R.sub.17,
R.sub.18, R.sub.19, R.sub.20, R.sub.21, R.sub.22, R.sub.23,
R.sub.24, R.sub.25, R.sub.27, R.sub.28, R.sub.29, R.sub.30, and
R.sub.31 is independently deuterium.
[0129] In yet another embodiment, R.sub.1 is chloride; R.sub.5 and
R.sub.26 are deuterium; and R.sub.2, R.sub.3, R.sub.4, R.sub.6,
R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11, R.sub.12, R.sub.13,
R.sub.14, R.sub.15, R.sub.16, R.sub.17, R.sub.18, R.sub.19,
R.sub.20, R.sub.21, R.sub.22, R.sub.23, R.sub.24, R.sub.25,
R.sub.27, R.sub.28, R.sub.29, R.sub.30, and R.sub.31 is
independently deuterium.
[0130] In yet another embodiment, R.sub.1 is
##STR00017##
R.sub.5 and R.sub.26 are deuterium; and at least one of R.sub.2,
R.sub.3, R.sub.4, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10,
R.sub.11, R.sub.12, R.sub.13, R.sub.14, R.sub.15, R.sub.16,
R.sub.17, R.sub.18, R.sub.19, R.sub.20, R.sub.21, R.sub.22,
R.sub.23, R.sub.24, R.sub.25, R.sub.27, R.sub.28, R.sub.29,
R.sub.30, and R.sub.31 is independently deuterium.
[0131] In yet another embodiment, R.sub.1 is
##STR00018##
R.sub.5 and R.sub.26 are deuterium; and R.sub.2, R.sub.3, R.sub.4,
R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11, R.sub.12,
R.sub.13, R.sub.14, R.sub.15, R.sub.16, R.sub.17, R.sub.18,
R.sub.19, R.sub.20, R.sub.21, R.sub.22, R.sub.23, R.sub.24,
R.sub.25, R.sub.27, R.sub.28, R.sub.29, R.sub.30, and R.sub.31 is
independently deuterium.
[0132] In yet another embodiment, Z is
##STR00019##
R.sub.5 and R.sub.26 are deuterium; and at least one of R.sub.2,
R.sub.3, R.sub.4, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10,
R.sub.11, R.sub.12, R.sub.13, R.sub.14, R.sub.15, R.sub.16,
R.sub.17, R.sub.18, R.sub.19, R.sub.20, R.sub.21, R.sub.22,
R.sub.23, R.sub.24, R.sub.25, R.sub.27, R.sub.28, R.sub.29,
R.sub.30, and R.sub.31 is independently deuterium.
[0133] In yet another embodiment, Z is
##STR00020##
R.sub.5 and R.sub.26 are deuterium; and R.sub.2, R.sub.3, R.sub.4,
R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11, R.sub.12,
R.sub.13, R.sub.14, R.sub.15, R.sub.16, R.sub.17, R.sub.18,
R.sub.19, R.sub.20, R.sub.21, R.sub.22, R.sub.23, R.sub.24,
R.sub.25, R.sub.27, R.sub.28, R.sub.29, R.sub.30, and R.sub.31 is
independently deuterium.
[0134] In yet another embodiment, Z is
##STR00021##
R.sub.5 and R.sub.26 are deuterium; and at least one of R.sub.2,
R.sub.3, R.sub.4, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10,
R.sub.11, R.sub.12, R.sub.13, R.sub.14, R.sub.15, R.sub.16,
R.sub.17, R.sub.18, R.sub.19, R.sub.20, R.sub.21, R.sub.22,
R.sub.23, R.sub.24, R.sub.25, R.sub.27, R.sub.28, R.sub.29,
R.sub.30, and R.sub.31 is independently deuterium.
[0135] In yet another embodiment, Z is
##STR00022##
R.sub.5 and R.sub.26 are deuterium; and R.sub.2, R.sub.3, R.sub.4,
R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11, R.sub.12,
R.sub.13, R.sub.14, R.sub.15, R.sub.16, R.sub.17, R.sub.18,
R.sub.19, R.sub.20, R.sub.21, R.sub.22, R.sub.23, R.sub.24,
R.sub.25, R.sub.27, R.sub.28, R.sub.29, R.sub.30, and R.sub.31 is
independently deuterium.
[0136] In yet another embodiment, R.sub.5 or R.sub.26 is
hydrogen.
[0137] In yet another embodiment, R.sub.5 and R.sub.26 are
hydrogen.
[0138] In yet another embodiment, R.sub.1 is chloride; R.sub.5 and
R.sub.26 are hydrogen; and at least one of R.sub.2, R.sub.3,
R.sub.4, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11,
R.sub.12, R.sub.13, R.sub.14, R.sub.15, R.sub.16, R.sub.17,
R.sub.18, R.sub.19, R.sub.20, R.sub.21, R.sub.22, R.sub.23,
R.sub.24, R.sub.25, R.sub.27, R.sub.28, R.sub.29, R.sub.30, and
R.sub.31 is independently deuterium.
[0139] In yet another embodiment, R.sub.1 is chloride; R.sub.5 and
R.sub.26 are hydrogen; and R.sub.2, R.sub.3, R.sub.4, R.sub.6,
R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11, R.sub.12, R.sub.13,
R.sub.14, R.sub.15, R.sub.16, R.sub.17, R.sub.18, R.sub.19,
R.sub.20, R.sub.21, R.sub.22, R.sub.23, R.sub.24, R.sub.25,
R.sub.27, R.sub.28, R.sub.29, R.sub.30, and R.sub.31 is
independently deuterium.
[0140] In yet another embodiment, R.sub.1 is
##STR00023##
R.sub.5 and R.sub.26 are hydrogen; and at least one of R.sub.2,
R.sub.3, R.sub.4, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10,
R.sub.11, R.sub.12, R.sub.13, R.sub.14, R.sub.15, R.sub.16,
R.sub.17, R.sub.18, R.sub.19, R.sub.20, R.sub.21, R.sub.22,
R.sub.23, R.sub.24, R.sub.25, R.sub.27, R.sub.28, R.sub.29,
R.sub.30, and R.sub.31 is independently deuterium.
[0141] In yet another embodiment, R.sub.1 is
##STR00024##
R.sub.5 and R.sub.26 are hydrogen; and R.sub.2, R.sub.3, R.sub.4,
R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11, R.sub.12,
R.sub.13, R.sub.14, R.sub.15, R.sub.16, R.sub.17, R.sub.18,
R.sub.19, R.sub.20, R.sub.21, R.sub.22, R.sub.23, R.sub.24,
R.sub.25, R.sub.27, R.sub.28, R.sub.29, R.sub.30, and R.sub.31 is
independently deuterium.
[0142] In yet another embodiment, Z is
##STR00025##
R.sub.5 and R.sub.26 are hydrogen; and at least one of R.sub.2,
R.sub.3, R.sub.4, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10,
R.sub.11, R.sub.12, R.sub.13, R.sub.14, R.sub.15, R.sub.16,
R.sub.17, R.sub.18, R.sub.19, R.sub.20, R.sub.21, R.sub.22,
R.sub.23, R.sub.24, R.sub.25, R.sub.27, R.sub.28, R.sub.29,
R.sub.30, and R.sub.31 is independently deuterium.
[0143] In yet another embodiment, Z is
##STR00026##
R.sub.5 and R.sub.26 are hydrogen; and R.sub.2, R.sub.3, R.sub.4,
R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11, R.sub.12,
R.sub.13, R.sub.14, R.sub.15, R.sub.16, R.sub.17, R.sub.18,
R.sub.19, R.sub.20, R.sub.21, R.sub.22, R.sub.23, R.sub.24,
R.sub.25, R.sub.27, R.sub.28, R.sub.29, R.sub.30, and R.sub.31 is
independently deuterium.
[0144] In yet another embodiment, Z is
##STR00027##
R.sub.5 and R.sub.26 are hydrogen; and at least one of R.sub.2,
R.sub.3, R.sub.4, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10,
R.sub.11, R.sub.12, R.sub.13, R.sub.14, R.sub.15, R.sub.16,
R.sub.17, R.sub.18, R.sub.19, R.sub.20, R.sub.21, R.sub.22,
R.sub.23, R.sub.24, R.sub.25, R.sub.27, R.sub.28, R.sub.29,
R.sub.30, and R.sub.31 is independently deuterium.
[0145] In yet another embodiment, Z is
##STR00028##
R.sub.5 and R.sub.26 are hydrogen; and R.sub.2, R.sub.3, R.sub.4,
R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11, R.sub.12,
R.sub.13, R.sub.14, R.sub.15, R.sub.16, R.sub.17, R.sub.18,
R.sub.19, R.sub.20, R.sub.21, R.sub.22, R.sub.23, R.sub.24,
R.sub.25, R.sub.27, R.sub.28, R.sub.29, R.sub.30, and R.sub.31 is
independently deuterium.
[0146] In certain embodiments, R.sub.1 is chloride.
[0147] In certain embodiments, R.sub.1 is
##STR00029##
[0148] In certain embodiments, Z is
##STR00030##
[0149] In certain embodiments, Z is
##STR00031##
[0150] In yet another embodiment, the compound as disclosed herein
is selected from the group consisting of:
##STR00032## ##STR00033## ##STR00034## ##STR00035## ##STR00036##
##STR00037## ##STR00038## ##STR00039## ##STR00040## ##STR00041##
##STR00042## ##STR00043## ##STR00044## ##STR00045## ##STR00046##
##STR00047## ##STR00048## ##STR00049## ##STR00050## ##STR00051##
##STR00052## ##STR00053## ##STR00054## ##STR00055## ##STR00056##
##STR00057## ##STR00058## ##STR00059## ##STR00060## ##STR00061##
##STR00062## ##STR00063## ##STR00064## ##STR00065## ##STR00066##
##STR00067## ##STR00068## ##STR00069## ##STR00070## ##STR00071##
##STR00072## ##STR00073## ##STR00074## ##STR00075## ##STR00076##
##STR00077## ##STR00078## ##STR00079## ##STR00080## ##STR00081##
##STR00082## ##STR00083## ##STR00084## ##STR00085## ##STR00086##
##STR00087##
[0151] In yet another embodiment, the compound as disclosed herein
is selected from the group consisting of:
##STR00088## ##STR00089##
or a pharmaceutically acceptable salt, solvate, or prodrug
thereof.
[0152] In another embodiment, at least one of the positions
represented as D independently has deuterium enrichment of no less
than about 1%, no less than about 5%, no less than about 10%, no
less than about 20%, no less than about 50%, no less than about
70%, no less than about 80%, no less than about 90%, or no less
than about 98%.
[0153] In a further embodiment, said compound is substantially a
single enantiomer, a mixture of about 90% or more by weight of the
(-)-enantiomer and about 10% or less by weight of the
(+)-enantiomer, a mixture of about 90% or more by weight of the
(+)-enantiomer and about 10% or less by weight of the
(-)-enantiomer, substantially an individual diastereomer, or a
mixture of about 90% or more by weight of an individual
diastereomer and about 10% or less by weight of any other
diastereomer.
[0154] In certain embodiments, the compound as disclosed herein
contains about 60% or more by weight of the (-)-enantiomer of the
compound and about 40% or less by weight of (+)-enantiomer of the
compound. In certain embodiments, the compound as disclosed herein
contains about 70% or more by weight of the (-)-enantiomer of the
compound and about 30% or less by weight of (+)-enantiomer of the
compound. In certain embodiments, the compound as disclosed herein
contains about 80% or more by weight of the (-)-enantiomer of the
compound and about 20% or less by weight of (+)-enantiomer of the
compound. In certain embodiments, the compound as disclosed herein
contains about 90% or more by weight of the (-)-enantiomer of the
compound and about 10% or less by weight of the (+)-enantiomer of
the compound. In certain embodiments, the compound as disclosed
herein contains about 95% or more by weight of the (-)-enantiomer
of the compound and about 5% or less by weight of (+)-enantiomer of
the compound. In certain embodiments, the compound as disclosed
herein contains about 99% or more by weight of the (-)-enantiomer
of the compound and about 1% or less by weight of (+)-enantiomer of
the compound.
[0155] In certain embodiments, the compound as disclosed herein
contains about 60% or more by weight of the (+)-enantiomer of the
compound and about 40% or less by weight of (-)-enantiomer of the
compound. In certain embodiments, the compound as disclosed herein
contains about 70% or more by weight of the (+)-enantiomer of the
compound and about 30% or less by weight of (-)-enantiomer of the
compound. In certain embodiments, the compound as disclosed herein
contains about 80% or more by weight of the (+)-enantiomer of the
compound and about 20% or less by weight of (-)-enantiomer of the
compound. In certain embodiments, the compound as disclosed herein
contains about 90% or more by weight of the (+)-enantiomer of the
compound and about 10% or less by weight of the (-)-enantiomer of
the compound. In certain embodiments, the compound as disclosed
herein contains about 95% or more by weight of the (+)-enantiomer
of the compound and about 5% or less by weight of (-)-enantiomer of
the compound. In certain embodiments, the compound as disclosed
herein contains about 99% or more by weight of the (+)-enantiomer
of the compound and about 1% or less by weight of (-)-enantiomer of
the compound.
[0156] The deuterated compound as disclosed herein may also contain
less prevalent isotopes for other elements, including, but not
limited to, .sup.13C or .sup.14C for carbon, .sup.33S, .sup.34S, or
.sup.36S for sulfur, .sup.15N for nitrogen, and .sup.17O or
.sup.18O for oxygen.
[0157] In certain embodiments, without being bound by any theory,
the compound disclosed herein may expose a patient to a maximum of
about 0.000005% D.sub.2O or about 0.00001% DHO, assuming that all
of the C-D bonds in the compound as disclosed herein are
metabolized and released as D.sub.2O or DHO. This quantity is a
small fraction of the naturally occurring background levels of
D.sub.2O or DHO in circulation. In certain embodiments, the levels
of D.sub.2O shown to cause toxicity in animals is much greater than
even the maximum limit of exposure because of the deuterium
enriched compound as disclosed herein. Thus, in certain
embodiments, the deuterium-enriched compound disclosed herein
should not cause any additional toxicity because of the use of
deuterium.
[0158] In one embodiment, the deuterated compounds disclosed herein
maintain the beneficial aspects of the corresponding
non-isotopically enriched molecules while substantially increasing
the maximum tolerated dose, decreasing toxicity, increasing the
half-life (T.sub.1/2), lowering the maximum plasma concentration
(C.sub.max) of the minimum efficacious dose (MED), lowering the
efficacious dose and thus decreasing the non-mechanism-related
toxicity, and/or lowering the probability of drug-drug
interactions.
[0159] Isotopic hydrogen can be introduced into a compound as
disclosed herein by synthetic techniques that employ deuterated
reagents, whereby incorporation rates are pre-determined; and/or by
exchange techniques, wherein incorporation rates are determined by
equilibrium conditions, and may be highly variable depending on the
reaction conditions. Synthetic techniques, where tritium or
deuterium is directly and specifically inserted by tritiated or
deuterated reagents of known isotopic content, may yield high
tritium or deuterium abundance, but can be limited by the chemistry
required. Exchange techniques, on the other hand, may yield lower
tritium or deuterium incorporation, often with the isotope being
distributed over many sites on the molecule.
[0160] The compounds as disclosed herein can be prepared by methods
known to one of skill in the art and routine modifications thereof,
and/or following procedures similar to those described in the
Example section herein and routine modifications thereof, and/or
procedures found in Wu et al., Journal of Medicinal Chemistry 1997,
40(11), 1682-1689, Wu et al., Synth. Commun. 1999, 29(20),
3509-3516, and Wu et al., Journal of Medicinal Chemistry 1999,
42(22), 4485-4499, and references cited therein and routine
modifications thereof. Compounds as disclosed herein can also be
prepared as shown in any of the following schemes and routine
modifications thereof.
[0161] For example, certain compounds as disclosed herein can be
prepared as shown in Scheme 1.
##STR00090##
[0162] 5-amino-isoxazole 2 reacts with thiophene-3-sulfonyl
chloride 3, in the presence of a base, such as sodium hydride, in
an appropriate solvent, such as anhydrous tetrahydrofuran, to give
a thiophene-methyl ester, which is then treated with a base, such
as sodium hydroxide, to give thiophene-carboxylic acid 4. Catechol
5 is treated with a base, such as cesium carbonate, in appropriate
solvents, such dimethylformamide and dichloromethane, at an
elevated temperature and under an inert atmosphere, such as
nitrogen, to affored benzodioxole 6, which is then reacted with
formaldehyde in the presence of an acid, such as hydrochloric acid,
and in the presence of a catalyst, such as tetrabutylammonium
bromide, in an appropriate solvent, such as ether, to yield
chloromethyl-benzodioxole 7. Compound 4 is treated with coupling
reagents, such as 1,1'-carbonyldiimidazole and
N,O-dimethylhydroxylamine, in the presence of a base, such as
imidazole, in an appropriate solvent, such as anhydrous
tetrahydrofuran, to make a weinreb amide intermediate, which is
then reacted with a Grignard reagent formed from compound 5, in an
appropriate solvent, such as anhydrous tetrahydrofuran, to afford
thiophene 8 of Formula I.
[0163] Deuterium can be incorporated to different positions
synthetically, according to the synthetic procedures as shown in
Scheme 1, by using appropriate deuterated intermediates. For
example, to introduce deuterium at one or more positions selected
from R.sub.2, R.sub.3, and R.sub.4,
5-amino-4-chloro-3-methylisoxazole with the corresponding deuterium
substitutions can be used. To introduce deuterium at one or more
positions selected from R.sub.6, and R.sub.7,
2-(methoxycarbonyl)thiophene-3-sulfonyl chloride with the
corresponding deuterium substitutions can be used. To introduce
deuterium at one or more positions selected from R.sub.8, R.sub.9,
R.sub.10, R.sub.11, R.sub.12, R.sub.13, R.sub.14, R.sub.30, and
R.sub.31, 5-(chloromethyl)-6-methylbenzo[d][1,3]dioxole with the
corresponding deuterium substitutions can be used. These deuterated
intermediates are either commercially available, or can be prepared
by methods known to one of skill in the art or following procedures
similar to those described in the Example section herein and
routine modifications thereof.
[0164] Certain compounds of Formula I can be prepared as shown in
Scheme 2.
##STR00091##
[0165] Amino-dimethylisoxazole 8 reacts with thiophene-3-sulfonyl
chloride 9, in the presence of a base, such as sodium hydride, in
an appropriate solvent, such as anhydrous tetrahydrofuran, to give
a thiophene-methyl ester 10. Compound 10 is then reacted with a
N-protecting group (PG), such as bromomethyl methyl ether, in an
appropriate solvent, such as anyhydrous tetrahydrofuran, in the
presence of a base, such as N,N-diisopropylethylamine to give a
protected methyl ester thiopene intermediate, which is then treated
with a base, such as sodium hydroxide, in an appropriate solvent,
such as tetrahydrofuran, to give a protected thiophene carboxylic
acid 11. Compound 11 reacts with a cholorinating agent, such as
oxalyl chloride, in the presence of a catalyst, such as pyridine,
in appropriate solvents, such as chloroform and terahydrofuran, to
give thiophene carboxylic acid chloride 12. Aniline 13 is converted
into acetophenone 14 by following the procedure disclosed in Wu,
Synth. Commun. 1999, 29(20), 3509-3516, which then reacts with
Compound 11, in an appropriate solvent, such as anhydrous
tetrahydrofuran, to give a protected thiophene intermediate, which
is then deprotected by treating with an acid, such as hydrochloric
acid, in an appropriate solvent, such as methanol, at an elevated
temperature to afford thiophene 15 of Formula I.
[0166] Deuterium can be incorporated to different positions
synthetically, according to the synthetic procedures as shown in
Scheme 2, by using appropriate deuterated intermediates. For
example, to introduce deuterium at one or more positions selected
from R.sub.2, R.sub.3, R.sub.4, R.sub.27, R.sub.28, and R.sub.29,
5-amino-3,4-dimethylixoxazole with the corresponding deuterium
substitutions can be used. To introduce deuterium at one or more
positions selected from R.sub.6, and R.sub.7,
2-(methoxycarbonyl)thiophene-3-sulfonyl chloride with the
corresponding deuterium substitutions can be used. To introduce
deuterium at one or more positions selected from R.sub.15,
R.sub.16, R.sub.27, R.sub.18, R.sub.19, R.sub.20, R.sub.21,
R.sub.22, R.sub.23, R.sub.24, and R.sub.25,
2-amino-3,5-dimethylacetophenone with the corresponding deuterium
substitutions can be used. These deuterated intermediates are
either commercially available, or can be prepared by methods known
to one of skill in the art or following procedures similar to those
described in the Example section herein and routine modifications
thereof.
[0167] Exemplary conditions for forming and removing suitable
N-protecting groups may be found in Greene and Wuts, Protective
Groups in Organic Synthesis, 3.sup.rd Ed., John Wiley & Sons,
New York, N.Y., 1999. Suitable N-protecting groups include but are
not limited to those selected from methoxymethyl (MOM),
benzyloxymethyl (BOM), 2-(trimethylsilyl)ethoxymethyl (SEM),
methoxyethoxymethyl (MEM), or t-butyl groups. In addition, the
heteroaryl sulfonamide-NH moiety has reactivity similar to
carboxylic acids, and accordingly, methods used to protect
carboxylic acids may be applicable to protecting the nitrogen NH of
the sulfonamides described herein. Exemplary conditions for forming
and removing suitable carboxylic acid protecting groups may be
found in Greene and Wuts, Protective Groups in Organic Synthesis,
3.sup.rd Ed., John Wiley & Sons, New York, N.Y., 1999.
[0168] It is to be understood that the compounds disclosed herein
may contain one or more chiral centers, chiral axes, and/or chiral
planes, as described in "Stereochemistry of Carbon Compounds" Eliel
and Wilen, John Wiley & Sons, New York, 1994, pp. 1119-1190.
Such chiral centers, chiral axes, and chiral planes may be of
either the (R) or (S) configuration, or may be a mixture
thereof.
[0169] Another method for characterizing a composition containing a
compound having at least one chiral center is by the effect of the
composition on a beam of polarized light. When a beam of plane
polarized light is passed through a solution of a chiral compound,
the plane of polarization of the light that emerges is rotated
relative to the original plane. This phenomenon is known as optical
activity, and compounds that rotate the plane of polarized light
are said to be optically active. One enantiomer of a compound will
rotate the beam of polarized light in one direction, and the other
enantiomer will rotate the beam of light in the opposite direction.
The enantiomer that rotates the polarized light in the clockwise
direction is the (+) enantiomer, and the enantiomer that rotates
the polarized light in the counterclockwise direction is the (-)
enantiomer. Included within the scope of the compositions described
herein are compositions containing between 0 and 100% of the (+)
and/or (-) enantiomer of compounds disclosed herein.
[0170] Where a compound as disclosed herein contains an alkenyl or
alkenylene group, the compound may exist as one or mixture of
geometric cis/trans (or Z/E) isomers. Where structural isomers are
interconvertible via a low energy barrier, the compound disclosed
herein may exist as a single tautomer or a mixture of tautomers.
This can take the form of proton tautomerism in the compound
disclosed herein that contains for example, an imino, keto, or
oxime group; or so-called valence tautomerism in the compound that
contain an aromatic moiety. It follows that a single compound may
exhibit more than one type of isomerism.
[0171] The compounds disclosed herein may be enantiomerically pure,
such as a single enantiomer or a single diastereomer, or be
stereoisomeric mixtures, such as a mixture of enantiomers, a
racemic mixture, or a diastereomeric mixture. As such, one of skill
in the art will recognize that administration of a compound in its
(R) form is equivalent, for compounds that undergo epimerization in
vivo, to administration of the compound in its (S) form.
Conventional techniques for the preparation/isolation of individual
enantiomers include chiral synthesis from a suitable optically pure
precursor or resolution of the racemate using, for example, chiral
chromatography, recrystallization, resolution, diastereomeric salt
formation, or derivatization into diastereomeric adducts followed
by separation.
[0172] When the compound disclosed herein contains an acidic or
basic moiety, it may also disclosed as a pharmaceutically
acceptable salt (See, Berge et al., J. Pharm. Sci. 1977, 66, 1-19;
and "Handbook of Pharmaceutical Salts, Properties, and Use," Stah
and Wermuth, Ed.; Wiley-VCH and VHCA, Zurich, 2002).
[0173] Suitable acids for use in the preparation of
pharmaceutically acceptable salts include, but are not limited to,
acetic acid, 2,2-dichloroacetic acid, acylated amino acids, adipic
acid, alginic acid, ascorbic acid, L-aspartic acid, benzenesulfonic
acid, benzoic acid, 4-acetamidobenzoic acid, boric acid,
(+)-camphoric acid, camphorsulfonic acid,
(+)-(1S)-camphor-10-sulfonic acid, capric acid, caproic acid,
caprylic acid, cinnamic acid, citric acid, cyclamic acid,
cyclohexanesulfamic acid, dodecylsulfuric acid,
ethane-1,2-disulfonic acid, ethanesulfonic acid,
2-hydroxy-ethanesulfonic acid, formic acid, fumaric acid,
galactaric acid, gentisic acid, glucoheptonic acid, D-gluconic
acid, D-glucuronic acid, L-glutamic acid, .alpha.-oxo-glutaric
acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric
acid, hydroiodic acid, (+)-L-lactic acid, (.+-.)-DL-lactic acid,
lactobionic acid, lauric acid, maleic acid, (-)-L-malic acid,
malonic acid, (.+-.)-DL-mandelic acid, methanesulfonic acid,
naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid,
1-hydroxy-2-naphthoic acid, nicotinic acid, nitric acid, oleic
acid, orotic acid, oxalic acid, palmitic acid, pamoic acid,
perchloric acid, phosphoric acid, L-pyroglutamic acid, saccharic
acid, salicylic acid, 4-amino-salicylic acid, sebacic acid, stearic
acid, succinic acid, sulfuric acid, tannic acid, (+)-L-tartaric
acid, thiocyanic acid, p-toluenesulfonic acid, undecylenic acid,
and valeric acid.
[0174] Suitable bases for use in the preparation of
pharmaceutically acceptable salts, including, but not limited to,
inorganic bases, such as magnesium hydroxide, calcium hydroxide,
potassium hydroxide, zinc hydroxide, or sodium hydroxide; and
organic bases, such as primary, secondary, tertiary, and
quaternary, aliphatic and aromatic amines, including L-arginine,
benethamine, benzathine, choline, deanol, diethanolamine,
diethylamine, dimethylamine, dipropylamine, diisopropylamine,
2-(diethylamino)-ethanol, ethanolamine, ethylamine,
ethylenediamine, isopropylamine, N-methyl-glucamine, hydrabamine,
1H-imidazole, L-lysine, morpholine, 4-(2-hydroxyethyl)-morpholine,
methylamine, piperidine, piperazine, propylamine, pyrrolidine,
1-(2-hydroxyethyl)-pyrrolidine, pyridine, quinuclidine, quinoline,
isoquinoline, secondary amines, triethanolamine, trimethylamine,
triethylamine, N-methyl-D-glucamine,
2-amino-2-(hydroxymethyl)-1,3-propanediol, and tromethamine.
[0175] The compound as disclosed herein may also be designed as a
prodrug, which is a functional derivative of the compound as
disclosed herein and is readily convertible into the parent
compound in vivo. Prodrugs are often useful because, in some
situations, they may be easier to administer than the parent
compound. They may, for instance, be bioavailable by oral
administration whereas the parent compound is not. The prodrug may
also have enhanced solubility in pharmaceutical compositions over
the parent compound. A prodrug may be converted into the parent
drug by various mechanisms, including enzymatic processes and
metabolic hydrolysis. See Harper, Progress in Drug Research 1962,
4, 221-294; Morozowich et al. in "Design of Biopharmaceutical
Properties through Prodrugs and Analogs," Roche Ed., APHA Acad.
Pharm. Sci. 1977; "Bioreversible Carriers in Drug in Drug Design,
Theory and Application," Roche Ed., APHA Acad. Pharm. Sci. 1987;
"Design of Prodrugs," Bundgaard, Elsevier, 1985; Wang et al., Curr.
Pharm. Design 1999, 5, 265-287; Pauletti et al., Adv. Drug.
Delivery Rev. 1997, 27, 235-256; Mizen et al., Pharm. Biotech.
1998, 11, 345-365; Gaignault et al., Pract. Med. Chem. 1996,
671-696; Asgharnejad in "Transport Processes in Pharmaceutical
Systems," Amidon et al., Ed., Marcell Dekker, 185-218, 2000; Balant
et al., Eur. J. Drug Metab. Pharmacokinet. 1990, 15, 143-53;
Balimane and Sinko, Adv. Drug Delivery Rev. 1999, 39, 183-209;
Browne, Clin. Neuropharmacol. 1997, 20, 1-12; Bundgaard, Arch.
Pharm. Chem. 1979, 86, 1-39; Bundgaard, Controlled Drug Delivery
1987, 17, 179-96; Bundgaard, Adv. Drug Delivery Rev. 1992, 8, 1-38;
Fleisher et al., Adv. Drug Delivery Rev. 1996, 19, 115-130;
Fleisher et al., Methods Enzymol. 1985, 112, 360-381; Farquhar et
al., J. Pharm. Sci. 1983, 72, 324-325; Freeman et al., J. Chem.
Soc., Chem. Commun. 1991, 875-877; Friis and Bundgaard, Eur. J.
Pharm. Sci. 1996, 4, 49-59; Gangwar et al., Des. Biopharm. Prop.
Prodrugs Analogs, 1977, 409-421; Nathwani and Wood, Drugs 1993, 45,
866-94; Sinhababu and Thakker, Adv. Drug Delivery Rev. 1996, 19,
241-273; Stella et al., Drugs 1985, 29, 455-73; Tan et al., Adv.
Drug Delivery Rev. 1999, 39, 117-151; Taylor, Adv. Drug Delivery
Rev. 1996, 19, 131-148; Valentino and Borchardt, Drug Discovery
Today 1997, 2, 148-155; Wiebe and Knaus, Adv. Drug Delivery Rev.
1999, 39, 63-80; Waller et al., Br. J. Clin. Pharmac. 1989, 28,
497-507.
Pharmaceutical Composition
[0176] Disclosed herein are pharmaceutical compositions comprising
a compound as disclosed herein as an active ingredient, including a
single enantiomer, a mixture of the (+)-enantiomer and the
(-)-enantiomer, a mixture of about 90% or more by weight of the
(-)-enantiomer and about 10% or less by weight of the
(+)-enantiomer, a mixture of about 90% or more by weight of the
(+)-enantiomer and about 10% or less by weight of the
(-)-enantiomer, an individual diastereomer, or a mixture of
diastereomers thereof; or a pharmaceutically acceptable salt,
solvate, or prodrug thereof, in a pharmaceutically acceptable
vehicle, carrier, diluent, or excipient, or a mixture thereof; in
combination with one or more pharmaceutically acceptable excipients
or carriers.
[0177] Disclosed herein are pharmaceutical compositions in modified
release dosage forms, which comprise a compound as disclosed
herein, including a single enantiomer, a mixture of the
(+)-enantiomer and the (-)-enantiomer, a mixture of about 90% or
more by weight of the (-)-enantiomer and about 10% or less by
weight of the (+)-enantiomer, a mixture of about 90% or more by
weight of the (+)-enantiomer and about 10% or less by weight of the
(-)-enantiomer, an individual diastereomer, or a mixture of
diastereomers thereof; or a pharmaceutically acceptable salt,
solvate, or prodrug thereof; and one or more release controlling
excipients or carriers as described herein. Suitable modified
release dosage vehicles include, but are not limited to,
hydrophilic or hydrophobic matrix devices, water-soluble separating
layer coatings, enteric coatings, osmotic devices, multiparticulate
devices, and combinations thereof. The pharmaceutical compositions
may also comprise non-release controlling excipients or
carriers.
[0178] Further disclosed herein are pharmaceutical compositions in
enteric coated dosage forms, which comprise a compound as disclosed
herein, including a single enantiomer, a mixture of the
(+)-enantiomer and the (-)-enantiomer, a mixture of about 90% or
more by weight of the (-)-enantiomer and about 10% or less by
weight of the (+)-enantiomer, a mixture of about 90% or more by
weight of the (+)-enantiomer and about 10% or less by weight of the
(-)-enantiomer, an individual diastereomer, or a mixture of
diastereomers thereof, or a pharmaceutically acceptable salt,
solvate, or prodrug thereof; and one or more release controlling
excipients or carriers for use in an enteric coated dosage form.
The pharmaceutical compositions may also comprise non-release
controlling excipients or carriers.
[0179] Further disclosed herein are pharmaceutical compositions in
effervescent dosage forms, which comprise a compound as disclosed
herein, including a single enantiomer, a mixture of the
(+)-enantiomer and the (-)-enantiomer, a mixture of about 90% or
more by weight of the (-)-enantiomer and about 10% or less by
weight of the (+)-enantiomer, a mixture of about 90% or more by
weight of the (+)-enantiomer and about 10% or less by weight of the
(-)-enantiomer, an individual diastereomer, or a mixture of
diastereomers thereof; or a pharmaceutically acceptable salt,
solvate, or prodrug thereof; and one or more release controlling
excipients or carriers for use in an enteric coated dosage form.
The pharmaceutical compositions may also comprise non-release
controlling excipients or carriers.
[0180] Additionally disclosed are pharmaceutical compositions in a
dosage form that has an instant releasing component and at least
one delayed releasing component, and is capable of giving a
discontinuous release of the compound in the form of at least two
consecutive pulses separated in time from 0.1 up to 24 hours. The
pharmaceutical compositions comprise a compound as disclosed
herein, including a single enantiomer, a mixture of the
(+)-enantiomer and the (-)-enantiomer, a mixture of about 90% or
more by weight of the (-)-enantiomer and about 10% or less by
weight of the (+)-enantiomer, a mixture of about 90% or more by
weight of the (+)-enantiomer and about 10% or less by weight of the
(-)-enantiomer, an individual diastereomer, or a mixture of
diastereomers thereof; or a pharmaceutically acceptable salt,
solvate, or prodrug thereof; and one or more release controlling
and non-release controlling excipients or carriers, such as those
excipients or carriers suitable for a disruptable semi-permeable
membrane and as swellable substances.
[0181] Disclosed herein also are pharmaceutical compositions in a
dosage form for oral administration to a subject, which comprise a
compound as disclosed herein, including a single enantiomer, a
mixture of the (+)-enantiomer and the (-)-enantiomer, a mixture of
about 90% or more by weight of the (-)-enantiomer and about 10% or
less by weight of the (+)-enantiomer, a mixture of about 90% or
more by weight of the (+)-enantiomer and about 10% or less by
weight of the (-)-enantiomer, an individual diastereomer, or a
mixture of diastereomers thereof; or a pharmaceutically acceptable
salt, solvate, or prodrug thereof; and one or more pharmaceutically
acceptable excipients or carriers, enclosed in an intermediate
reactive layer comprising a gastric juice-resistant polymeric
layered material partially neutralized with alkali and having
cation exchange capacity and a gastric juice-resistant outer
layer.
[0182] Disclosed herein are pharmaceutical compositions that
comprise about 0.1 to about 1000 mg, about 1 to about 800 mg, about
2 to about 400 mg, about 1 mg about 5 mg, about 10 mg, about 50 mg,
about 100 mg, about 150 mg, about 200 mg, about 300 mg, about 500
mg, about 1000 mg of one or more compounds as disclosed herein, as
film-coated tablets for oral administration. The pharmaceutical
compositions further comprise microcrystalline cellulose, lactose
monohydrate, hydroxypropyl methylcellulose, sodium starch
glycolate, magnesium stearate, dibasic sodium phosphate, ascorbyl
palmitate, edetate disodium dihydrate, monobasic sodium
phosphatestearic acid, anatase titanium dioxide, yellow iron oxide,
red iron oxide, and pharmaceutical talc.
[0183] The pharmaceutical compositions disclosed herein may be
disclosed in unit-dosage forms or multiple-dosage forms.
Unit-dosage forms, as used herein, refer to physically discrete
units suitable for administration to human and animal subjects and
packaged individually as is known in the art. Each unit-dose
contains a predetermined quantity of the active ingredient(s)
sufficient to produce the desired therapeutic effect, in
association with the required pharmaceutical carriers or
excipients. Examples of unit-dosage forms include ampoules,
syringes, and individually packaged tablets and capsules.
Unit-dosage forms may be administered in fractions or multiples
thereof. A multiple-dosage form is a plurality of identical
unit-dosage forms packaged in a single container to be administered
in segregated unit-dosage form. Examples of multiple-dosage forms
include vials, bottles of tablets or capsules, or bottles of pints
or gallons.
[0184] The compound as disclosed herein may be administered alone,
or in combination with one or more other compounds disclosed
herein, one or more other active ingredients. The pharmaceutical
compositions that comprise a compound disclosed herein may be
formulated in various dosage forms for oral, parenteral, and
topical administration. The pharmaceutical compositions may also be
formulated as a modified release dosage form, including delayed-,
extended-, prolonged-, sustained-, pulsatile-, controlled-,
accelerated- and fast-, targeted-, programmed-release, and gastric
retention dosage forms. These dosage forms can be prepared
according to conventional methods and techniques known to those
skilled in the art (see, Remington: The Science and Practice of
Pharmacy, supra; Modified-Release Drug Deliver Technology, Rathbone
et al., Eds., Drugs and the Pharmaceutical Science, Marcel Dekker,
Inc.: New York, N.Y., 2002; Vol. 126).
[0185] The pharmaceutical compositions disclosed herein may be
administered at once, or multiple times at intervals of time. It is
understood that the precise dosage and duration of treatment may
vary with the age, weight, and condition of the patient being
treated, and may be determined empirically using known testing
protocols or by extrapolation from in vivo or in vitro test or
diagnostic data. It is further understood that for any particular
individual, specific dosage regimens should be adjusted over time
according to the individual need and the professional judgment of
the person administering or supervising the administration of the
formulations.
[0186] In the case wherein the patient's condition does not
improve, upon the doctor's discretion the administration of the
compounds may be administered chronically, that is, for an extended
period of time, including throughout the duration of the patient's
life in order to ameliorate or otherwise control or limit the
symptoms of the patient's disease, disorder or condition.
[0187] In the case wherein the patient's status does improve, upon
the doctor's discretion the administration of the compounds may be
given continuously or temporarily suspended for a certain length of
time (i.e., a "drug holiday").
[0188] Once improvement of the patient's conditions has occurred, a
maintenance dose is administered if necessary. Subsequently, the
dosage or the frequency of administration, or both, can be reduced,
as a function of the symptoms, to a level at which the improved
disease, disorder or condition is retained. Patients can, however,
require intermittent treatment on a long-term basis upon any
recurrence of symptoms.
A. Oral Administration
[0189] The pharmaceutical compositions disclosed herein may be
formulated in solid, semisolid, or liquid dosage forms for oral
administration. As used herein, oral administration also includes
buccal, lingual, and sublingual administration. Suitable oral
dosage forms include, but are not limited to, tablets, capsules,
pills, troches, lozenges, pastilles, cachets, pellets, medicated
chewing gum, granules, bulk powders, effervescent or
non-effervescent powders or granules, solutions, emulsions,
suspensions, solutions, wafers, sprinkles, elixirs, and syrups. In
addition to the active ingredient(s), the pharmaceutical
compositions may contain one or more pharmaceutically acceptable
carriers or excipients, including, but not limited to, binders,
fillers, diluents, disintegrants, wetting agents, lubricants,
glidants, coloring agents, dye-migration inhibitors, sweetening
agents, and flavoring agents.
[0190] Binders or granulators impart cohesiveness to a tablet to
ensure the tablet remaining intact after compression. Suitable
binders or granulators include, but are not limited to, starches,
such as corn starch, potato starch, and pre-gelatinized starch
(e.g., STARCH 1500); gelatin; sugars, such as sucrose, glucose,
dextrose, molasses, and lactose; natural and synthetic gums, such
as acacia, alginic acid, alginates, extract of Irish moss, Panwar
gum, ghatti gum, mucilage of isabgol husks, carboxymethylcellulose,
methylcellulose, polyvinylpyrrolidone (PVP), Veegum, larch
arabogalactan, powdered tragacanth, and guar gum; celluloses, such
as ethyl cellulose, cellulose acetate, carboxymethyl cellulose
calcium, sodium carboxymethyl cellulose, methyl cellulose,
hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC),
hydroxypropyl methyl cellulose (HPMC); microcrystalline celluloses,
such as AVICEL-PH-101, AVICEL-PH-103, AVICEL RC-581, AVICEL-PH-105
(FMC Corp., Marcus Hook, Pa.); and mixtures thereof. Suitable
fillers include, but are not limited to, talc, calcium carbonate,
microcrystalline cellulose, powdered cellulose, dextrates, kaolin,
mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch,
and mixtures thereof. The binder or filler may be present from
about 50 to about 99% by weight in the pharmaceutical compositions
disclosed herein.
[0191] Suitable diluents include, but are not limited to, dicalcium
phosphate, calcium sulfate, lactose, sorbitol, sucrose, inositol,
cellulose, kaolin, mannitol, sodium chloride, dry starch, and
powdered sugar. Certain diluents, such as mannitol, lactose,
sorbitol, sucrose, and inositol, when present in sufficient
quantity, can impart properties to some compressed tablets that
permit disintegration in the mouth by chewing. Such compressed
tablets can be used as chewable tablets.
[0192] Suitable disintegrants include, but are not limited to,
agar; bentonite; celluloses, such as methylcellulose and
carboxymethylcellulose; wood products; natural sponge;
cation-exchange resins; alginic acid; gums, such as guar gum and
Veegum HV; citrus pulp; cross-linked celluloses, such as
croscarmellose; cross-linked polymers, such as crospovidone;
cross-linked starches; calcium carbonate; microcrystalline
cellulose, such as sodium starch glycolate; polacrilin potassium;
starches, such as corn starch, potato starch, tapioca starch, and
pre-gelatinized starch; clays; aligns; and mixtures thereof. The
amount of disintegrant in the pharmaceutical compositions disclosed
herein varies upon the type of formulation, and is readily
discernible to those of ordinary skill in the art. The
pharmaceutical compositions disclosed herein may contain from about
0.5 to about 15% or from about 1 to about 5% by weight of a
disintegrant.
[0193] Suitable lubricants include, but are not limited to, calcium
stearate; magnesium stearate; mineral oil; light mineral oil;
glycerin; sorbitol; mannitol; glycols, such as glycerol behenate
and polyethylene glycol (PEG); stearic acid; sodium lauryl sulfate;
talc; hydrogenated vegetable oil, including peanut oil, cottonseed
oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean
oil; zinc stearate; ethyl oleate; ethyl laureate; agar; starch;
lycopodium; silica or silica gels, such as AEROSIL.RTM. 200 (W.R.
Grace Co., Baltimore, Md.) and CAB-O-SIL.RTM. (Cabot Co. of Boston,
Mass.); and mixtures thereof. The pharmaceutical compositions
disclosed herein may contain about 0.1 to about 5% by weight of a
lubricant.
[0194] Suitable glidants include colloidal silicon dioxide,
CAB-O-SIL.RTM. (Cabot Co. of Boston, Mass.), and asbestos-free
talc. Coloring agents include any of the approved, certified, water
soluble FD&C dyes, and water insoluble FD&C dyes suspended
on alumina hydrate, and color lakes and mixtures thereof. A color
lake is the combination by adsorption of a water-soluble dye to a
hydrous oxide of a heavy metal, resulting in an insoluble form of
the dye. Flavoring agents include natural flavors extracted from
plants, such as fruits, and synthetic blends of compounds which
produce a pleasant taste sensation, such as peppermint and methyl
salicylate. Sweetening agents include sucrose, lactose, mannitol,
syrups, glycerin, and artificial sweeteners, such as saccharin and
aspartame. Suitable emulsifying agents include gelatin, acacia,
tragacanth, bentonite, and surfactants, such as polyoxyethylene
sorbitan monooleate (TWEEN.RTM. 20), polyoxyethylene sorbitan
monooleate 80 (TWEEN.RTM. 80), and triethanolamine oleate.
Suspending and dispersing agents include sodium
carboxymethylcellulose, pectin, tragacanth, Veegum, acacia, sodium
carbomethylcellulose, hydroxypropyl methylcellulose, and
polyvinylpyrolidone. Preservatives include glycerin, methyl and
propylparaben, benzoic add, sodium benzoate and alcohol. Wetting
agents include propylene glycol monostearate, sorbitan monooleate,
diethylene glycol monolaurate, and polyoxyethylene lauryl ether.
Solvents include glycerin, sorbitol, ethyl alcohol, and syrup.
Examples of non-aqueous liquids utilized in emulsions include
mineral oil and cottonseed oil. Organic acids include citric and
tartaric acid. Sources of carbon dioxide include sodium bicarbonate
and sodium carbonate.
[0195] It should be understood that many carriers and excipients
may serve several functions, even within the same formulation.
[0196] The pharmaceutical compositions disclosed herein may be
formulated as compressed tablets, tablet triturates, chewable
lozenges, rapidly dissolving tablets, multiple compressed tablets,
or enteric-coating tablets, sugar-coated, or film-coated tablets.
Enteric-coated tablets are compressed tablets coated with
substances that resist the action of stomach acid but dissolve or
disintegrate in the intestine, thus protecting the active
ingredients from the acidic environment of the stomach.
Enteric-coatings include, but are not limited to, fatty acids,
fats, phenylsalicylate, waxes, shellac, ammoniated shellac, and
cellulose acetate phthalates. Sugar-coated tablets are compressed
tablets surrounded by a sugar coating, which may be beneficial in
covering up objectionable tastes or odors and in protecting the
tablets from oxidation. Film-coated tablets are compressed tablets
that are covered with a thin layer or film of a water-soluble
material. Film coatings include, but are not limited to,
hydroxyethylcellulose, sodium carboxymethylcellulose, polyethylene
glycol 4000, and cellulose acetate phthalate. Film coating imparts
the same general characteristics as sugar coating. Multiple
compressed tablets are compressed tablets made by more than one
compression cycle, including layered tablets, and press-coated or
dry-coated tablets.
[0197] The tablet dosage forms may be prepared from the active
ingredient in powdered, crystalline, or granular forms, alone or in
combination with one or more carriers or excipients described
herein, including binders, disintegrants, controlled-release
polymers, lubricants, diluents, and/or colorants. Flavoring and
sweetening agents are especially useful in the formation of
chewable tablets and lozenges.
[0198] The pharmaceutical compositions disclosed herein may be
formulated as soft or hard capsules, which can be made from
gelatin, methylcellulose, starch, or calcium alginate. The hard
gelatin capsule, also known as the dry-filled capsule (DFC),
consists of two sections, one slipping over the other, thus
completely enclosing the active ingredient. The soft elastic
capsule (SEC) is a soft, globular shell, such as a gelatin shell,
which is plasticized by the addition of glycerin, sorbitol, or a
similar polyol. The soft gelatin shells may contain a preservative
to prevent the growth of microorganisms. Suitable preservatives are
those as described herein, including methyl- and propyl-parabens,
and sorbic acid. The liquid, semisolid, and solid dosage forms
disclosed herein may be encapsulated in a capsule. Suitable liquid
and semisolid dosage forms include solutions and suspensions in
propylene carbonate, vegetable oils, or triglycerides. Capsules
containing such solutions can be prepared as described in U.S. Pat.
Nos. 4,328,245; 4,409,239; and 4,410,545. The capsules may also be
coated as known by those of skill in the art in order to modify or
sustain dissolution of the active ingredient.
[0199] The pharmaceutical compositions disclosed herein may be
formulated in liquid and semisolid dosage forms, including
emulsions, solutions, suspensions, elixirs, and syrups. An emulsion
is a two-phase system, in which one liquid is dispersed in the form
of small globules throughout another liquid, which can be
oil-in-water or water-in-oil. Emulsions may include a
pharmaceutically acceptable non-aqueous liquids or solvent,
emulsifying agent, and preservative. Suspensions may include a
pharmaceutically acceptable suspending agent and preservative.
Aqueous alcoholic solutions may include a pharmaceutically
acceptable acetal, such as a di(lower alkyl) acetal of a lower
alkyl aldehyde (the term "lower" means an alkyl having between 1
and 6 carbon atoms), e.g., acetaldehyde diethyl acetal; and a
water-miscible solvent having one or more hydroxyl groups, such as
propylene glycol and ethanol. Elixirs are clear, sweetened, and
hydroalcoholic solutions. Syrups are concentrated aqueous solutions
of a sugar, for example, sucrose, and may also contain a
preservative. For a liquid dosage form, for example, a solution in
a polyethylene glycol may be diluted with a sufficient quantity of
a pharmaceutically acceptable liquid carrier, e.g., water, to be
measured conveniently for administration.
[0200] Other useful liquid and semisolid dosage forms include, but
are not limited to, those containing the active ingredient(s)
disclosed herein, and a dialkylated mono- or poly-alkylene glycol,
including, 1,2-dimethoxymethane, diglyme, triglyme, tetraglyme,
polyethylene glycol-350-dimethyl ether, polyethylene
glycol-550-dimethyl ether, polyethylene glycol-750-dimethyl ether,
wherein 350, 550, and 750 refer to the approximate average
molecular weight of the polyethylene glycol. These formulations may
further comprise one or more antioxidants, such as butylated
hydroxytoluene (BHT), butylated hydroxyanisole (BHA), propyl
gallate, vitamin E, hydroquinone, hydroxycoumarins, ethanolamine,
lecithin, cephalin, ascorbic acid, malic acid, sorbitol, phosphoric
acid, bisulfite, sodium metabisulfite, thiodipropionic acid and its
esters, and dithiocarbamates.
[0201] The pharmaceutical compositions disclosed herein for oral
administration may be also formulated in the forms of liposomes,
micelles, microspheres, or nanosystems. Micellar dosage forms can
be prepared as described in U.S. Pat. No. 6,350,458.
[0202] The pharmaceutical compositions disclosed herein may be
formulated as non-effervescent or effervescent, granules and
powders, to be reconstituted into a liquid dosage form.
Pharmaceutically acceptable carriers and excipients used in the
non-effervescent granules or powders may include diluents,
sweeteners, and wetting agents. Pharmaceutically acceptable
carriers and excipients used in the effervescent granules or
powders may include organic acids and a source of carbon
dioxide.
[0203] Coloring and flavoring agents can be used in all of the
above dosage forms.
[0204] The pharmaceutical compositions disclosed herein may be
formulated as immediate or modified release dosage forms, including
delayed-, sustained, pulsed-, controlled, targeted-, and
programmed-release forms.
[0205] The pharmaceutical compositions disclosed herein may be
co-formulated with other active ingredients which do not impair the
desired therapeutic action, or with substances that supplement the
desired action, such as drotrecogin-.alpha., and
hydrocortisone.
B. Parenteral Administration
[0206] The pharmaceutical compositions disclosed herein may be
administered parenterally by injection, infusion, or implantation,
for local or systemic administration. Parenteral administration, as
used herein, include intravenous, intraarterial, intraperitoneal,
intrathecal, intraventricular, intraurethral, intrasternal,
intracranial, intramuscular, intrasynovial, and subcutaneous
administration.
[0207] The pharmaceutical compositions disclosed herein may be
formulated in any dosage forms that are suitable for parenteral
administration, including solutions, suspensions, emulsions,
micelles, liposomes, microspheres, nanosystems, and solid forms
suitable for solutions or suspensions in liquid prior to injection.
Such dosage forms can be prepared according to conventional methods
known to those skilled in the art of pharmaceutical science (see,
Remington: The Science and Practice of Pharmacy, supra).
[0208] The pharmaceutical compositions intended for parenteral
administration may include one or more pharmaceutically acceptable
carriers and excipients, including, but not limited to, aqueous
vehicles, water-miscible vehicles, non-aqueous vehicles,
antimicrobial agents or preservatives against the growth of
microorganisms, stabilizers, solubility enhancers, isotonic agents,
buffering agents, antioxidants, local anesthetics, suspending and
dispersing agents, wetting or emulsifying agents, complexing
agents, sequestering or chelating agents, cryoprotectants,
lyoprotectants, thickening agents, pH adjusting agents, and inert
gases.
[0209] Suitable aqueous vehicles include, but are not limited to,
water, saline, physiological saline or phosphate buffered saline
(PBS), sodium chloride injection, Ringers injection, isotonic
dextrose injection, sterile water injection, dextrose and lactated
Ringers injection. Non-aqueous vehicles include, but are not
limited to, fixed oils of vegetable origin, castor oil, corn oil,
cottonseed oil, olive oil, peanut oil, peppermint oil, safflower
oil, sesame oil, soybean oil, hydrogenated vegetable oils,
hydrogenated soybean oil, and medium-chain triglycerides of coconut
oil, and palm seed oil. Water-miscible vehicles include, but are
not limited to, ethanol, 1,3-butanediol, liquid polyethylene glycol
(e.g., polyethylene glycol 300 and polyethylene glycol 400),
propylene glycol, glycerin, N-methyl-2-pyrrolidone,
dimethylacetamide, and dimethylsulfoxide.
[0210] Suitable antimicrobial agents or preservatives include, but
are not limited to, phenols, cresols, mercurials, benzyl alcohol,
chlorobutanol, methyl and propyl p-hydroxybenzates, thimerosal,
benzalkonium chloride, benzethonium chloride, methyl- and
propyl-parabens, and sorbic acid. Suitable isotonic agents include,
but are not limited to, sodium chloride, glycerin, and dextrose.
Suitable buffering agents include, but are not limited to,
phosphate and citrate. Suitable antioxidants are those as described
herein, including bisulfate and sodium metabisulfite. Suitable
local anesthetics include, but are not limited to, procaine
hydrochloride. Suitable suspending and dispersing agents are those
as described herein, including sodium carboxymethylcelluose,
hydroxypropyl methylcellulose, and polyvinylpyrrolidone. Suitable
emulsifying agents include those described herein, including
polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan
monooleate 80, and triethanolamine oleate. Suitable sequestering or
chelating agents include, but are not limited to EDTA. Suitable pH
adjusting agents include, but are not limited to, sodium hydroxide,
hydrochloric acid, citric acid, and lactic acid. Suitable
complexing agents include, but are not limited to, cyclodextrins,
including .alpha.-cyclodextrin, .beta.-cyclodextrin,
hydroxypropyl-.beta.-cyclodextrin,
sulfobutylether-.beta.-cyclodextrin, and sulfobutylether
7-.beta.-cyclodextrin (CAPTISOL.RTM., CyDex, Lenexa, Kans.).
[0211] The pharmaceutical compositions disclosed herein may be
formulated for single or multiple dosage administration. The single
dosage formulations are packaged in an ampule, a vial, or a
syringe. The multiple dosage parenteral formulations must contain
an antimicrobial agent at bacteriostatic or fungistatic
concentrations. All parenteral formulations must be sterile, as
known and practiced in the art.
[0212] In one embodiment, the pharmaceutical compositions are
formulated as ready-to-use sterile solutions. In another
embodiment, the pharmaceutical compositions are formulated as
sterile dry soluble products, including lyophilized powders and
hypodermic tablets, to be reconstituted with a vehicle prior to
use. In yet another embodiment, the pharmaceutical compositions are
formulated as ready-to-use sterile suspensions. In yet another
embodiment, the pharmaceutical compositions are formulated as
sterile dry insoluble products to be reconstituted with a vehicle
prior to use. In still another embodiment, the pharmaceutical
compositions are formulated as ready-to-use sterile emulsions.
[0213] The pharmaceutical compositions disclosed herein may be
formulated as immediate or modified release dosage forms, including
delayed-, sustained, pulsed-, controlled, targeted-, and
programmed-release forms.
[0214] The pharmaceutical compositions may be formulated as a
suspension, solid, semi-solid, or thixotropic liquid, for
administration as an implanted depot. In one embodiment, the
pharmaceutical compositions disclosed herein are dispersed in a
solid inner matrix, which is surrounded by an outer polymeric
membrane that is insoluble in body fluids but allows the active
ingredient in the pharmaceutical compositions diffuse through.
[0215] Suitable inner matrixes include polymethylmethacrylate,
polybutylmethacrylate, plasticized or unplasticized
polyvinylchloride, plasticized nylon, plasticized
polyethyleneterephthalate, natural rubber, polyisoprene,
polyisobutylene, polybutadiene, polyethylene, ethylene-vinylacetate
copolymers, silicone rubbers, polydimethylsiloxanes, silicone
carbonate copolymers, hydrophilic polymers, such as hydrogels of
esters of acrylic and methacrylic acid, collagen, cross-linked
polyvinylalcohol, and cross-linked partially hydrolyzed polyvinyl
acetate.
[0216] Suitable outer polymeric membranes include polyethylene,
polypropylene, ethylene/propylene copolymers, ethylene/ethyl
acrylate copolymers, ethylene/vinylacetate copolymers, silicone
rubbers, polydimethyl siloxanes, neoprene rubber, chlorinated
polyethylene, polyvinylchloride, vinylchloride copolymers with
vinyl acetate, vinylidene chloride, ethylene and propylene, ionomer
polyethylene terephthalate, butyl rubber epichlorohydrin rubbers,
ethylene/vinyl alcohol copolymer, ethylene/vinyl acetate/vinyl
alcohol terpolymer, and ethylene/vinyloxyethanol copolymer.
C. Topical Administration
[0217] The pharmaceutical compositions disclosed herein may be
administered topically to the skin, orifices, or mucosa. The
topical administration, as used herein, include (intra)dermal,
conjuctival, intracorneal, intraocular, ophthalmic, auricular,
transdermal, nasal, vaginal, uretheral, respiratory, and rectal
administration.
[0218] The pharmaceutical compositions disclosed herein may be
formulated in any dosage forms that are suitable for topical
administration for local or systemic effect, including emulsions,
solutions, suspensions, creams, gels, hydrogels, ointments, dusting
powders, dressings, elixirs, lotions, suspensions, tinctures,
pastes, foams, films, aerosols, irrigations, sprays, suppositories,
bandages, dermal patches. The topical formulation of the
pharmaceutical compositions disclosed herein may also comprise
liposomes, micelles, microspheres, nanosystems, and mixtures
thereof.
[0219] Pharmaceutically acceptable carriers and excipients suitable
for use in the topical formulations disclosed herein include, but
are not limited to, aqueous vehicles, water-miscible vehicles,
non-aqueous vehicles, antimicrobial agents or preservatives against
the growth of microorganisms, stabilizers, solubility enhancers,
isotonic agents, buffering agents, antioxidants, local anesthetics,
suspending and dispersing agents, wetting or emulsifying agents,
complexing agents, sequestering or chelating agents, penetration
enhancers, cryopretectants, lyoprotectants, thickening agents, and
inert gases.
[0220] The pharmaceutical compositions may also be administered
topically by electroporation, iontophoresis, phonophoresis,
sonophoresis and microneedle or needle-free injection, such as
POWDERJECT.TM. (Chiron Corp., Emeryville, Calif.), and BIOJECT.TM.
(Bioject Medical Technologies Inc., Tualatin, Oreg.).
[0221] The pharmaceutical compositions disclosed herein may be
formulated in the forms of ointments, creams, and gels. Suitable
ointment vehicles include oleaginous or hydrocarbon vehicles,
including such as lard, benzoinated lard, olive oil, cottonseed
oil, and other oils, white petrolatum; emulsifiable or absorption
vehicles, such as hydrophilic petrolatum, hydroxystearin sulfate,
and anhydrous lanolin; water-removable vehicles, such as
hydrophilic ointment; water-soluble ointment vehicles, including
polyethylene glycols of varying molecular weight; emulsion
vehicles, either water-in-oil (W/O) emulsions or oil-in-water (O/W)
emulsions, including cetyl alcohol, glyceryl monostearate, lanolin,
and stearic acid (see, Remington: The Science and Practice of
Pharmacy, supra). These vehicles are emollient but generally
require addition of antioxidants and preservatives.
[0222] Suitable cream base can be oil-in-water or water-in-oil.
Cream vehicles may be water-washable, and contain an oil phase, an
emulsifier, and an aqueous phase. The oil phase is also called the
"internal" phase, which is generally comprised of petrolatum and a
fatty alcohol such as cetyl or stearyl alcohol. The aqueous phase
usually, although not necessarily, exceeds the oil phase in volume,
and generally contains a humectant. The emulsifier in a cream
formulation may be a nonionic, anionic, cationic, or amphoteric
surfactant.
[0223] Gels are semisolid, suspension-type systems. Single-phase
gels contain organic macromolecules distributed substantially
uniformly throughout the liquid carrier. Suitable gelling agents
include crosslinked acrylic acid polymers, such as carbomers,
carboxypolyalkylenes, Carbopol.RTM.; hydrophilic polymers, such as
polyethylene oxides, polyoxyethylene-polyoxypropylene copolymers,
and polyvinylalcohol; cellulosic polymers, such as hydroxypropyl
cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose,
hydroxypropyl methylcellulose phthalate, and methylcellulose; gums,
such as tragacanth and xanthan gum; sodium alginate; and gelatin.
In order to prepare a uniform gel, dispersing agents such as
alcohol or glycerin can be added, or the gelling agent can be
dispersed by trituration, mechanical mixing, and/or stirring.
[0224] The pharmaceutical compositions disclosed herein may be
administered rectally, urethrally, vaginally, or perivaginally in
the forms of suppositories, pessaries, bougies, poultices or
cataplasm, pastes, powders, dressings, creams, plasters,
contraceptives, ointments, solutions, emulsions, suspensions,
tampons, gels, foams, sprays, or enemas. These dosage forms can be
manufactured using conventional processes as described in
Remington: The Science and Practice of Pharmacy, supra.
[0225] Rectal, urethral, and vaginal suppositories are solid bodies
for insertion into body orifices, which are solid at ordinary
temperatures but melt or soften at body temperature to release the
active ingredient(s) inside the orifices. Pharmaceutically
acceptable carriers utilized in rectal and vaginal suppositories
include bases or vehicles, such as stiffening agents, which produce
a melting point in the proximity of body temperature, when
formulated with the pharmaceutical compositions disclosed herein;
and antioxidants as described herein, including bisulfite and
sodium metabisulfite. Suitable vehicles include, but are not
limited to, cocoa butter (theobroma oil), glycerin-gelatin,
carbowax (polyoxyethylene glycol), spermaceti, paraffin, white and
yellow wax, and appropriate mixtures of mono-, di- and
triglycerides of fatty acids, hydrogels, such as polyvinyl alcohol,
hydroxyethyl methacrylate, polyacrylic acid; glycerinated gelatin.
Combinations of the various vehicles may be used. Rectal and
vaginal suppositories may be prepared by the compressed method or
molding. The typical weight of a rectal and vaginal suppository is
about 2 to about 3 g.
[0226] The pharmaceutical compositions disclosed herein may be
administered ophthalmically in the forms of solutions, suspensions,
ointments, emulsions, gel-forming solutions, powders for solutions,
gels, ocular inserts, and implants.
[0227] The pharmaceutical compositions disclosed herein may be
administered intranasally or by inhalation to the respiratory
tract. The pharmaceutical compositions may be formulated in the
form of an aerosol or solution for delivery using a pressurized
container, pump, spray, atomizer, such as an atomizer using
electrohydrodynamics to produce a fine mist, or nebulizer, alone or
in combination with a suitable propellant, such as
1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane. The
pharmaceutical compositions may also be formulated as a dry powder
for insufflation, alone or in combination with an inert carrier
such as lactose or phospholipids; and nasal drops. For intranasal
use, the powder may comprise a bioadhesive agent, including
chitosan or cyclodextrin.
[0228] Solutions or suspensions for use in a pressurized container,
pump, spray, atomizer, or nebulizer may be formulated to contain
ethanol, aqueous ethanol, or a suitable alternative agent for
dispersing, solubilizing, or extending release of the active
ingredient disclosed herein, a propellant as solvent; and/or a
surfactant, such as sorbitan trioleate, oleic acid, or an
oligolactic acid.
[0229] The pharmaceutical compositions disclosed herein may be
micronized to a size suitable for delivery by inhalation, such as
about 50 micrometers or less, or about 10 micrometers or less.
Particles of such sizes may be prepared using a comminuting method
known to those skilled in the art, such as spiral jet milling,
fluid bed jet milling, supercritical fluid processing to form
nanoparticles, high pressure homogenization, or spray drying.
[0230] Capsules, blisters and cartridges for use in an inhaler or
insufflator may be formulated to contain a powder mix of the
pharmaceutical compositions disclosed herein; a suitable powder
base, such as lactose or starch; and a performance modifier, such
as l-leucine, mannitol, or magnesium stearate. The lactose may be
anhydrous or in the form of the monohydrate. Other suitable
excipients or carriers include dextran, glucose, maltose, sorbitol,
xylitol, fructose, sucrose, and trehalose. The pharmaceutical
compositions disclosed herein for inhaled/intranasal administration
may further comprise a suitable flavor, such as menthol and
levomenthol, or sweeteners, such as saccharin or saccharin
sodium.
[0231] The pharmaceutical compositions disclosed herein for topical
administration may be formulated to be immediate release or
modified release, including delayed-, sustained-, pulsed-,
controlled-, targeted, and programmed release.
D. Modified Release
[0232] The pharmaceutical compositions disclosed herein may be
formulated as a modified release dosage form. As used herein, the
term "modified release" refers to a dosage form in which the rate
or place of release of the active ingredient(s) is different from
that of an immediate dosage form when administered by the same
route. Modified release dosage forms include delayed-, extended-,
prolonged-, sustained-, pulsatile-, controlled-, accelerated- and
fast-, targeted-, programmed-release, and gastric retention dosage
forms. The pharmaceutical compositions in modified release dosage
forms can be prepared using a variety of modified release devices
and methods known to those skilled in the art, including, but not
limited to, matrix controlled release devices, osmotic controlled
release devices, multiparticulate controlled release devices,
ion-exchange resins, enteric coatings, multilayered coatings,
microspheres, liposomes, and combinations thereof. The release rate
of the active ingredient(s) can also be modified by varying the
particle sizes and polymorphorism of the active ingredient(s).
[0233] Examples of modified release include, but are not limited
to, those described in U.S. Pat. Nos. 3,845,770; 3,916,899;
3,536,809; 3,598,123; 4,008,719; 5,674,533; 5,059,595; 5,591,767;
5,120,548; 5,073,543; 5,639,476; 5,354,556; 5,639,480; 5,733,566;
5,739,108; 5,891,474; 5,922,356; 5,972,891; 5,980,945; 5,993,855;
6,045,830; 6,087,324; 6,113,943; 6,197,350; 6,248,363; 6,264,970;
6,267,981; 6,376,461; 6,419,961; 6,589,548; 6,613,358; and
6,699,500.
1. Matrix Controlled Release Devices
[0234] The pharmaceutical compositions disclosed herein in a
modified release dosage form may be fabricated using a matrix
controlled release device known to those skilled in the art (see,
Takada et al in "Encyclopedia of Controlled Drug Delivery," Vol. 2,
Mathiowitz ed., Wiley, 1999).
[0235] In one embodiment, the pharmaceutical compositions disclosed
herein in a modified release dosage form is formulated using an
erodible matrix device, which is water-swellable, erodible, or
soluble polymers, including synthetic polymers, and naturally
occurring polymers and derivatives, such as polysaccharides and
proteins.
[0236] Materials useful in forming an erodible matrix include, but
are not limited to, chitin, chitosan, dextran, and pullulan; gum
agar, gum arabic, gum karaya, locust bean gum, gum tragacanth,
carrageenans, gum ghatti, guar gum, xanthan gum, and scleroglucan;
starches, such as dextrin and maltodextrin; hydrophilic colloids,
such as pectin; phosphatides, such as lecithin; alginates;
propylene glycol alginate; gelatin; collagen; and cellulosics, such
as ethyl cellulose (EC), methylethyl cellulose (MEC), carboxymethyl
cellulose (CMC), CMEC, hydroxyethyl cellulose (HEC), hydroxypropyl
cellulose (HPC), cellulose acetate (CA), cellulose propionate (CP),
cellulose butyrate (CB), cellulose acetate butyrate (CAB), CAP,
CAT, hydroxypropyl methyl cellulose (HPMC), HPMCP, HPMCAS,
hydroxypropyl methyl cellulose acetate trimellitate (HPMCAT), and
ethylhydroxy ethylcellulose (EHEC); polyvinyl pyrrolidone;
polyvinyl alcohol; polyvinyl acetate; glycerol fatty acid esters;
polyacrylamide; polyacrylic acid; copolymers of ethacrylic acid or
methacrylic acid (EUDRAGIT.RTM., Rohm America, Inc., Piscataway,
N.J.); poly(2-hydroxyethyl-methacrylate); polylactides; copolymers
of L-glutamic acid and ethyl-L-glutamate; degradable lactic
acid-glycolic acid copolymers; poly-D-(-)-3-hydroxybutyric acid;
and other acrylic acid derivatives, such as homopolymers and
copolymers of butylmethacrylate, methylmethacrylate,
ethylmethacrylate, ethylacrylate,
(2-dimethylaminoethyl)methacrylate, and
(trimethylaminoethyl)methacrylate chloride.
[0237] In further embodiments, the pharmaceutical compositions are
formulated with a non-erodible matrix device. The active
ingredient(s) is dissolved or dispersed in an inert matrix and is
released primarily by diffusion through the inert matrix once
administered. Materials suitable for use as a non-erodible matrix
device included, but are not limited to, insoluble plastics, such
as polyethylene, polypropylene, polyisoprene, polyisobutylene,
polybutadiene, polymethylmethacrylate, polybutylmethacrylate,
chlorinated polyethylene, polyvinylchloride, methyl acrylate-methyl
methacrylate copolymers, ethylene-vinylacetate copolymers,
ethylene/propylene copolymers, ethylene/ethyl acrylate copolymers,
vinylchloride copolymers with vinyl acetate, vinylidene chloride,
ethylene and propylene, ionomer polyethylene terephthalate, butyl
rubber epichlorohydrin rubbers, ethylene/vinyl alcohol copolymer,
ethylene/vinyl acetate/vinyl alcohol terpolymer, and
ethylene/vinyloxyethanol copolymer, polyvinyl chloride, plasticized
nylon, plasticized polyethyleneterephthalate, natural rubber,
silicone rubbers, polydimethylsiloxanes, silicone carbonate
copolymers; hydrophilic polymers, such as ethyl cellulose,
cellulose acetate, crospovidone, and cross-linked partially
hydrolyzed polyvinyl acetate; and fatty compounds, such as carnauba
wax, microcrystalline wax, and triglycerides.
[0238] In a matrix controlled release system, the desired release
kinetics can be controlled, for example, via the polymer type
employed, the polymer viscosity, the particle sizes of the polymer
and/or the active ingredient(s), the ratio of the active
ingredient(s) versus the polymer, and other excipients or carriers
in the compositions.
[0239] The pharmaceutical compositions disclosed herein in a
modified release dosage form may be prepared by methods known to
those skilled in the art, including direct compression, dry or wet
granulation followed by compression, melt-granulation followed by
compression.
2. Osmotic Controlled Release Devices
[0240] The pharmaceutical compositions disclosed herein in a
modified release dosage form may be fabricated using an osmotic
controlled release device, including one-chamber system,
two-chamber system, asymmetric membrane technology (AMT), and
extruding core system (ECS). In general, such devices have at least
two components: (a) the core which contains the active
ingredient(s) and (b) a semipermeable membrane with at least one
delivery port, which encapsulates the core. The semipermeable
membrane controls the influx of water to the core from an aqueous
environment of use so as to cause drug release by extrusion through
the delivery port(s).
[0241] In addition to the active ingredient(s), the core of the
osmotic device optionally includes an osmotic agent, which creates
a driving force for transport of water from the environment of use
into the core of the device. One class of osmotic agents
water-swellable hydrophilic polymers, which are also referred to as
"osmopolymers" and "hydrogels," including, but not limited to,
hydrophilic vinyl and acrylic polymers, polysaccharides such as
calcium alginate, polyethylene oxide (PEO), polyethylene glycol
(PEG), polypropylene glycol (PPG), poly(2-hydroxyethyl
methacrylate), poly(acrylic) acid, poly(methacrylic) acid,
polyvinylpyrrolidone (PVP), crosslinked PVP, polyvinyl alcohol
(PVA), PVA/PVP copolymers, PVA/PVP copolymers with hydrophobic
monomers such as methyl methacrylate and vinyl acetate, hydrophilic
polyurethanes containing large PEO blocks, sodium croscarmellose,
carrageenan, hydroxyethyl cellulose (HEC), hydroxypropyl cellulose
(HPC), hydroxypropyl methyl cellulose (HPMC), carboxymethyl
cellulose (CMC) and carboxyethyl, cellulose (CEC), sodium alginate,
polycarbophil, gelatin, xanthan gum, and sodium starch
glycolate.
[0242] The other class of osmotic agents are osmogens, which are
capable of imbibing water to affect an osmotic pressure gradient
across the barrier of the surrounding coating. Suitable osmogens
include, but are not limited to, inorganic salts, such as magnesium
sulfate, magnesium chloride, calcium chloride, sodium chloride,
lithium chloride, potassium sulfate, potassium phosphates, sodium
carbonate, sodium sulfite, lithium sulfate, potassium chloride, and
sodium sulfate; sugars, such as dextrose, fructose, glucose,
inositol, lactose, maltose, mannitol, raffinose, sorbitol, sucrose,
trehalose, and xylitol; organic acids, such as ascorbic acid,
benzoic acid, fumaric acid, citric acid, maleic acid, sebacic acid,
sorbic acid, adipic acid, edetic acid, glutamic acid,
p-toluenesulfonic acid, succinic acid, and tartaric acid; urea; and
mixtures thereof.
[0243] Osmotic agents of different dissolution rates may be
employed to influence how rapidly the active ingredient(s) is
initially delivered from the dosage form. For example, amorphous
sugars, such as Mannogeme EZ (SPI Pharma, Lewes, Del.) can be used
to provide faster delivery during the first couple of hours to
promptly produce the desired therapeutic effect, and gradually and
continually release of the remaining amount to maintain the desired
level of therapeutic or prophylactic effect over an extended period
of time. In this case, the active ingredient(s) is released at such
a rate to replace the amount of the active ingredient metabolized
and excreted.
[0244] The core may also include a wide variety of other excipients
and carriers as described herein to enhance the performance of the
dosage form or to promote stability or processing.
[0245] Materials useful in forming the semipermeable membrane
include various grades of acrylics, vinyls, ethers, polyamides,
polyesters, and cellulosic derivatives that are water-permeable and
water-insoluble at physiologically relevant pHs, or are susceptible
to being rendered water-insoluble by chemical alteration, such as
crosslinking. Examples of suitable polymers useful in forming the
coating, include plasticized, unplasticized, and reinforced
cellulose acetate (CA), cellulose diacetate, cellulose triacetate,
CA propionate, cellulose nitrate, cellulose acetate butyrate (CAB),
CA ethyl carbamate, CAP, CA methyl carbamate, CA succinate,
cellulose acetate trimellitate (CAT), CA dimethylaminoacetate, CA
ethyl carbonate, CA chloroacetate, CA ethyl oxalate, CA methyl
sulfonate, CA butyl sulfonate, CA p-toluene sulfonate, agar
acetate, amylose triacetate, beta glucan acetate, beta glucan
triacetate, acetaldehyde dimethyl acetate, triacetate of locust
bean gum, hydroxlated ethylene-vinylacetate, EC, PEG, PPG, PEG/PPG
copolymers, PVP, HEC, HPC, CMC, CMEC, HPMC, HPMCP, HPMCAS, HPMCAT,
poly(acrylic) acids and esters and poly-(methacrylic) acids and
esters and copolymers thereof, starch, dextran, dextrin, chitosan,
collagen, gelatin, polyalkenes, polyethers, polysulfones,
polyethersulfones, polystyrenes, polyvinyl halides, polyvinyl
esters and ethers, natural waxes, and synthetic waxes.
[0246] Semipermeable membrane may also be a hydrophobic microporous
membrane, wherein the pores are substantially filled with a gas and
are not wetted by the aqueous medium but are permeable to water
vapor, as disclosed in U.S. Pat. No. 5,798,119. Such hydrophobic
but water-vapor permeable membrane are typically composed of
hydrophobic polymers such as polyalkenes, polyethylene,
polypropylene, polytetrafluoroethylene, polyacrylic acid
derivatives, polyethers, polysulfones, polyethersulfones,
polystyrenes, polyvinyl halides, polyvinylidene fluoride, polyvinyl
esters and ethers, natural waxes, and synthetic waxes.
[0247] The delivery port(s) on the semipermeable membrane may be
formed post-coating by mechanical or laser drilling. Delivery
port(s) may also be formed in situ by erosion of a plug of
water-soluble material or by rupture of a thinner portion of the
membrane over an indentation in the core. In addition, delivery
ports may be formed during coating process, as in the case of
asymmetric membrane coatings of the type disclosed in U.S. Pat.
Nos. 5,612,059 and 5,698,220.
[0248] The total amount of the active ingredient(s) released and
the release rate can substantially by modulated via the thickness
and porosity of the semipermeable membrane, the composition of the
core, and the number, size, and position of the delivery ports.
[0249] The pharmaceutical compositions in an osmotic
controlled-release dosage form may further comprise additional
conventional excipients or carriers as described herein to promote
performance or processing of the formulation.
[0250] The osmotic controlled-release dosage forms can be prepared
according to conventional methods and techniques known to those
skilled in the art (see, Remington: The Science and Practice of
Pharmacy, supra; Santus and Baker, J. Controlled Release 1995, 35,
1-21; Verma et al., Drug Development and Industrial Pharmacy 2000,
26, 695-708; Verma et al., J. Controlled Release 2002, 79,
7-27).
[0251] In certain embodiments, the pharmaceutical compositions
disclosed herein are formulated as AMT controlled-release dosage
form, which comprises an asymmetric osmotic membrane that coats a
core comprising the active ingredient(s) and other pharmaceutically
acceptable excipients or carriers. See, U.S. Pat. No. 5,612,059 and
WO 2002/17918. The AMT controlled-release dosage forms can be
prepared according to conventional methods and techniques known to
those skilled in the art, including direct compression, dry
granulation, wet granulation, and a dip-coating method.
[0252] In certain embodiments, the pharmaceutical compositions
disclosed herein are formulated as ESC controlled-release dosage
form, which comprises an osmotic membrane that coats a core
comprising the active ingredient(s), a hydroxylethyl cellulose, and
other pharmaceutically acceptable excipients or carriers.
3. Multiparticulate Controlled Release Devices
[0253] The pharmaceutical compositions disclosed herein in a
modified release dosage form may be fabricated a multiparticulate
controlled release device, which comprises a multiplicity of
particles, granules, or pellets, ranging from about 10 .mu.m to
about 3 mm, about 50 .mu.m to about 2.5 mm, or from about 100 .mu.m
to about 1 mm in diameter. Such multiparticulates may be made by
the processes know to those skilled in the art, including wet- and
dry-granulation, extrusion/spheronization, roller-compaction,
melt-congealing, and by spray-coating seed cores. See, for example,
Multiparticulate Oral Drug Delivery; Marcel Dekker: 1994; and
Pharmaceutical Pelletization Technology; Marcel Dekker: 1989.
[0254] Other excipients or carriers as described herein may be
blended with the pharmaceutical compositions to aid in processing
and forming the multiparticulates. The resulting particles may
themselves constitute the multiparticulate device or may be coated
by various film-forming materials, such as enteric polymers,
water-swellable, and water-soluble polymers. The multiparticulates
can be further processed as a capsule or a tablet.
4. Targeted Delivery
[0255] The pharmaceutical compositions disclosed herein may also be
formulated to be targeted to a particular tissue, receptor, or
other area of the body of the subject to be treated, including
liposome-, resealed erythrocyte-, and antibody-based delivery
systems. Examples include, but are not limited to, U.S. Pat. Nos.
6,316,652; 6,274,552; 6,271,359; 6,253,872; 6,139,865; 6,131,570;
6,120,751; 6,071,495; 6,060,082; 6,048,736; 6,039,975; 6,004,534;
5,985,307; 5,972,366; 5,900,252; 5,840,674; 5,759,542; and
5,709,874.
Methods of Use
[0256] Disclosed are methods for treating, preventing, or
ameliorating one or more symptoms of an endothelin-mediated
disorder, comprising administering to a subject having or being
suspected to have such a disorder, a therapeutically effective
amount of a compound as disclosed herein or a pharmaceutically
acceptable salt, solvate, and prodrug thereof.
[0257] Endothelin-mediated disorders include, but are not limited
to, hypertension, cardiovascular disease, cardiac disease,
pulmonary hypertension, neonatal pulmonary hypertension,
erythropoietin-mediated hypertension, respiratory disease,
inflammatory disease, opthalmologic disease, gastroenteric disease,
renal failure, endotoxin shock, menstrual disorder, obstetric
condition, wound, laminitis, erectile dysfunction, menopause,
osteoporosis, metabolic bone disorder, climacteric disorder,
disorder associated with the reduction in ovarian function in
middle-aged women, pre-eclampsia, management of labor during
pregnancy, nitric oxide attenuated disorder, anaphylactic shock,
interstitial lung disease, congestive heart failure, hemorrhagic
shock, immunosuppressant-mediated renal vasoconstriction and/or any
disorder which can be lessened, alleviated, or prevented by
administering an endothelin receptor modulator. Endothelin-mediated
disorders also include conditions that result from therapy with
agents, such as erythropoietin and immunosuppressants, which
elevate endothelin levels.
[0258] Also disclosed are methods of treating, preventing, or
ameliorating one or more symptoms of a disorder associated with one
or more endothelin receptors, including, ET.sub.A and ET.sub.B, by
administering to a subject having or being suspected to have such a
disorder, a therapeutically effective amount of a compound as
disclosed herein or a pharmaceutically acceptable salt, solvate,
and prodrug thereof.
[0259] Further disclosed are methods of treating, preventing, or
ameliorating one or more symptoms of a disorder responsive to
modulation of one or more endothelin receptors, including ET.sub.A
and ET.sub.B, comprising administering to a subject having or being
suspected to have such a disorder, a therapeutically effective
amount of a compound as disclosed herein or a pharmaceutically
acceptable salt, solvate, and prodrug thereof.
[0260] Furthermore, disclosed herein are methods of modulating the
activity of one or more endothelin receptors, including ET.sub.A
and ET.sub.B, comprising contacting the receptor(s) with one or
more of the compounds as disclosed herein or a pharmaceutically
acceptable salt, solvate, and prodrug thereof. In one embodiment,
the receptor(s) is expressed by a cell.
[0261] Disclosed herein are methods for treating a subject,
including a human, having or suspected of having a disorder
involving, but not limited to, hypertension, cardiovascular
disease, cardiac disease, pulmonary hypertension, neonatal
pulmonary hypertension, erythropoietin-mediated hypertension,
respiratory disease, inflammatory disease, opthalmologic disease,
gastroenteric disease, renal failure, endotoxin shock, menstrual
disorder, obstetric condition, wound, laminitis, erectile
dysfunction, menopause, osteoporosis, metabolic bone disorder,
climacteric disorder, disorder associated with the reduction in
ovarian function in middle-aged women, pre-eclampsia, management of
labor during pregnancy, nitric oxide attenuated disorder,
anaphylactic shock, interstitial lung disease, congestive heart
failure, hemorrhagic shock, immunosuppressant-mediated renal
vasoconstriction and/or any disorder which can lessened,
alleviated, or prevented by administering an endothelin receptor
modulator, or for preventing such disorder, in a subject prone to
the disorder; comprising administering to the subject a
therapeutically effective amount of a compound of as disclosed
herein or a pharmaceutically acceptable salt, solvate, and prodrug
thereof.
[0262] Disclosed herein are methods for treating a subject,
including a human, having or suspected of having a disorder
involving, but not limited to, hypertension, cardiovascular
disease, cardiac disease, pulmonary hypertension, neonatal
pulmonary hypertension, erythropoietin-mediated hypertension,
respiratory disease, inflammatory disease, opthalmologic disease,
gastroenteric disease, renal failure, endotoxin shock, menstrual
disorder, obstetric condition, wound, laminitis, erectile
dysfunction, menopause, osteoporosis, metabolic bone disorder,
climacteric disorder, disorder associated with the reduction in
ovarian function in middle-aged women, pre-eclampsia, management of
labor during pregnancy, nitric oxide attenuated disorder,
anaphylactic shock, interstitial lung disease, congestive heart
failure, hemorrhagic shock, immunosuppressant-mediated renal
vasoconstriction and/or any disorder which can lessened,
alleviated, or prevented by administering an endothelin receptor
modulator; or for preventing such a disorder, in a subject prone to
the disorder; comprising administering to the subject a
therapeutically effective amount of a compound as disclosed herein
or a pharmaceutically acceptable salt, solvate, or prodrug thereof;
so as to affect decreased inter-individual variation in plasma
levels of the compound or a metabolite thereof, during the
treatment of the disease as compared to the corresponding
non-isotopically enriched compound.
[0263] In certain embodiments, the inter-individual variation in
plasma levels of the compounds as disclosed herein, or metabolites
thereof, is decreased by greater than about 5%, greater than about
10%, greater than about 20%, greater than about 30%, greater than
about 40%, or by greater than about 50% as compared to the
corresponding non-isotopically enriched compound.
[0264] Disclosed herein are methods for treating a subject,
including a human, having or suspected of having a disorder
involving, but not limited to, hypertension, cardiovascular
disease, cardiac disease, pulmonary hypertension, neonatal
pulmonary hypertension, erythropoietin-mediated hypertension,
respiratory disease, inflammatory disease, opthalmologic disease,
gastroenteric disease, renal failure, endotoxin shock, menstrual
disorder, obstetric condition, wound, laminitis, erectile
dysfunction, menopause, osteoporosis, metabolic bone disorder,
climacteric disorder, disorder associated with the reduction in
ovarian function in middle-aged women, pre-eclampsia, management of
labor during pregnancy, nitric oxide attenuated disorder,
anaphylactic shock, interstitial lung disease, congestive heart
failure, hemorrhagic shock, immunosuppressant-mediated renal
vasoconstriction and/or any disorder which can lessened,
alleviated, or prevented by administering an endothelin receptor
modulator; or for preventing such a disorder, in a subject prone to
the disorder; comprising administering to the subject a
therapeutically effective amount of a compound as disclosed herein
or a pharmaceutically acceptable salt, solvate, or prodrug thereof;
so as to affect increased average plasma levels of the compound or
decreased average plasma levels of at least one metabolite of the
compound per dosage unit as compared to the corresponding
non-isotopically enriched compound.
[0265] In certain embodiments, the average plasma levels of the
compound as disclosed herein are increased by greater than about
5%, greater than about 10%, greater than about 20%, greater than
about 30%, greater than about 40%, or greater than about 50% as
compared to the corresponding non-isotopically enriched
compounds.
[0266] In certain embodiments, the average plasma levels of a
metabolite of the compound as disclosed herein are decreased by
greater than about 5%, greater than about 10%, greater than about
20%, greater than about 30%, greater than about 40%, or greater
than about 50% as compared to the corresponding non-isotopically
enriched compounds
[0267] Plasma levels of the compound as disclosed herein, or
metabolites thereof, may be measured using the methods described by
Li et al. (Rapid Communications in Mass Spectrometry 2005, 19,
1943-1950).
[0268] Disclosed herein are methods for treating a subject,
including a human, having or suspected of having a disorder
involving, but not limited to, hypertension, cardiovascular
disease, cardiac disease, pulmonary hypertension, neonatal
pulmonary hypertension, erythropoietin-mediated hypertension,
respiratory disease, inflammatory disease, opthalmologic disease,
gastroenteric disease, renal failure, endotoxin shock, menstrual
disorder, obstetric condition, wound, laminitis, erectile
dysfunction, menopause, osteoporosis, metabolic bone disorder,
climacteric disorder, disorder associated with the reduction in
ovarian function in middle-aged women, pre-eclampsia, management of
labor during pregnancy, nitric oxide attenuated disorder,
anaphylactic shock, interstitial lung disease, congestive heart
failure, hemorrhagic shock, immunosuppressant-mediated renal
vasoconstriction and/or any disorder which can lessened,
alleviated, or prevented by administering an endothelin receptor
modulator; or for preventing such disorder, in a subject prone to
the disorder; comprising administering to the subject a
therapeutically effective amount of a compound as disclosed herein
or a pharmaceutically acceptable salt, solvate, or prodrug thereof;
so as to affect a decreased inhibition of, and/or metabolism by at
least one cytochrome P.sub.450 or monoamine oxidase isoform in the
subject during the treatment of the disease as compared to the
corresponding non-isotopically enriched compound.
[0269] Examples of cytochrome P.sub.450 isoforms in a mammalian
subject include, but are not limited to, CYP1A1, CYP1A2, CYP1B1,
CYP2A6, CYP2A13, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6,
CYP2E1, CYP2G1, CYP2J2, CYP2R1, CYP2S1, CYP3A4, CYP3A5, CYP3A5P1,
CYP3A5P2, CYP3A7, CYP4A11, CYP4B1, CYP4F2, CYP4F3, CYP4F8, CYP4F11,
CYP4F12, CYP4X1, CYP4Z1, CYP5A1, CYP7A1, CYP7B1, CYP8A1, CYP8B1,
CYP11A1, CYP11B1, CYP11B2, CYP17, CYP19, CYP21, CYP24, CYP26A1,
CYP26B1, CYP27A1, CYP27B1, CYP39, CYP46, and CYP51.
[0270] Examples of monoamine oxidase isoforms in a mammalian
subject include, but are not limited to, MAO.sub.A, and
MAO.sub.B.
[0271] In certain embodiments, the decrease in inhibition of the
cytochrome P.sub.450 or monoamine oxidase isoform by a compound as
disclosed herein is greater than about 5%, greater than about 10%,
greater than about 20%, greater than about 30%, greater than about
40%, or greater than about 50% as compared to the corresponding
non-isotopically enriched compounds.
[0272] The inhibition of the cytochrome P.sub.450 isoform is
measured by the method of Ko et al. (British Journal of Clinical
Pharmacology, 2000, 49, 343-351). The inhibition of the MAO.sub.A
isoform is measured by the method of Weyler et al. (J. Biol. Chem.
1985, 260, 13199-13207). The inhibition of the MAO.sub.B isoform is
measured by the method of Uebelhack et al. (Pharmacopsychiatry,
1998, 31, 187-192).
[0273] Disclosed herein are methods for treating a subject,
including a human, having or suspected of having a disorder
involving, but not limited to, hypertension, cardiovascular
disease, cardiac disease, pulmonary hypertension, neonatal
pulmonary hypertension, erythropoietin-mediated hypertension,
respiratory disease, inflammatory disease, opthalmologic disease,
gastroenteric disease, renal failure, endotoxin shock, menstrual
disorder, obstetric condition, wound, laminitis, erectile
dysfunction, menopause, osteoporosis, metabolic bone disorder,
climacteric disorder, disorder associated with the reduction in
ovarian function in middle-aged women, pre-eclampsia, management of
labor during pregnancy, nitric oxide attenuated disorder,
anaphylactic shock, interstitial lung disease, congestive heart
failure, hemorrhagic shock, immunosuppressant-mediated renal
vasoconstriction and/or any disorder which can lessened,
alleviated, or prevented by administering an endothelin receptor
modulator; or for preventing such disorder, in a subject prone to
the disorder; comprising administering to the subject a
therapeutically effective amount of a compound of a compound as
disclosed herein or a pharmaceutically acceptable salt, solvate, or
prodrug thereof; so as to affect a decreased metabolism via at
least one polymorphically-expressed cytochrome P.sub.450 isoform in
the subject during the treatment of the disorder as compared to the
corresponding non-isotopically enriched compound.
[0274] Examples of polymorphically-expressed cytochrome P.sub.450
isoforms in a mammalian subject include, but are not limited to,
CYP2C8, CYP2C9, CYP2C19, and CYP2D6.
[0275] In certain embodiments, the decrease in metabolism of the
compound as disclosed herein by at least one
polymorphically-expressed cytochrome P.sub.450 isoforms cytochrome
P.sub.450 isoform is greater than about 5%, greater than about 10%,
greater than about 20%, greater than about 30%, greater than about
40%, or greater than about 50% as compared to the corresponding
non-isotopically enriched compound.
[0276] The metabolic activities of the cytochrome P.sub.450
isoforms are measured by the method described in Example 9. The
metabolic activities of the monoamine oxidase isoforms are measured
by the methods described in Examples 10, 11, and 12.
[0277] Disclosed herein are methods for treating a subject,
including a human, having or suspected of having a disorder
involving, but not limited to, hypertension, cardiovascular
disease, cardiac disease, pulmonary hypertension, neonatal
pulmonary hypertension, erythropoietin-mediated hypertension,
respiratory disease, inflammatory disease, opthalmologic disease,
gastroenteric disease, renal failure, endotoxin shock, menstrual
disorder, obstetric condition, wound, laminitis, erectile
dysfunction, menopause, osteoporosis, metabolic bone disorder,
climacteric disorder, disorder associated with the reduction in
ovarian function in middle-aged women, pre-eclampsia, management of
labor during pregnancy, nitric oxide attenuated disorder,
anaphylactic shock, interstitial lung disease, congestive heart
failure, hemorrhagic shock, immunosuppressant-mediated renal
vasoconstriction and/or any disorder which can lessened,
alleviated, or prevented by administering an endothelin receptor
modulator, or for preventing such disorder, in a subject prone to
the disorder; comprising administering to the subject a
therapeutically effective amount of a compound as disclosed herein
or prodrug thereof; so as to affect at least one
statistically-significantly improved disorder-control and/or
disorder-eradication endpoint, as compared to the corresponding
non-isotopically enriched compound.
[0278] Examples of statistically-significantly improved
disorder-control and/or disorder-eradication endpoints include, but
are not limited to, statistically-significant decrease in mean
blood pressure, decrease in mean diastolic blood pressure, decrease
in mean systolic blood pressure, decrease in pulmonary arterial
pressure, increased survival rate, and an increase in the
therapeutic index with respect to hepatotoxicity.
[0279] Disclosed herein are methods for treating a subject,
including a human, having or suspected of having a disorder
involving, but not limited to, hypertension, cardiovascular
disease, cardiac disease, pulmonary hypertension, neonatal
pulmonary hypertension, erythropoietin-mediated hypertension,
respiratory disease, inflammatory disease, opthalmologic disease,
gastroenteric disease, renal failure, endotoxin shock, menstrual
disorder, obstetric condition, wound, laminitis, erectile
dysfunction, menopause, osteoporosis, metabolic bone disorder,
climacteric disorder, disorder associated with the reduction in
ovarian function in middle-aged women, pre-eclampsia, management of
labor during pregnancy, nitric oxide attenuated disorder,
anaphylactic shock, interstitial lung disease, congestive heart
failure, hemorrhagic shock, immunosuppressant-mediated renal
vasoconstriction and/or any disorder which can lessened,
alleviated, or prevented by administering an endothelin receptor
modulator, or for preventing such disorder, in a subject prone to
the disorder; comprising administering to the subject a
therapeutically effective amount of a compound disclosed herein or
a pharmaceutically acceptable salt, solvate, or prodrug thereof; so
as to affect an improved clinical effect as compared to the
corresponding non-isotopically enriched compound. Examples of
improved clinical effects include, but are not limited to,
maintenance of clinical benefit, statistically-significant decrease
in mean blood pressure, decrease in mean diastolic blood pressure,
decrease in mean systolic blood pressure, decrease in pulmonary
arterial pressure, increased survival rate, and an increase in the
therapeutic index with respect to hepatotoxicity.
[0280] Disclosed herein are methods for treating a subject,
including a human, having or suspected of having a disorder
involving, but not limited to, hypertension, cardiovascular
disease, cardiac disease, pulmonary hypertension, neonatal
pulmonary hypertension, erythropoietin-mediated hypertension,
respiratory disease, inflammatory disease, opthalmologic disease,
gastroenteric disease, renal failure, endotoxin shock, menstrual
disorder, obstetric condition, wound, laminitis, erectile
dysfunction, menopause, osteoporosis, metabolic bone disorder,
climacteric disorder, disorder associated with the reduction in
ovarian function in middle-aged women, pre-eclampsia, management of
labor during pregnancy, nitric oxide attenuated disorder,
anaphylactic shock, interstitial lung disease, congestive heart
failure, hemorrhagic shock, immunosuppressant-mediated renal
vasoconstriction and/or any disorder which can lessened,
alleviated, or prevented by administering an endothelin receptor
modulator, or for preventing such disorder, in a subject prone to
the disorder; comprising administering to the subject a
therapeutically effective amount of a compound as disclosed herein
or a pharmaceutically acceptable salt, solvate, or prodrug thereof;
so as to affect prevention of recurrence of abnormal cardiac
parameters as the primary clinical benefit, which includes absence
of statistically-significant abnormality in mean blood pressure,
mean diastolic blood pressure, systolic blood pressure, and
pulmonary arterial pressure, and maintenance of increased survival
rate, and/or maintain absence of hepatotoxicity, as compared to the
corresponding non-isotopically enriched compound.
[0281] Disclosed herein are methods for treating a subject,
including a human, having or suspected of having a disorder
involving, but not limited to, hypertension, cardiovascular
disease, cardiac disease, pulmonary hypertension, neonatal
pulmonary hypertension, erythropoietin-mediated hypertension,
respiratory disease, inflammatory disease, opthalmologic disease,
gastroenteric disease, renal failure, endotoxin shock, menstrual
disorder, obstetric condition, wound, laminitis, erectile
dysfunction, menopause, osteoporosis, metabolic bone disorder,
climacteric disorder, disorder associated with the reduction in
ovarian function in middle-aged women, pre-eclampsia, management of
labor during pregnancy, nitric oxide attenuated disorder,
anaphylactic shock, interstitial lung disease, congestive heart
failure, hemorrhagic shock, immunosuppressant-mediated renal
vasoconstriction and/or any disorder which can lessened,
alleviated, or prevented by administering an endothelin receptor
modulator, or for preventing such disorder, in a subject prone to
the disorder; comprising administering to the subject a
therapeutically effective amount of a compound disclosed herein or
a pharmaceutically acceptable salt, solvate, or prodrug thereof; so
as to allow the treatment of, but not limited to, hypertension,
cardiovascular disease, cardiac disease, pulmonary hypertension,
neonatal pulmonary hypertension, erythropoietin-mediated
hypertension, respiratory disease, inflammatory disease,
opthalmologic disease, gastroenteric disease, renal failure,
endotoxin shock, menstrual disorder, obstetric condition, wound,
laminitis, erectile dysfunction, menopause, osteoporosis, metabolic
bone disorder, climacteric disorder, disorder associated with the
reduction in ovarian function in middle-aged women, pre-eclampsia,
management of labor during pregnancy, nitric oxide attenuated
disorder, anaphylactic shock, interstitial lung disease, congestive
heart failure, hemorrhagic shock, immunosuppressant-mediated renal
vasoconstriction and/or any disorder which can lessened,
alleviated, or prevented by administering an endothelin receptor
modulator while reducing or eliminating deleterious changes in any
diagnostic hepatobiliary function endpoints as compared to the
corresponding non-isotopically enriched compound.
[0282] Examples of diagnostic hepatobiliary function endpoints
include, but are not limited to, alanine aminotransferase ("ALT"),
serum glutamic-pyruvic transaminase ("SGPT"), aspartate
aminotransferase ("AST" or "SGOT"), ALT/AST ratios, serum aldolase,
alkaline phosphatase ("ALP"), ammonia levels, bilirubin,
gamma-glutamyl transpeptidase ("GGTP," ".gamma.-GTP," or "GGT"),
leucine aminopeptidase ("LAP"), liver biopsy, liver
ultrasonography, liver nuclear scan, 5'-nucleotidase, and blood
protein. Hepatobiliary endpoints are compared to the stated normal
levels as given in "Diagnostic and Laboratory Test Reference",
4.sup.th edition, Mosby, 1999. These assays are run by accredited
laboratories according to standard protocol.
[0283] Depending on the disorder to be treated and the subject's
condition, the compound as disclosed herein may be administered by
oral, parenteral (e.g., intramuscular, intraperitoneal,
intravenous, ICV, intracistemal injection or infusion, subcutaneous
injection, or implant), inhalation, nasal, vaginal, rectal,
sublingual, or topical (e.g., transdermal or local) routes of
administration, and may be formulated, alone or together, in
suitable dosage unit with pharmaceutically acceptable carriers,
adjuvants and vehicles appropriate for each route of
administration.
[0284] The dose may be in the form of one, two, three, four, five,
six, or more sub-doses that are administered at appropriate
intervals per day. The dose or sub-doses can be administered in the
form of dosage units containing from 0.1 to 500 milligram, from 0.1
to 200 milligrams, or from 0.5 to 100 milligram active
ingredient(s) per dosage unit, and if the condition of the patient
requires, the dose can, by way of alternative, be administered as a
continuous infusion.
[0285] In certain embodiments, an appropriate dosage level is about
0.001 to about 100 mg per kg patient body weight per day (mg/kg per
day), about 0.01 to about 50 mg/kg per day, about 0.01 to about 25
mg/kg per day, or about 0.05 to about 10 mg/kg per day, which may
be administered in single or multiple doses. A suitable dosage
level may be about 0.01 to 25 mg/kg per day, about 0.05 to 10 mg/kg
per day, or about 0.1 to 5 mg/kg per day. Within this range the
dosage may be 0.005 to 0.05, 0.05 to 0.5 or 0.5 to 5.0 mg/kg per
day.
Combination Therapy
[0286] The compounds disclosed herein may also be combined or used
in combination with other agents useful in the treatment,
prevention, or amelioration of one or more symptoms of the
disorders for which the compound disclosed herein are useful,
including, but not limited to, hypertension, cardiovascular
disease, cardiac disease, pulmonary hypertension, neonatal
pulmonary hypertension, erythropoietin-mediated hypertension,
respiratory disease, inflammatory disease, opthalmologic disease,
gastroenteric disease, renal failure, endotoxin shock, menstrual
disorder, obstetric condition, wound, laminitis, erectile
dysfunction, menopause, osteoporosis, metabolic bone disorder,
climacteric disorder, disorder associated with the reduction in
ovarian function in middle-aged women, pre-eclampsia, management of
labor during pregnancy, nitric oxide attenuated disorder,
anaphylactic shock, interstitial lung disease, congestive heart
failure, hemorrhagic shock, immunosuppressant-mediated renal
vasoconstriction, any disorder which can lessened, alleviated, or
prevented by administering an endothelin receptor modulator, and/or
disorders that result from therapy with agents, such as
erythropoietin and immunosuppressants, which elevate endothelin
levels.
[0287] Such other agents, or drugs, may be administered, by a route
and in an amount commonly used therefor, simultaneously or
sequentially with an amine salt disclosed herein. When a compound
as disclosed herein is used contemporaneously with one or more
other drugs, a pharmaceutical composition containing such other
drugs in addition to the compound disclosed herein may be utilized,
but is not required. Accordingly, the pharmaceutical compositions
disclosed herein include those that also contain one or more other
active ingredients or therapeutic agents, in addition to the
compound disclosed herein.
[0288] In certain embodiments, the compounds disclosed herein can
be combined with one or more other compounds known to modulate the
activity of one or more endothelin receptors, including ET.sub.A
and ET.sub.B. Non-limiting examples of other endothelin antagonists
are those described in U.S. Pat. Nos. 6,852,745; 6,686,382;
6,683,103; 6,432,994; 6,248,767; 5,962,490; 5,783,705; 5,594,021;
5,591,761; 5,571,821; and 5,514,691.
[0289] In certain embodiments, the compounds disclosed herein can
be combined with one or more endothelin antagonist known in the
art, including, but not limited to, Bosentan,
cyclo(D-Glu-L-Ala-allo-D-lle-L-Leu-D-Trp) (BE-18257B); cyclic
pentapeptides related to BE-18257B, such as
cyclo(D-Asp-Pro-D-Val-Leu-D-Trp) (BQ-123) (U.S. Pat. No. 5,114,918;
and EP A10 436 189); and other peptide and non-peptidic ET.sub.A
antagonists that have been identified in, for example, U.S. Pat.
Nos. 6,953,780; 6,946,481; 6,686,382; 6,683,103; 6,852,745;
6,835,741; 6,673,824; 6,670,367; 6,670,362; 6,432,994; 6,248,767;
5,962,490; 5,783,705; 5,594,021; 5,591,761; 5,571,821; 5,514,691;
5,352,800; 5,352,659; 5,334,598; 5,248,807; 5,240,910; 5,198,548;
5,187,195; and 5,082,838.
[0290] These known endothelin antagonists also include other cyclic
pentapeptides, acyltripeptides, hexapeptide analogs, anthraquinone
derivatives, indanecarboxylic acids,
N-pyriminylbenzenesulfonamides, benzenesulfonamides,
naphthalenesulfonamides (Canadian Pat. App. Nos. 2,067,288 and
2,071,193; EP A10 569 193; EP A10 558 258; EP A10 436 189; U.S.
Pat. Nos. 5,612,359; 5,594,021; 5,591,761; 5,571,821; 5,514,696;
5,514,691; 5,464,853; 5,378,715; 5,270,313; 5,208,243; WO 96/31492;
WO 97/27979; WO93/08799; Nakajima et al., J. Antibiot. 1991, 44,
1348-1356; Miyata et al., J. Antibiot. 1992, 45, 74-8; Ishikawa et
al., J. Med. Chem. 1992, 35, 2139-2142; Cody et al., Med. Chem.
Res. 1993, 3, 154-162; Miyata et al., J. Antibiot. 1992, 45,
1041-1046; Miyata et al., J. Antibiot. 1992, 45, 1029-1040;
Fujimoto et al., FEBS Lett. 1992, 305, 41-44; EP A1 0 496 452;
Clozel et al., Nature 1993, 365, 759-761; Nishikibe et al., Life
Sci. 1993, 52, 717-724; and Benigni et al., Kidney Int. 1993, 44,
440-444).
[0291] Additional known endothelin antagonists include those
described in DE 4341663; EP 743307; EP 733626; EP 713875; EP
682016; EP 658548; EP 633259; EP 628569; EP 617001; EP 601386; EP
555537; EP 552417; EP 526708; EP 510526; EP 496452; EP 436189; GB
2295616; GB 2277446; GB 2276383; GB 2275926; GB 2266890; JP
8059635; JP 7330622; JP 7316188; JP 7258098; JP 7133254; JP
6256261; JP 6122625; U.S. Pat. Nos. 6,080,774; 5,780,473;
5,543,521; 5,965,732; 5,571,821; 5,559,105; 5,541,186; 5,482,960;
5,420,123; 5,389,620; 5,292,740; WO 96/33190; WO 96/33170; WO
96/31492; WO 96/30358; WO 96/23773; WO 96/22978; WO 96/20177; WO
96/19459; WO 96/19455; WO 96/15109; WO 96/12706; WO 96/11927; WO
96/11914; WO 96/09818; WO 96/08487; WO 96/08483; WO 96/08486; WO
96/07653; WO 96/06095; WO 96/04905; WO 95/35107; WO 95/33752; WO
95/33748; WO 95/26957; WO 95/26716; WO 95/26360; WO 95/15963; WO
95/15944; WO 95/13262; WO 95/12611; WO 95/05376; WO 95/08989; WO
95/08550; WO 95/05374; WO 95/05372; WO 95/04534; WO 95/04530; WO
95/03295; WO 95/03044; WO 94/25013; WO 94/24084; WO 94/21590; WO
94/21259; WO 94/14434; WO 94/03483; WO 94/02474; WO 93/25580; WO
93/23404; WO 93/21219; and WO 93/08799.
[0292] These known endothelin antagonists also include BQ-123
(Ihara et al., Life Sciences 1992, 50, 247-255); PD 156707
(Reynolds et al., J. Pharm. Exper. Ther. 1995, 273, 1410-1417);
L-754,142 (Williams et al., J. Pharm. Exper. Ther. 1995, 275,
1518-1526); SB 209670 (Ohlstein et al., Proc. Natl. Acad. Sci. USA
1994, 91, 8052-8056); SB 217242 (Ohlstein et al., J. Pharm. Exper.
Ther. 1996, 276, 609-615); A-127722 (Opgenorth et al., J. Pharm.
Exper. Ther. 1996, 276, 473-481); TAK-044 (Masuda et al., J. Pharm.
Exper. Ther. 1996, 279, 675-685 (1996).
[0293] In certain embodiments, the compounds disclosed herein can
be combined with other compounds that are used in treatment of
congestive heart failure, including, but not limited to, loop
diuretics, such as bumetanide, furosemide, and torsemide; thiazide
diuretics, such as chlorthalidone, hydrochlorothiazide (HCTZ),
amiloride, and spironolactone; long-acting nitrates, such as
glyceryl trinitrate, isosorbide dinitrate, isosorbide mononitrate,
and molsidomin pentaerythritol tetranitrate; .beta.-blockers, such
as alprenolol, oxprenolol, pindolol, propranolol, timolol, sotalol,
nadolol, mepindolol, carteolol, tertatolol, bopindolol, bupranolol,
penbutolol, cloranolol, practolol, metoprolol, atenolol,
acebutolol, betaxolol, bevantolol, bisoprolol, celiprolol, esmolol,
epanolol, s-atenolol, nebivolol, talinolol, labetalol, and
carvedilol; calcium channel blockers, such as amlodipine,
felodipine, isradipine, nicardipine, nifedipine, nimodipine,
nisoldipine, nitrendipine, lacidipine, nilvadipine, manidipine,
barnidipine, lercanidipine, cilnidipine, benidipine, mibefradil,
verapamil, gallopamil, diltiazem, fendiline, bepridil, lidoflazine,
and perhexyline; renin inhibitors, such as aliskiren, remikiren;
angiotensin converting enzyme (ACE) inhibitors, such as alacepril,
benazepril, captopril, ceranapril, delapril, enalapril, fosinopril,
lisinopril, moexipril, perindopril, quinapril, ramipril, spirapril,
trandolapril, and zofenopril; angiotensin receptor blockers (ARBs),
such as candesartan, eprosartan, irbesartan, losartan, olmesartan,
tasosartan, telmisartan, valsartan; and aldosterone antagonists,
such as spironolactone and eplerenone.
[0294] The compounds disclosed herein can also be administered in
combination with other classes of compounds, including, but not
limited to, endothelin converting enzyme (ECE) inhibitors, such as
phosphoramidon; thromboxane receptor antagonists, such as
ifetroban; potassium channel openers; thrombin inhibitors, such as
hirudin; growth factor inhibitors, such as modulators of PDGF
activity; platelet activating factor (PAF) antagonists;
anti-platelet agents, such as GPIIb/IIIa blockers (e.g., abdximab,
eptifibatide, and tirofiban), P2Y(AC) antagonists (e.g.,
clopidogrel, ticlopidine and CS-747), and aspirin; anticoagulants,
such as warfarin; low molecular weight heparins, such as
enoxaparin; Factor VIIa Inhibitors and Factor Xa Inhibitors; renin
inhibitors; neutral endopeptidase (NEP) inhibitors; vasopepsidase
inhibitors (dual NEP-ACE inhibitors), such as omapatrilat and
gemopatrilat; HMG CoA reductase inhibitors, such as pravastatin,
lovastatin, atorvastatin, simvastatin, NK-104 (a.k.a. itavastatin,
nisvastatin, or nisbastatin), and ZD-4522 (also known as
rosuvastatin, or atavastatin or visastatin); squalene synthetase
inhibitors; fibrates; bile acid sequestrants, such as questran;
niacin; anti-atherosclerotic agents, such as ACAT inhibitors; MTP
Inhibitors; calcium channel blockers, such as amlodipine besylate;
potassium channel activators; alpha-adrenergic agents;
beta-adrenergic agents, such as carvedilol and metoprolol;
antiarrhythmic agents; diuretics, such as chlorothlazide,
hydrochlorothiazide, flumethiazide, hydroflumethiazide,
bendroflumethiazide, methylchlorothiazide, trichloromethiazide,
polythiazide, benzothlazide, ethacrynic acid, tricrynafen,
chlorthalidone, furosenilde, musolimine, bumetanide, triamterene,
amiloride, and spironolactone; thrombolytic agents, such as tissue
plasminogen activator (tPA), recombinant tPA, streptokinase,
urokinase, prourokinase, and anisoylated plasminogen streptokinase
activator complex (APSAC); anti-diabetic agents, such as biguanides
(e.g. metformin), glucosidase inhibitors (e.g., acarbose),
insulins, meglitinides (e.g., repaglinide), sulfonylureas (e.g.,
glimepiride, glyburide, and glipizide), thiozolidinediones (e.g.
troglitazone, rosiglitazone and pioglitazone), and PPAR-gamma
agonists; mineralocorticoid receptor antagonists, such as
spironolactone and eplerenone; growth hormone secretagogues; aP2
inhibitors; non-steroidal antiinflammatory drugs (NSAIDS), such as
aspirin and ibuprofen; phosphodiesterase inhibitors, such as PDE
III inhibitors (e.g., cilostazol) and PDE V inhibitors (e.g.,
sildenafil, tadalafil, vardenafil); protein tyrosine kinase
inhibitors; antiinflammatories; antiproliferatives, such as
methotrexate, FK506 (tacrolimus, Prograf), mycophenolate mofetil;
chemotherapeutic agents; immunosuppressants; anticancer agents and
cytotoxic agents (e.g., alkylating agents, such as nitrogen
mustards, alkyl sulfonates, nitrosoureas, ethylenimines, and
triazenes); antimetabolites, such as folate antagonists, purine
analogues, and pyrridine analogues; antibiotics, such as
anthracyclines, bleomycins, mitomycin, dactinomycin, and
plicamycin; enzymes, such as L-asparaginase; farnesyl-protein
transferase inhibitors; hormonal agents, such as glucocorticoids
(e.g., cortisone), estrogens/antiestrogens,
androgens/antiandrogens, progestins, and luteinizing
hormone-releasing hormone anatagonists, and octreotide acetate;
microtubule-disruptor agents, such as ecteinascidins;
microtubule-stablizing agents, such as pacitaxel, docetaxel, and
epothilones A-F; plant-derived products, such as vinca alkaloids,
epipodophyllotoxins, and taxanes; and topoisomerase inhibitors;
prenyl-protein transferase inhibitors; and cyclosporins; steroids,
such as prednisone and dexamethasone; cytotoxic drugs, such as
azathiprine and cyclophosphamide; TNF-alpha inhibitors, such as
tenidap; anti-TNF antibodies or soluble TNF receptor, such as
etanercept, rapamycin, and leflunimide; and cyclooxygenase-2
(COX-2) inhibitors, such as celecoxib and rofecoxib; and
miscellaneous agents such as, hydroxyurea, procarbazine, mitotane,
hexamethylmelamine, gold compounds, platinum coordination
complexes, such as cisplatin, satraplatin, and carboplatin.
[0295] These other therapeutic agents may be used, for example, in
the amounts indicated in the Physicians' Desk Reference (PDR) or as
otherwise determined by one of ordinary skill in the art.
Kits/Articles of Manufacture
[0296] For use in the therapeutic applications described herein,
kits and articles of manufacture are also described herein. Such
kits can comprise a carrier, package, or container that is
compartmentalized to receive one or more containers such as vials,
tubes, and the like, each of the container(s) comprising one of the
separate elements to be used in a method described herein. Suitable
containers include, for example, bottles, vials, syringes, and test
tubes. The containers can be formed from a variety of materials
such as glass or plastic.
[0297] For example, the container(s) can comprise one or more
compounds described herein, optionally in a composition or in
combination with another agent as disclosed herein. The
container(s) optionally have a sterile access port (for example the
container can be an intravenous solution bag or a vial having a
stopper pierceable by a hypodermic injection needle). Such kits
optionally comprise a compound with an identifying description or
label or instructions relating to its use in the methods described
herein.
[0298] A kit will typically comprise one or more additional
containers, each with one or more of various materials (such as
reagents, optionally in concentrated form, and/or devices)
desirable from a commercial and user standpoint for use of a
compound described herein. Non-limiting examples of such materials
include, but are not limited to, buffers, diluents, filters,
needles, syringes; carrier, package, container, vial and/or tube
labels listing contents and/or instructions for use, and package
inserts with instructions for use. A set of instructions will also
typically be included.
[0299] A label can be on or associated with the container. A label
can be on a container when letters, numbers or other characters
forming the label are attached, molded or etched into the container
itself; a label can be associated with a container when it is
present within a receptacle or carrier that also holds the
container, e.g., as a package insert. A label can be used to
indicate that the contents are to be used for a specific
therapeutic application. The label can also indicate directions for
use of the contents, such as in the methods described herein. These
other therapeutic agents may be used, for example, in the amounts
indicated in the Physicians' Desk Reference (PDR) or as otherwise
determined by one of ordinary skill in the art.
[0300] The invention is further illustrated by the following
examples:
Example 1
2-[2-(6-Methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3-sulfonic
acid (4-chloro-3-methyl-isoxazol-5-yl)-amide
##STR00092##
[0301] Step 1
##STR00093##
[0303] 5-amino-4-chloro-3-methylisoxazole: At about 0.degree. C.,
N-chlorosuccinimide (1.85 g, 10.2 mmol) was slowly added to a
solution of 5-amino-3-methylisoxazole (1 g, 10.2 mmol) in 20 mL of
dichloromethane. Under continuous stirring, the mixture was
maintained at about 0.degree. C. for about 1 hour and then at
ambient temperature for about 2 hours. The mixture was washed with
aqueous 1N sodium hydroxide. After standard extractive work up, the
residue was washed with hexane to afford the product
5-amino-4-chloro-3-methylisoxazole (0.5 g, 37%). .sup.1H NMR (300
MHz, CDCl.sub.3) .delta. 4.64 (br. s, 2H), 2.17 (s, 3H).
Step 2
##STR00094##
[0305]
3-(4-Chloro-3-methyl-isoxazol-5-ylsulfamoyl)-thiophene-2-carboxylic
acid: At about 0.degree. C., sodium hydride (60% dispersion in
mineral oil, 458 mg, 19 mmol) was added to a solution of
5-amino-4-chloro-3-methylisoxazole (1.1 g, 8.3 mmol) in anhydrous
tetrahydrofuran (30 mL). The resulting mixture was stirred for
about 10 minutes and 2-(methoxycarbonyl)thiophene-3-sulfonyl
chloride (1.95 g, 8.11 mmol) was slowly added. Under continuous
stirring, the mixture was maintained at ambient temperature for
about 4 hours. The mixture was then diluted with hexanes (30 mL)
and the resulting precipitate was filtered and washed with hexanes.
The precipitate was then dissolved in 1 N sodium hydroxide and
stirred at ambient temperature for about 1 hour. After acidifying
to pH .about.2 with 2 N hydrochloric acid, the resulting
precipitate was filtered, washed with water, and dried in vacuo to
give the desired product
3-[(4-chloro-3-methyl-5-isoxazolyl)sulfamoyl]-2-thiophenecarboxylic
acid (1.2 g, 45%) as a yellow powder. .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 7.82 (d, J=5.4 Hz, 1H), 7.53 (d, J=5.4 Hz, 1H),
2.24 (s, 3H); LC-MS: m/z=323 (MH).sup.+.
Step 3
##STR00095##
[0307] 5-Methyl-benzo[1,3]dioxole: 4-methylcatechol (15 g, 120.9
mmol) was added to a suspension of cesium carbonate (50 g, 154
mmol) in dimethylformamide (60 mL). The mixture was put under
vacuum and purged with nitrogen three times. At ambient
temperature, dichloromethane (15.4 g, 181.3 mmol) was added, and
then the reaction mixture was heated at about 110.degree. C. for
about 2 hours. After cooling to ambient temperature, the reaction
was quenched with water (500 mL) and extracted with ether-pentane
(1:1 ratio, 3.times.500 mL). The combined organic layers were
washed with water (3.times.1000 mL), dried over anhydrous magnesium
sulfate, filtered and concentrated in vacuo to afford the desired
product (50 g, 30%). .sup.1H NMR (300 MHz, CDCl.sub.3) .delta.
6.71-6.59 (m, 3H), 5.88 (s, 2H), 2.27 (s, 3H); GC-MS: m/z=136
(MH).sup.+.
Step 4
##STR00096##
[0309] 5-(Chloromethyl)-6-methylbenzo[d][1,3]dioxole: At about
0.degree. C., 5-methylbenzo[d][1,3]dioxole (500 mg, 3.68 mmol) and
formaldehyde (37% in water, 0.7 mL) were sequentially added to a
mixture of dichloromethane (6.8 mL), tetrabutylammonium bromide (80
mg) and concentrated hydrochloric acid (6.5 mL). Under continuous
stirring, the mixture was maintained at about 0.degree. C. for
about 1 hour and then at ambient temperature for about 4 hours. The
mixture was diluted with ether (100 mL). After standard extractive
workup, the resulting solid residue was heated with hexanes (100
mL) and the insolubles were removed by filtration. The filtrate was
concentrated to give desired product (420 mg, 62%). .sup.1H NMR
(300 MHz, CDCl.sub.3) .delta. 6.89 (s, 1H), 6.69 (s, 1H), 5.94 (s,
3H), 4.56 (s, 2H), 2.35 (s, 3H); GC-MS: m/z=184 (MH).sup.+.
Step 5
##STR00097##
[0311]
2-[2-(6-Methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3-sulfonic
acid (4-chloro-3-methyl-isoxazol-5-yl)-amide:
1,1'-carbonyldiimidazole (600 mg) was added to a solution of
3-[(4-chloro-3-methyl-5-isoxazolyl)sulfamoyl]-2-thiophenecarboxylic
acid (900 mg, 2.79 mmol) in anhydrous tetrahydrofuran (20 mL). The
mixture was stirred at ambient temperature for about 15 minutes and
then sequentially treated with imidazole (380 mg, 5.58 mmol) and
N,O-dimethylhydroxylamine hydrochloride (420 mg, 4.3 mmol). Under
continuous stirring, the mixture was maintained at ambient
temperature for about 4 hours. The solvent was removed in vacuo and
the residue was partitioned between ethyl acetate (100 mL) and 1 N
hydrochloric acid (30 mL). The organic layer was dried over
anhydrous magnesium sulfate, filtered and concentrated. The
resulting residue was treated with toluene and re-concentrated. The
resulting red oil was dissolved in anhydrous tetrahydrofuran (20
mL), cooled to about 0.degree. C., and then treated with a Grignard
reagent prepared from 5-chloromethyl-6-methyl-benzo[1,3]dioxole
(800 mg, 4.36 mmol) and magnesium turnings (826 mg, 34.4 mmol) in
tetrahydrofuran (50 mL). Under continuous stirring, the mixture was
maintained at about 0.degree. C. for about 1 hour and then at
ambient temperature for about 2 hours. At about 0.degree. C., the
reaction mixture was quenched with a mixture of concentrated
hydrochloric acid (20 mL) and methanol (50 mL). The mixture was
stirred at about 0.degree. C. for about 10 minutes, and then
concentrated in vacuo. The aqueous residue was partitioned between
ethyl acetate (100 mL) and 1 N hydrochloric acid (30 mL). The crude
product was isolated using standard extractive work up and purified
by prep-TLC (eluted with CH.sub.2Cl.sub.2:MeOH=7:1) to give
2-[2-(6-methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3-sulfonic
acid (4-chloro-3-methyl-isoxazol-5-yl) amide (150 mg, 30%) as a
yellow solid. .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.77 (d,
J=5.1 Hz, 1H), 7.40 (d, J=5.1 Hz, 1H), 6.74 (d, J=4.2 Hz, 2H), 5.94
(s, 3H), 4.76 (s, 2H), 2.04 (s, 3H), 1.99 (s, 3H); ESI-MS: m/z=455
(MH).sup.+; HPLC purity: 95%.
Example 2
[0312]
d.sub.2-2-[2-(6-Methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3-s-
ulfonic acid (4-chloro-3-methyl-isoxazol-5-yl)-amide
##STR00098##
Step 1
##STR00099##
[0314] 5-amino-4-chloro-3-methylisoxazole: The title compound was
made by following the procedure set forth in Example 1, step 1.
Step 2
##STR00100##
[0316]
3-(4-Chloro-3-methyl-isoxazol-5-ylsulfamoyl-thiophene-2-carboxylic
acid: The title compound was made by following the procedure set
forth in Example 1, step 2.
Step 3
##STR00101##
[0318] d.sub.2-5-Methyl-benzo[1,3]dioxole: 4-methylcatechol (5 g,
40.3 mmol) was added to a suspension of cesium carbonate (20 g, 61
mmol) in dimethylformamide (60 mL). The mixture was put under
vacuum and purged with nitrogen three times.
d.sub.2-Dichloromethane (3.7 g, 61 mmol) was then added at ambient
temperature, and the mixture was heated at about 110.degree. C. for
about 2 hours. After cooling to ambient temperature, the reaction
mixture was partitioned between water (400 mL) and ether-pentane
(1:1 ratio, 600 mL). The organic layer was extracted, washed with
water (3.times.200 mL), dried over anhydrous magnesium sulfate,
filtered and concentrated in vacuo to afford the desired product (2
g, 37%). .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 6.71-6.59 (m,
3H), 2.27 (s, 3H).
Step 4
##STR00102##
[0320] d.sub.2-5-(Chloromethyl)-6-methylbenzo[d][1,3]dioxole: At
about 0.degree. C., d.sub.2-5-Methylbenzo[d][1,3]dioxole (2 g, 14.5
mmol) and formaldehyde (37% in water, 4 mL) were sequentially added
to a mixture of dichloromethane (26 mL), tetrabutylammonium bromide
(320 mg) and concentrated hydrochloric acid (26 mL). Under
continuous stirring, the mixture was maintained at about 0.degree.
C. for about 1 hour and then at ambient temperature for 4 hours.
After standard extractive workup, the resulting solid residue was
heated with hexanes (100 mL) and the insolubles were removed by
filtration. The filtrate was concentrated in vacuo to give desired
product (2 g, 74%). .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 6.80
(s, 1H), 6.67 (s, 1H), 4.54 (s, 2H), 2.33 (s, 3H); GC-MS: m/z=184
(MH).sup.+.
Step 5
##STR00103##
[0322]
d.sub.2-2-[2-(6-Methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3-s-
ulfonic acid (4-chloro-3-methyl-isoxazol-5-yl)-amide:
1,1'-carbonyldiimidazole (250 mg) was added to a solution of
3-[(4-chloro-3-methyl-5-isoxazolyl)sulfamoyl]-2-thiophenecarboxylic
acid (400 mg, 10.1 mmol) in anhydrous tetrahydrofuran (20 mL). The
resulting mixture was stirred at ambient temperature for about 15
minutes and then sequentially treated with imidazole (168 mg, 2.5
mmol) and N,O -dimethylhydroxylamine hydrochloride (184 mg, 1.89
mmol). Under continuous stirring, the mixture was maintained at
ambient temperature for about 4 hours. The solvent was removed in
vacuo and the residue was partitioned between ethyl acetate (100
mL) and 1 N hydrochloric acid (30 mL). The organic layer was
extracted, dried over anhydrous magnesium sulfate, filtered, and
concentrated. The residue was treated with toluene (30 mL) and
re-concentrated. The resulting red oil was dissolved in anhydrous
tetrahydrofuran (20 mL), cooled to about 0.degree. C. in an
ice-bath, and treated with a Grignard reagent prepared from
d.sub.2-5-chloromethyl-6-methyl-benzo[1,3]dioxole (800 mg, 4.29
mmol) and magnesium turnings (826 mg, 34.4 mmol) in tetrahydrofuran
(50 mL). Under continuous stirring, the mixture was maintained at
about 0.degree. C. for about 1 hour and then at ambient temperature
for about 2 hours. At about 0.degree. C., the reaction mixture was
quenched with a mixture of concentrated hydrochloric acid (20 mL)
and methanol (50 mL). After continuous stirring at about 0.degree.
C. for about 10 minutes, the reaction mixture was concentrated in
vacuo. The aqueous residue was partitioned between ethyl acetate
(100 mL) and 1 N hydrochloric acid (30 mL). The crude product was
isolated using standard extractive work up and purified by prep-TLC
(eluted with CH.sub.2Cl.sub.2:MeOH=7:1) to give
d.sub.2-2-[2-(6-methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3-sulfoni-
c acid (4-chloro-3-methyl-isoxazol-5-yl) amide (120 mg, 24%) as a
yellow solid. .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.75 (d,
J=5.1 Hz, 1H), 7.40 (d, J=5.1 Hz, 1H), 6.72 (d, J=3.9 Hz, 2H), 4.76
(s, 2H), 2.04 (s, 3H), 1.99 (s, 3H); ESI-MS: m/z=457 (MH).sup.+;
HPLC purity: 95%.
Example 3
[0323]
d.sub.3-2-[2-(6-Methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3-s-
ulfonic acid (4-chloro-3-methyl-isoxazol-5-yl)-amide
##STR00104##
Step 1
##STR00105##
[0325] 5-amino-4-chloro-3-methylisoxazole: The title compound was
made by following the procedure set forth in Example 1, step 1.
Step 2
##STR00106##
[0327]
3-(4-Chloro-3-methyl-isoxazol-5-ylsulfamoyl-thiophene-2-carboxylic
acid: The title compound was made by following the procedure set
forth in Example 1, step 2.
Step 3
##STR00107##
[0329] d.sub.3-5-Methyl-benzo[1,3]dioxole: A mixture of
5-methylbenzo[d][1,3]dioxole (1.25 g, 9.2 mmol), 10% palladium on
carbon (251 mg), sodium formate (376 mg) and deuterium oxide (5 mL)
was heated at about 135.degree. C. for about 48 hours. The mixture
was cooled to ambient temperature, extracted with pentane
(3.times.50 mL), and the solvent removed in vacuo to afford the
product d.sub.3-5-methyl-benzo[1,3]dioxole (1.0 g, 80%). .sup.1H
NMR (300 MHz, CDCl.sub.3) .delta. 6.72-6.60 (m, 3H), 5.90 (s,
2H).
Step 4
##STR00108##
[0331] d.sub.3-5-(Chloromethyl)-6-methylbenzo[d][1,3]dioxole: At
about 0.degree. C., d.sub.3-5-methylbenzo[d][1,3]dioxole (900 mg,
6.47 mmol) and formaldehyde (37% in water, 1.5 mL) were
sequentially added to a mixture of dichloromethane (13 mL),
tetrabutylammonium bromide (160 mg) and concentrated hydrochloric
acid (13 mL). Under continuous stirring, the resulting mixture was
maintained at about 0.degree. C. for about 1 hour and then at
ambient temperature for about 4 hours. The mixture was diluted with
ether (100 mL). After standard extractive workup, the solid residue
was heated with hexanes (100 mL), and the insolubles were removed
by filtration. The filtrate was concentrated in vacuo to give
desired product (800 mg, 67%). .sup.1H NMR (300 MHz, CDCl.sub.3)
.delta. 6.80 (s, 1H), 6.70 (s, 1H), 5.94 (s, 3H), 4.57 (s, 2H).
Step 5
##STR00109##
[0333]
d.sub.3-2-[2-(6-Methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3-s-
ulfonic acid (4-chloro-3-methyl-isoxazol-5-yl)-amide:
1,1'-carbonyldiimidazole (250 mg) was added to a solution of
3-[(4-chloro-3-methyl-5-isoxazolyl)sulfamoyl]-2-thiophenecarboxylic
acid (400 mg, 10.1 mmol) in anhydrous tetrahydrofuran (20 mL).
Under continuous stirring, the mixture was maintained at ambient
temperature for about 15 minutes, imidazole (168 mg, 2.5 mmol) and
N,O-dimethylhydroxylamine hydrochloride (184 mg, 1.89 mmol) were
sequentially added, and the mixture was maintained at ambient
temperature for about 4 hours. The solvent was removed in vacuo and
the residue was partitioned between ethyl acetate (100 mL) and 1 N
hydrochloric acid (30 mL). The organic layer was separated and
dried over anhydrous magnesium sulfate, filtered and concentrated.
The residue was treated with toluene (20 mL) and re-concentrated.
The resulting red oil was dissolved in anhydrous tetrahydrofuran
(20 mL), cooled to about 0.degree. C., and treated with a Grignard
reagent prepared from
d.sub.3-5-chloromethyl-6-methyl-benzo[1,3]dioxole (800 mg, 4.29
mmol) and magnesium turnings (826 mg, 34.4 mmol) in tetrahydrofuran
(50 mL). Under continuous stirring, the reaction mixture was
maintained at about 0.degree. C. for about 1 hour, and then at
ambient temperature for about 2 hours. At about 0.degree. C., the
reaction mixture was quenched with a mixture of concentrated
hydrochloric acid (20 mL) and methanol (50 mL). After stirring at
about 0.degree. C. for about 10 minutes, the reaction mixture was
concentrated in vacuo. The aqueous residue was partitioned between
ethyl acetate (100 mL) and 1 N hydrochloric acid (30 mL). The crude
product was isolated using standard extractive work up and purified
by prep-TLC (eluted with CH.sub.2Cl.sub.2: MeOH=7:1) to give
d.sub.3-2-[2-(6-methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3-sulfoni-
c acid (4-chloro-3-methyl-isoxazol-5-yl) amide (40 mg, 10%) as a
yellow solid. .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.75 (d,
J=5.4 Hz, 1H), 7.40 (d, J=5.1 Hz, 1H), 6.72 (d, J=4.2 Hz, 2H), 5.93
(s, 3H), 4.76 (s, 2H), 1.99 (s, 3H); ESI-MS: m/z=458 (MH).sup.+;
HPLC purity: 96%.
Example 4
[0334]
d.sub.5-2-[2-(6-Methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3-s-
ulfonic acid (4-chloro-3-methyl-isoxazol-5-yl)-amide
##STR00110##
Step 1
##STR00111##
[0336] 5-amino-4-chloro-3-methylisoxazole: The title compound was
made by following the procedure set forth in Example 1, step 1.
Step 2
##STR00112##
[0338]
3-(4-Chloro-3-methyl-isoxazol-5-ylsulfamoyl-thiophene-2-carboxylic
acid: The title compound was made by following the procedure set
forth in Example 1, step 2.
Step 3
##STR00113##
[0340] d.sub.2-5-Methyl-benzo[1,3]dioxole: The title compound was
made by following the procedure set forth in Example 2, step 3.
Step 4
##STR00114##
[0342] d.sub.5-5-Methyl-benzo[1,3]dioxole: A mixture of
d.sub.2-5-methylbenzo[d]-[1,3]dioxole (2.2 g, 16.2 mmol), 10%
palladium on carbon (500 mg), sodium formate (800 mg) and deuterium
oxide (10 mL) was heated at about 135.degree. C. for about 48
hours. The reaction mixture was cooled to ambient temperature,
extracted with pentane (3.times.50 mL), and the solvent was removed
in vacuo to afford the product d.sub.5-5-methyl-benzo[1,3]dioxole
(800 mg, 30%), which was used directly in next reaction without
further purification.
Step 5
##STR00115##
[0344] d.sub.5-5-(Chloromethyl)-6-methylbenzo[d][1,3]dioxole: At
about 0.degree. C., d.sub.5-5-methylbenzo[d]-[1,3]dioxole (800 mg,
5.67 mmol) and formaldehyde (37% in water, 0.5 mL) were
sequentially added to a mixture of dichloromethane (5 mL),
tetrabutylammonium bromide (120 mg) and concentrated hydrochloric
acid (5 mL). Under continuous stirring, the resulting mixture was
maintained at about 0.degree. C. for about 1 hour and then at
ambient temperature for about 4 hours. The reaction mixture was
diluted with ether (100 mL). After standard extractive workup the
resulting solid was heated with hexanes (100 mL), and the
insolubles were removed by filtration. The filtrate was
concentrated in vacuo to give desired product (780 mg, 76%).
.sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 6.78 (s, 1H), 6.66 (s,
1H), 4.57 (s, 2H).
Step 6
##STR00116##
[0346]
d.sub.5-2-[2-(6-Methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3-s-
ulfonic acid (4-chloro-3-methyl-isoxazol-5-yl)-amide:
1,1'-carbonyldiimidazole (18.8 mg) was added to a solution of
3-[(4-chloro-3-methyl-5-isoxazolyl)sulfamoyl]-2-thiophenecarboxylic
acid (300 mg, 7.5 mmol) in anhydrous tetrahydrofuran (20 mL). Under
continuous stirring, the mixture was maintained at ambient
temperature for about 15 minutes, imidazole (126 mg, 18.8 mmol) and
N,O-dimethylhydroxylamine hydrochloride (138 mg, 1.42 mmol) were
sequentially added, and the mixture was maintained at ambient
temperature for about 4 hours. The solvent was removed in vacuo and
the residue was partitioned between ethyl acetate (100 mL) and 1 N
hydrochloric acid (30 mL). The organic layer was dried over
anhydrous magnesium sulfate, filtered and concentrated. The residue
was treated with toluene and re-concentrated. The resulting red oil
was dissolved in anhydrous tetrahydrofuran (20 mL), cooled to about
0.degree. C. and treated with a Grignard reagent prepared from
d.sub.5-5-chloromethyl-6-methyl-benzo[1,3]dioxole (750 mg, 3.97
mmol) and magnesium turnings (800 mg, 32 mmol) in tetrahydrofuran
(50 mL). Under continuous stirring, the reaction mixture was
maintained at about 0.degree. C. for about 1 hour, and then at
ambient temperature for about 2 hours. At about 0.degree. C., the
reaction mixture was quenched with a mixture of concentrated
hydrochloric acid (20 mL) and methanol (50 mL). After stirring at
about 0.degree. C. for about 10 minutes, the reaction mixture was
concentrated in vacuo. The aqueous residue was partitioned between
ethyl acetate (100 mL) and 1 N hydrochloric acid (30 mL). The crude
product was isolated using standard extractive work up and purified
by prep-TLC (eluted with CH.sub.2Cl.sub.2:MeOH=7:1) to give
d.sub.5-2-[2-(6-methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3-sulfoni-
c acid (4-chloro-3-methyl-isoxazol-5-yl) amide (90 mg, 25%) as a
yellow solid. .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.75 (d,
J=5.4 Hz, 1H), 7.40 (d, J=5.1 Hz, 1H), 6.72 (d, J=4.2 Hz, 2H), 4.76
(s, 2H), 1.99 (s, 3H); ESI-MS: m/z=460 (MH).sup.+; HPLC purity:
98%.
Example 6
[0347]
d.sub.11-2-[2-(6-Methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3--
sulfonic acid (4-chloro-3-methyl isoxazol-5-yl)-amide
##STR00117##
Step 1
##STR00118##
[0349] d.sub.3-5-Amino-4-chloro-3-methylisoxazole: A mixture of
5-amino-4-chloro-3-methylisoxazole (10 mmol, Wako Pure Chemical
Industries, Ltd. Jersey City, N.J.) and 10% palladium on carbon
(240 mg) in deuterium oxide (40 mL) is degassed by bubbling a
stream of nitrogen into the mixture for about 2 minutes. Sodium
formate (400 mg) is added, the vessel is sealed and the reaction is
heated to 80-160.degree. C. for 5-48 hours. The mixture is cooled,
extracted with ethyl acetate, dried and concentrated under reduced
pressure to give the desired product
d.sub.3-5-amino-4-chloro-3-methylisoxazole.
Step 2
##STR00119##
[0351]
d.sub.3-3-(4-Chloro-3-methyl-isoxazol-5-ylsulfamoyl-thiophene-2-car-
boxylic acid: The procedure is carried out as in Wu et al., Journal
of Medicinal Chemistry 1997, 40(11), 1682-1689. Sodium hydride (60%
dispersion in mineral oil, 1.50 g, 37.4 mmol) is added to a
solution of d.sub.3-5-amino-4-chloro-3-methylisoxazole (17.7 mmol)
in anhydrous tetrahydrofuran (60 mL) at about 0.degree. C. The
resulting mixture is stirred for about 10 minutes and
2-(methoxycarbonyl)thiophene-3-sulfonyl chloride (3.0 g, 12.5 mmol,
Oakwood Products, Inc. West Columbia, S.C.) is added dropwise. The
reaction is stirred at ambient temperature for about 4 hours,
diluted with hexanes (60 mL), and the resulting precipitate is
filtered and washed with hexanes. The precipitate is then dissolved
in 1 N sodium hydroxide and stirred at ambient temperature for
about 1 hour. After acidifying to pH .about.2 with 2 N hydrochloric
acid, the resulting precipitate is filtered, washed with water, and
dried under vacuum, to give the title compound as a yellow
powder.
Step 3
##STR00120##
[0353] d.sub.3-5-Methyl-benzo[1,3]dioxole: d.sub.3-4-Methylcatechol
(23.9 mmol, Cambridge Isotopes laboratories, Inc. Andover, Mass.)
is added to a suspension of cesium carbonate (11.6 g, 35.6 mmol) in
dimethylformamide (60 mL). The mixture is evacuated and flushed
with nitrogen three times. d.sub.2-Dichloromethane (2.29 mL, 26.3
mmol, 99.9% D) is added at ambient temperature, the reaction
mixture is heated at about 110.degree. C. for about 2 hours, cooled
to ambient temperature, and partitioned between water and
ether-pentane. The title product is isolated using standard
extractive work up.
Step 4
##STR00121##
[0355] d.sub.5-5-(Chloromethyl)-6-methylbenzo[d][1,3]dioxole: The
procedure is carried out as in Wu et al., Journal of Medicinal
Chemistry 1997, 40(11), 1690-1697. At about 0.degree. C.,
d.sub.5-5-Methylbenzo[d]-[1,3]dioxole (81 mmol) and formaldehyde
(30% in water, 20 mL, 267 mmol) are sequentially added to a mixture
of ether (100 mL) and concentrated hydrochloric acid (100 mL).
Under continuous stirring, the mixture is maintained at about
0.degree. C. for about 1 hour and then at ambient temperature for
about 4 hours. The mixture is diluted with ether (100 mL). After
standard extractive workup the solid residue is heated with hexanes
(100 mL), and the insolubles are removed by filtration. The
filtrate is concentrated to give a mixture of
d.sub.5-5-methylbenzo[d]-[1,3]dioxole and
d.sub.5-5-(chloromethyl)-6-methylbenzo-[d][1,3]dioxole (7:3) as a
white solid.
Step 5
##STR00122##
[0357]
d.sub.8-2-[2-(6-Methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3-s-
ulfonic acid (4-chloro-3-methyl-isoxazol-5-yl)-amide: The procedure
is carried out as in Wu et al., Journal of Medicinal Chemistry
1997, 40(11), 1690-1697. 1,1'-Carbonyldiimidazole (2.76 g, 17.04
mmol) is added to a solution of
d.sub.3-3-[(4-chloro-3-methyl-5-isoxazolyl)sulfamoyl]-2-thiophenecarboxyl-
ic acid (15.49 mmol) in anhydrous tetrahydrofuran (70 mL). The
mixture is stirred at ambient temperature for about 15 minutes
before imidazole (2.11 g, 30.98 mmol) and N,O-dimethylhydroxylamine
hydrochloride (2.31 g, 23.24 mmol) are sequentially added. Under
continuous stirring, the mixture is maintained at ambient
temperature for about 4 hours, the solvent is removed in vacuo, and
the residue is partitioned between ethyl acetate and 1 N
hydrochloric acid. The organic layer is dried over magnesium
sulfate and concentrated. The residue is treated with toluene and
re-concentrated. The resulting red oil is dissolved in dry
tetrahydrofuran (20 mL) and treated at about 0.degree. C. with a
Grignard reagent prepared from
d.sub.5-5-chloromethyl-6-methyl-benzo[1,3]dioxole (82.02 mmol) and
magnesium turnings (2.3 g, 95.69 mmol) in tetrahydrofuran (100 mL).
Under continuous stirring, the mixture is maintained at about
0.degree. C. for about 1 hour, and then at ambient temperature for
about 2 hours. While cooling, the reaction is quenched with a
mixture of concentrated hydrochloric acid (20 mL) and methanol (50
mL). The mixture is stirred at about 0.degree. C. for about 10
minutes, and then concentrated. The aqueous residue is partitioned
between ethyl acetate and 1 N hydrochloric acid. The crude product
is isolated using standard extractive work up and purified by
preparative HPLC to affored the title compound as a yellow
solid.
Step 6
##STR00123##
[0359]
d.sub.11-2-[2-(6-Methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3--
sulfonic acid (4-chloro-3-methyl-isoxazol-5-yl)-amide:
d.sub.8-2-[2-(6-Methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3-sulfoni-
c acid (4-chloro-3-methyl-isoxazol-5-yl)-amide (0.014 mmol) is
taken up in 0.5 ml of d.sub.4-methanol and added dropwise to a 0.1M
solution of sodium carbonate in deuterium oxide (pH=11.4). Under
continuous stirring, the solution is maintained at ambient
temperature for 1-96 hours, diluted with ethyl acetate, washed with
brine and dried over anhydrous magnesium sulfate. The solvent is
removed in vacuo to yield the product
d.sub.11-2-[2-(6-methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3-sulfon-
ic acid (4-chloro-3-methyl-isoxazol-5-yl)-amide.
Example 7
[0360]
d.sub.17-3-(3,4-Dimethyl-isoxazol-5-ylsulfamoyl)-thiophene-2-carbox-
ylic acid (2-acetyl-4,6-dimethylphenyl)-amide
##STR00124##
Step 1
##STR00125##
[0362] d.sub.6-2-Amino-3,5-dimethylacetophenone: The procedure is
carried out as in Wu et al., Synth. Commun. 1999, 29(20),
3509-3516. d.sub.6-2,4-Dimethylaniline is available from C/D/N
Isotopes Inc. (Pointe-Claire, Quebec).
Step 2
##STR00126##
[0364] d.sub.6-5-Amino-3,4-dimethylisoxazole: A mixture of
5-amino-3,4-dimethylisoxazole (10 mmol, Sigma-Aldrich) and 10%
palladium on carbon (240 mg) in deuterium oxide (40 mL) is degassed
by bubbling a stream of nitrogen into the mixture for about 2
minutes. Sodium formate (400 mg) is added, the vessel is sealed and
the reaction is heated to 80-160.degree. C. for 5-48 hours. The
mixture is cooled, extracted with ethyl acetate, dried and
concentrated under reduced pressure to give the desired product
d.sub.6-5-amino-3,4-dimethylisoxazole.
Step 3
##STR00127##
[0366]
d.sub.6-3-(3,4-Dimethyl-isoxazol-5-ylsulfamoyl)-thiophene-2-carboxy-
lic acid methyl ester: The procedure is carried out as in Wu et
al., Journal of Medicinal Chemistry 1997, 40(11), 1682-1689. Sodium
hyrdride (60% dispersion in mineral oil, 1.50 g, 37.4 mmol) is
added to a solution of d.sub.3-5-amino-4-chloro-3-methylisoxazole
(17.7 mmol) in anhydrous tetrahydrofuran (60 mL) at about 0.degree.
C. Under continuous stirring, the resulting mixture is maintained
at about 0.degree. C. for about 10 minutes, and
2-(methoxycarbonyl)thiophene-3-sulfonyl chloride (3.0 g, 12.5 mmol,
Oakwood Products, Inc. West Columbia, S.C.) is added dropwise.
Under continuous stirring, the reaction mixture is maintained at
ambient temperature for about 4 hours, the mixture is diluted with
hexanes (60 mL), the resulting precipitate is filtered and washed
with hexanes, and dried in vacuo to give the title compound.
Step 4
##STR00128##
[0368]
d.sub.6-3-[(3,4-Dimethyl-isoxazol-5-yl)-methoxymethyl-sulfamoyl]-th-
iophene-2-carboxylic acid methyl ester: The procedure is carried
out as in Wu et al., Journal of Medicinal Chemistry 1999, 42(22),
4485-4499. N,N-diisopropylethylamine (1.9 g, 15.0 mmol) and
bromomethyl methyl ether (1.5 g, 12.0 mmol) are sequentially added
to a solution of
d.sub.6-3-(3,4-dimethyl-isoxazol-5-ylsulfamoyl)-thiophene-2-carboxylic
acid methyl ester (10.0 mmol) in anhydrous tetrahydrofuran (50 mL)
at about 0.degree. C. Under continuous stirring, the reaction is
maintained at about 0.degree. C. for about 2 hours, and then at
ambient temperature for about 6 hours. Morpholine (0.87 g, 10.0
mmol) is added (to scavenge the excess bromomethyl methyl ether),
and the mixture is maintained at ambient temperature and stirred
for about hour. The mixture is concentrated, and the resulting
residue is dissolved in ethyl acetate (200 mL) and washed with 1 N
hydrochloric acid (2.times.150 mL). The organic layer is dried over
magnesium sulfate and concentrated to give
d.sub.6-3-[(3,4-dimethyl-isoxazol-5-yl)-methoxymethyl-sulfamoyl]-thiophen-
e-2-carboxylic acid methyl ester.
Step 5
##STR00129##
[0370]
d.sub.6-3-[(3,4-Dimethyl-isoxazol-5-yl)-methoxymethyl-sulfamoyl]-th-
iophene-2-carboxylic acid: The procedure is carried out as in Wu et
al., Journal of Medicinal Chemistry 1999, 42(22), 4485-4499. 1 N
sodium hydroxide (30 mL) is added to a solution of
d.sub.6-3-[(3,4-dimethyl-isoxazol-5-yl)-methoxymethyl-sulfamoyl]-thiophen-
e-2-carboxylic acid methyl ester (7.8 mmol) in tetrahydrofuran (30
mL). Under continuous stirring, the resulting mixture is maintained
at ambient temperature for about 3 hours, and then partitioned
between 1 N hydrochloric acid (200 mL) and ethyl acetate (200 mL).
The organic layer is dried with magnesium sulfate and concentrated
to give the title compound.
Step 6
##STR00130##
[0372]
d.sub.6-3-[(3,4-Dimethyl-isoxazol-5-yl)-methoxymethyl-sulfamoyl]-th-
iophene-2-carboxylic acid chloride: The procedure is carried out as
in Wu et al, Journal of Medicinal Chemistry 1999, 42(22),
4485-4499. At 0.degree. C., a catalytic amount of pyridine and
oxalyl chloride (2 M in dichloromethane, 4.5 mL, 9.0 mmol) are
sequentially added to a solution of
d.sub.6-3-[(3,4-dimethyl-isoxazol-5-yl)-methoxymethyl-sulfamoyl]-thiop-
hene-2-carboxylic acid (4.1 mmol) in a mixture of tetrahydrofuran
(10 mL) and chloroform (5 mL). Under continuous stirring, the
mixture is maintained at ambient temperature for about 15 hours,
and then concentrated in vacuo to afford the title compound.
Step 7
##STR00131##
[0374]
d.sub.12-3-(3,4-Dimethyl-5-ylsulfamoyl)-thiophene-2-carboxylic acid
(2-acetyl-4,6-dimethylphenyl)-amide: The procedure is carried out
as in Wu et al., Journal of Medicinal Chemistry 1999, 42(22),
4485-4499.
d.sub.6-3-[(3,4-dimethyl-isoxazol-5-yl)-methoxymethyl-sulfamoyl]-thiophen-
e-2-carboxylic acid chloride (2.54 mmol) is added to a solution of
d.sub.6-2-amino-3,5-dimethylacetophenone (10.15 mmol) in anhydrous
tetrahydrofuran (30 mL). Under continuous stirring, the mixture is
maintained at ambient temperature for about 15 hours, and then
concentrated in vacuo. The resulting residue is partitioned between
1 N hydrochloric acid (200 mL) and ethyl acetate (200 mL). The
organic layer is concentrated, the residue is dissolved in methanol
(20 mL), and concentrated hydrochloric acid (10 mL) is added. The
reaction is heated at about 70.degree. C. for about 2 hours, cooled
to ambient temperature, and then poured into iced water (250 mL).
The resulting brown precipitate is collected by filtration, and
then purified by reverse-phase HPLC to afford the title
compound.
Step 8
##STR00132##
[0376]
d.sub.17-3-(3,4-Dimethyl-5-ylsulfamoyl)-thiophene-2-carboxylic acid
(2-acetyl-4,6-dimethylphenyl)-amide: The procedure is carried out
as in Example 6, step 6, but substituting
d.sub.12-3-(3,4-Dimethyl-isoxazol-5-ylsulfamoyl)-thiophene-2-carboxylic
acid (2-acetyl-4,6-dimethylphenyl)-amide for
d.sub.8-2-[2-(6-Methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3-sulfoni-
c acid (4-chloro-3-methyl-isoxazol-5-yl)-amide.
[0377] The following compounds can generally be made using the
methods described above. It is expected that these compounds when
made will have activity similar to those that have been made in the
examples above.
##STR00133## ##STR00134## ##STR00135## ##STR00136## ##STR00137##
##STR00138## ##STR00139## ##STR00140## ##STR00141## ##STR00142##
##STR00143## ##STR00144## ##STR00145## ##STR00146## ##STR00147##
##STR00148## ##STR00149## ##STR00150## ##STR00151## ##STR00152##
##STR00153## ##STR00154## ##STR00155## ##STR00156## ##STR00157##
##STR00158## ##STR00159## ##STR00160## ##STR00161## ##STR00162##
##STR00163## ##STR00164## ##STR00165## ##STR00166## ##STR00167##
##STR00168## ##STR00169## ##STR00170## ##STR00171## ##STR00172##
##STR00173## ##STR00174## ##STR00175## ##STR00176## ##STR00177##
##STR00178## ##STR00179## ##STR00180## ##STR00181## ##STR00182##
##STR00183## ##STR00184## ##STR00185## ##STR00186## ##STR00187##
##STR00188## ##STR00189## ##STR00190##
[0378] Changes in the metabolic properties of the compounds of
Examples 1 to 7 and their analogs as compared to the
non-isotopically enriched analogs can be shown using the following
assays. Other compounds listed above, which have not yet been made
and/or tested, are predicted to have changed metabolic properties
as shown by one or more of these assays as well.
Example 8
In Vitro Liver Microsomal Stability Assay
[0379] Liver microsomal stability assays are conducted at 1 mg per
mL liver microsome protein with an NADPH-generating system in 2%
NaHCO.sub.3 (2.2 mM NADPH, 25.6 mM glucose 6-phosphate, 6 units per
mL glucose 6-phosphate dehydrogenase and 3.3 mM MgCl.sub.2). Test
compounds are prepared as solutions in 20% acetonitrile-water and
added to the assay mixture (final assay concentration 5 microgram
per mL) and incubated at 37.degree. C. Final concentration of
acetonitrile in the assay should be <1%. Aliquots (50 .mu.L) are
taken out at times 0, 15, 30, 45, and 60 min, and diluted with ice
cold acetonitrile (200 .mu.L) to stop the reactions. Samples are
centrifuged at 12,000 RPM for 10 min to precipitate proteins.
Supernatants are transferred to microcentrifuge tubes and stored
for LC/MS/MS analysis of the degradation half-life of the test
compounds.
Example 9
In Vitro Metabolism Using Human Cytochrome P.sub.450 Enzymes
[0380] The cytochrome P.sub.450 enzymes are expressed from the
corresponding human cDNA using a baculovirus expression system (BD
Biosciences, San Jose, Calif.). A 0.25 milliliter reaction mixture
containing 0.8 milligrams per milliliter protein, 1.3 millimolar
NADP.sup.+, 3.3 millimolar glucose-6-phosphate, 0.4 U/mL
glucose-6-phosphate dehydrogenase, 3.3 millimolar magnesium
chloride and 0.2 millimolar of a compound of Formula I, the
corresponding non-isotopically enriched compound or standard or
control in 100 millimolar potassium phosphate (pH 7.4) is incubated
at 37.degree. C. for 20 min. After incubation, the reaction is
stopped by the addition of an appropriate solvent (e.g.,
acetonitrile, 20% trichloroacetic acid, 94% acetonitrile/6% glacial
acetic acid, 70% perchloric acid, 94% acetonitrile/6% glacial
acetic acid) and centrifuged (10,000 g) for 3 min. The supernatant
is analyzed by HPLC/MS/MS.
TABLE-US-00001 Cytochrome P.sub.450 Standard CYP1A2 Phenacetin
CYP2A6 Coumarin CYP2B6 [.sup.13C]-(S)-mephenytoin CYP2C8 Paclitaxel
CYP2C9 Diclofenac CYP2C19 [.sup.13C]-(S)-mephenytoin CYP2D6
(+/-)-Bufuralol CYP2E1 Chlorzoxazone CYP3A4 Testosterone CYP4A
[.sup.13C]-Lauric acid
Example 10
Monoamine Oxidase A Inhibition and Oxidative Turnover
[0381] The procedure is carried out as described in Weyler, Journal
of Biological Chemistry 1985, 260, 13199-13207. Monoamine oxidase A
activity is measured spectrophotometrically by monitoring the
increase in absorbance at 314 nm on oxidation of kynuramine with
formation of 4-hydroxyquinoline. The measurements are carried out,
at 30.degree. C., in 50 mM NaP.sub.i buffer, pH 7.2, containing
0.2% Triton X-100 (monoamine oxidase assay buffer), plus 1 mM
kynuramine, and the desired amount of enzyme in 1 mL total
volume.
Example 11
Monoamine Oxidase B Inhibition and Oxidative Turnover
[0382] The procedure is carried out as described in Uebelhack,
Pharmacopsychiatry 1998, 31, 187-192.
Example 12
Preparation of Platelet-Rich Plasma and Platelets
[0383] Venous blood from healthy subjects is collected between 8
and 8:30 a.m. after overnight fasting into EDTA-containing
vacutainer tubes (11.6 mg EDTA/mL blood).
[0384] After centrifugation of the blood at 250.times.g for 15 min
at 20.degree. C., the supernatant platelet-rich plasma (PRP) is
collected and the number of platelets in PRP and counted with a
cell counter (MOLAB, Hilden, Germany). PRP (2 mL) is spun at
1,500.times.g for 10 min to yield a platelet pellet. The pellet is
washed three times with ice-cold saline, resuspended in 2 mL
Soerensen phosphate buffer, pH 7.4, and stored at -18.degree. C.
for one day.
Example 13
MAO Assay
[0385] Fresh PRP or frozen platelet suspension (100 .mu.L) is
generally preincubated for 10 min in the absence or presence of the
compound of Formula I at 37.degree. C. in 100 .mu.L of 0.9% NaCl
solution or phosphate buffer pH 7.4, respectively.
2-Phenyllethylamine-[ethyl-1-.sup.14C]hydrochloride (PEA) solution
(specific activity 56 Ci/mol, Amersham, 50 .mu.L) is then added in
a final concentration of 5 .mu.M and the incubation is continued
for 30 min. The reaction is terminated by the addition of 50 .mu.L
4M HClO.sub.4. The reaction product of MAO, phenylacetaldehyde, is
extracted into 2 mL of n-hexane. An aliquot of the organic phase is
added to scintillator cocktail and the radioactivity is determined
using a liquid scintillation counter. Product formation is linear
with time for at least 60 min with appropriate platelet numbers.
Blank values are obtained by including 2 mM pargyline in the
incubation mixtures.
Example 14
[0386] Pharmacology-In Vitro Assays
[0387] In vitro characterization of modulation of ET.sub.A and
ET.sub.B is carried out as described in Hwan-Soo, J. Med. Chem.
1997, 40, 3217-3227.
Receptor Binding Assays
[0388] All samples are kept at 4.degree. C. throughout the process
of membrane isolation. MMQ cells (prolactin secreting rat pituitary
cells known to contain ET.sub.A receptors), porcine cerebellar
tissues (known to contain ET.sub.B receptors), or Chinese hamster
ovary cells (CHO) permanently transfected with the human ET.sub.A
or ET.sub.B receptor are homogenized in 25 mL of 10 mM Hepes (pH
7.4) containing 0.25 M sucrose and a protease inhibitor cocktail
(50 mM EDTA, 0.1 mM PMSF, and 5 microgram/mL Pepstatin A, and
0.025% Bacitracin) using a micro ultrasonic cell disruptor
(Kontes). The mixture is centrifuged at 1,000 g for 10 min. The
supernatant is collected and centrifuged at 60,000 g for 60 min.
The precipitate is resuspended in 20 mM Tris, pH 7.4, containing
protease inhibitor cocktail, and centrifuged again. The final
membrane pellet is resuspended in 20 mM Tris, pH 7.4, containing
protease inhibitors, and stored at -80.degree. C. until used.
Protein content is determined by the Bio-Rad dye-binding protein
assay.
[0389] Binding assays are performed in 96-well microtiter plates
pretreated with 0.1% BSA. Membranes are diluted 100-fold in buffer
B (20 mM Tris, 100 mM NaCl, 10 mM MgCl.sub.2, pH 7.4, with 0.2%
BSA, 0.1 mM PMSF, 5 microgram/mL Pepstatin A, 0.025% bacitracin,
and 50 mM EDTA) to a final concentration of 0.2 mg/mL of protein.
In competition binding studies, membranes (0.02 mg) are incubated
with 0.1 nM of [.sup.125I]ET-1 (for ETA assay in MMQ or CHO cells)
or [.sup.125I]ET-3 (for ET.sub.B assay in porcine cerebellum or CHO
cells) in buffer B (final volume: 0.2 mL) in the presence of
increasing concentrations of the test compound for 3 hours at
25.degree. C. After incubation, unbound ligand is separated from
bound ligand by a vacuum filtration method using glass-fiber filter
strips in PHD cell harvesters (Cambridge Technology, Inc.,
Cambridge, Mass.), washing the filter strips three times with
saline (1 mL).
[0390] Nonspecific binding is determined in the presence of 1
micromolar unlabeled ET-1. IC.sub.50 values are calculated using an
average of at least two separate determinations.
[0391] Phosphoinositol Hydrolysis Assays. ET.sub.A
[0392] MMQ cells (0.4.times.10 cells/mL) are labeled with 10
microCurie/mL of [.sup.3H]-myoinositol in RPMI for 16 hr. The cells
are washed with PBS and then incubated with buffer A (140 mM NaCl,
5 mM KCl, 2 mM CaCl.sub.2, 0.8 mM MgSO.sub.4, 5 mM glucose, 25 mM
Hepes, pH 7.4) containing protease inhibitors and 10 mM LiCl for 60
minutes. The cells are incubated with test compounds for 5 min and
then challenged with 1 nM ET-1. ET-1 challenge was terminated by
the addition of 1.5 mL of 1:2 (v/v) chloroform-methanol. Total
inositol phosphates are extracted after adding chloroform and water
to give final proportions of 1:1:0.9 (v/v/v)
chloroform-methanol-water. The upper aqueous phase (1 mL) is
retained, and a small portion (100 microliter) is counted. The rest
of the aqueous sample is analyzed by batch chromatography using
anion-exchange resin AG1-X8 (Bio-Rad).
Phosphoinositol Hydrolysis Assays. ETB
[0393] Chinese hamster ovary cells (CHO) permanently transfected
with the human ETB receptor are grown to confluence in 24-well
tissue culture plates and labeled with 5 microCurie/well of
[.sup.3H]myoinositol in F-12 media+10% FBS+1.times.P/S/F. The
adherent cells are washed gently with PBS and then incubated in 200
microliter of buffer A containing protease inhibitors and 10 mM
LiCl for 60 min at 37.degree. C. in a CO.sub.2 incubator. Test
compounds are then added followed by the addition of 1 nM ET-1 and
incubated for 30 min at 37.degree. C. The cells are then
solubilized by the addition of 50 microliters of 1 N NaOH and then
neutralized by the addition of 50 microliters of 1 N HCl. The
solubilized cell suspension is transferred to glass tubes and
extracted by the addition of 1.5 mL of 1:2 (v/v)
chloroform-methanol. Total inositol phosphates are extracted and
analyzed by batch chromatography on anion exchange resin as above.
All IC.sub.50 values are calculated using an average of at least
two separate determinations.
Example 15
In Vitro Inhibition of Human Cytochrome P.sub.450 Enzymes
CYP2C9
Solution A: NADPH-Regenerating System
[0394] To a glass tube on ice were added sequentially: Water (8 mL)
in NADP+ (20 mg), glucose-6-phosphate (20 mg), magnesium chloride
hexahydrate (13.3 mg) and glucose-6-phosphate dehydrogenase (60
units).
Solution B
[0395] To a glass tube on ice were added sequentially: 0.5 M
KH.sub.2PO.sub.4 (pH 7.4, 2.4 mL), water (8.988 mL), CYP2C9 (600
.mu.L of 1 picomol/microliter), and dibenzylfluorescein (2 mM in
100% acetonitrile, 12 microliter).
[0396] Solution A was transferred to a 96-well black plate (80
microliter per well), followed by various concentrations of a
solution of Compound in 10% acetonitrile-water (20 microliter per
well). The reaction was initiated by adding 100 microliter of
solution B to each well of the 96-well plate. The plate was
incubated for 40 minutes at 37.degree. C. in the dark. The reaction
was stopped by adding 75 microliters of stop buffer (2 N NaOH) to
each well, and incubating at 37.degree. C. for 2 hours. The end
point was measured in a fluorometer plate reader at
.lamda..sub.ex=485 nm and .lamda..sub.em=538 nm. Sulfaphenazole was
used as positive control (IC.sub.50=1.4 micromolar). Compounds
having structural Formula (I) that have been tested in this assay,
demonstrate that it takes more two times the amount of deuterated
compound to inhibit CYP2C9, as compared to the non-isotopically
enriched drug. For example, it took 3.2 times the amount of the
compound of Example 2 (IC.sub.50 0.32 .mu.M) to inhibit CYP2C9 than
non-isotopically enriched sixtaxsentan (IC.sub.50 0.1 .mu.M).
CYP3A4
Solution A: NADPH-Regenerating System
[0397] To a glass tube on ice were added sequentially: Water (8 mL)
in NADP+ (20 mg), glucose-6-phosphate (20 mg), magnesium chloride
hexahydrate (13.3 mg) and glucose-6-phosphate dehydrogenase (60
units).
Solution B
[0398] To a glass tube on ice were added sequentially: 0.5 M
KH.sub.2PO.sub.4 (pH 7.4, 9.6 mL), water (2.328 mL), CYP3A4 (60
.mu.L of 1 picomol/microliter), and dibenzylfluorescein (2 mM in
100% acetonitrile, 12 microliter).
[0399] Solution A was transferred to a 96-well black plate (80
microliter per well), followed by various concentrations of a
solution of Compound in 20% acetonitrile-water (20 microliter per
well). The reaction was initiated by adding 100 microliter of
solution B to each well of the 96-well plate. The plate was
incubated for 10 minutes at 37.degree. C. in the dark. The reaction
was stopped by adding 75 microliter of stop buffer (2 N NaOH) to
each well, and incubating at 37.degree. C. for 2 hours. The end
point was measured in a fluorometer plate reader at
.lamda..sub.ex=485 nm and .lamda..sub.em=538 nm. Ketoconazole was
used as positive control (IC.sub.50=5.7 nanomolar). Compounds
having structural Formula (I) that have been tested in this assay,
demonstrate that it takes more two times the amount of deuterated
compound to inhibit CYP3A4, as compared to the non-isotopically
enriched drug. For example, it took 2.3 times the amount of the
compound of Example 2 (IC.sub.50 21.2 .mu.M) to inhibit CYP3A4 than
non-isotopically enriched sixtaxsentan (IC.sub.50 9.1 .mu.M).
[0400] The examples set forth above are disclosed to give complete
disclosure and description of how to make and use the claimed
embodiments, and are not intended to limit the scope of what is
disclosed herein. Modifications that are obvious are intended to be
within the scope of the following claims. All publications,
patents, and patent applications cited in this specification are
incorporated herein by reference as if each such publication,
patent or patent application were specifically and individually
indicated to be incorporated herein by reference. However, with
respect to any similar or identical terms found in both the
incorporated publications or references and those explicitly put
forth or defined in this document, then those terms definitions or
meanings explicitly put forth in this document shall control in all
respects.
* * * * *